

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## **IMAGES ARE BEST AVAILABLE COPY.**

As rescanning documents *will not* correct images,  
Please do not report the images to the  
Image Problem Mailbox.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : A01H 1/00, C07H 21/00	A1	(11) International Publication Number: <b>WO 92/03918</b>	(43) International Publication Date: 19 March 1992 (19.03.92)
(21) International Application Number: PCT/US91/06185 (22) International Filing Date: 28 August 1991 (28.08.91) (30) Priority data: 574,748 29 August 1990 (29.08.90) US 575,962 31 August 1990 (31.08.90) US (60) Parent Application or Grant (63) Related by Continuation US 574,748 (CIP) Filed on 29 August 1990 (29.08.90) (71) Applicant (for all designated States except US): GEN- PHARM INTERNATIONAL, INC. [US/US]; 2375 Garcia Avenue, Mountain View, CA 94043 (US). (72) Inventors: and (75) Inventors/Applicants (for US only): LONBERG, Nils [US/ US]; 550 Battery Street, #1202, San Francisco, CA 94111 (US); KAY, Robert, M. [US/US]; 155 Jackson Street, #2301, San Francisco, CA 94111 (US).		(74) Agent: HESLIN, James, M.; Townsend and Townsend, One Market Plaza, 2000 Steuart Tower, San Francisco, CA 94105 (US). (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (Euro- pean patent), GN (OAPI patent), GR (European pa- tent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.  Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: TRANSGENIC NON-HUMAN ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES

**(57) Abstract**

The invention relates to transgenic non-human animals capable of producing heterologous antibodies, i.e., antibodies encoded by immunoglobulin heavy and light chain genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, transgenes encoding unrearranged heterologous human immunoglobulin heavy and light chains are introduced into a non-human animal thereby forming a transgenic animal capable of producing antibodies encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line capable of producing a monoclonal heterologous antibody. The invention also relates to heavy and light chain immunoglobulin transgenes for making such transgenic non-human animals as well as methods and vectors for disrupting endogenous immunoglobulin loci in the transgenic animal. The invention also includes methods to generate a synthetic immunoglobulin variable region gene segment repertoire used in transgene construction and methods to induce heterologous antibody production using animals containing heterologous rearranged or unrearranged heavy and light chain immunoglobulin transgenes.

# + DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

## *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU*	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

**TRANSGENIC NON-HUMAN ANIMALS CAPABLE  
OF PRODUCING HETEROLOGOUS ANTIBODIES**

TECHNICAL FIELD

The invention relates to transgenic non-human animals capable of producing heterologous antibodies, transgenes used to produce such transgenic animals, immortalized B-cells capable of producing heterologous antibodies, methods and vectors for disrupting endogenous immunoglobulin loci, methods to generate a synthetic immunoglobulin variable region gene segment repertoire, and methods to induce heterologous antibody production.

## BACKGROUND OF THE INVENTION

One of the major impediments facing the development of in vivo applications for monoclonal antibodies in humans is the intrinsic immunogenicity of non-human immunoglobulins. Patients respond to therapeutic doses of rodent monoclonal antibodies by making antibodies against the rodent immunoglobulin sequences. These human anti-mouse antibodies (HAMA) neutralize the therapeutic antibodies and can cause acute toxicity. The HAMA response is less dramatic in immunodeficient patients. Therefore, intrinsic immunogenicity has not prevented the use of rodent monoclonal antibodies for the treatment of graft rejection, which involves the temporary attenuation of the patient's immune response. Rodent antibodies may also be useful for treating certain lymphomas that involve immunodeficiencies. However, even immunodeficient patients can mount a HAMA response which leads to a reduction in safety and efficacy.

The present technology for generating monoclonal antibodies involves pre-exposing, or priming, an animal (usually a rat or mouse) with antigen. This pre-exposure leads to the formation of splenic B-cells that secrete immunoglobulin molecules with high affinity for the antigen. Spleen cells from a primed animal are then fused with myeloma cells to form

immortal, antibody secreting, hybridoma cells. Individual hybridoma clones are screened to identify those cells producing immunoglobulins directed against a particular antigen.

The genetic engineering of individual antibody genes has been proposed. Two genetic engineering approaches have been reported: chimeric antibodies and complementarity-determining-region (CDR) grafting. The simplest approach, chimeric antibodies, takes advantage of the fact that the variable and constant portions of an antibody molecule are encoded on separate exons. By simply fusing the variable region exons of a rearranged mouse antibody gene with a human constant region exons, a hybrid antibody gene can be obtained (Morrison, S.L., et al. (1984), Proc. Natl. Acad. Sci. USA, 81, 6851-6855). The major problem with this approach is that while the highly immunogenic mouse Fc region is eliminated, the remaining mouse Fab sequences are still immunogenic (Bruggemann, et al. (1989), J. Exp. Med., 170, 2153-2157). The CDR grafting approach uses computer modeling to generate a completely artificial antibody in which the only mouse sequences are those involved in antigen binding (Riechmann, L., et al. (1988), Nature, 332, 323-327). Each of these approaches requires the prior characterization of a rodent monoclonal antibody directed against the antigen of interest, and both require the generation of a stable transfected cell line that produces high levels of the engineered antibody.

Another approach to the production of human antibodies is a proposal involving the construction of bacterial expression libraries containing immunoglobulin cDNA sequences (Orlandi, et al. (1989), Proc. Natl. Acad. Sci. USA, 86, 3833-3837, and Huse, et al. (1989), Science, 246, 1275-1281). This technique reportedly has only been used to generate antibody fragments derived from mouse cDNA sequences.

A number of experiments have reported the use of transfected cell lines to determine the specific DNA sequences required for Ig gene rearrangement (reviewed by Lewis and Gellert (1989), Cell, 59, 585-588). Such reports have identified putative sequences and concluded that the accessibility of these sequences to the recombinase enzymes

used for rearrangement is modulated by transcription (Yancopoulos and Alt (1985), Cell, 40, 271-281). The sequences for V(D)J joining are reportedly a highly conserved, near-palindromic heptamer and a less well conserved AT-rich nanomer separated by a spacer of either 12 or 23 bp (Tonegawa (1983), Nature, 302, 575-581; Hesse, et al. (1989), Genes in Dev., 3, 1053-1061). Efficient recombination reportedly occurs only between sites containing recombination signal sequences with different length spacer regions.

10           The production of transgenic mice containing various forms of immunoglobulin genes has also been reported. Rearranged mouse immunoglobulin heavy or light chain genes have been used to produce transgenic mice. Such transgenes reportedly are capable of excluding the rearrangement of  
15   endogenous Ig genes. See e.g. Weaver et al. (1985), Cell, 42, 117-127; Iglesias, et al. (1987), Nature, 330, 482-484; Storb et al. (1985), Banbury Reports, 20, 197-207; Neuberger et al. (1989), Nature, 338, 350-352; Hagman et al. (1989), J. Exp. Med., 169, 1911-1929; and Storb (1989) in Immunoglobulin Genes,  
20   Academic Press, T. Honjo, F.W. Alt and T.H. Rabbitts eds. pp. 303-326. In addition, functionally rearranged human Ig genes including the  $\mu$  or  $\gamma 1$  constant region have been expressed in transgenic mice. Yamamura, et al. (1986), Proc. Natl. Acad. Sci. USA, 83, 2152-2156; Nussenzweig, et al. (1987), Science,  
25   236, 816-819. In the case of the  $\mu$  rearranged heavy chain gene, allelic exclusion of endogenous immunoglobulin gene loci was reported.

Allelic exclusion, however, does not always occur in all transgenic B-cells. See e.g. Rath, et al. (1989), J. Immunol., 143, 2074-2080 (rearranged  $\mu$  gene construct); Manz, et al. (1988), J. Exp. Med., 168, 1363-1381 ( $\mu$  transgenes lacking transmembrane exons did not prevent rearrangement of the endogenous genes); Ritchie, et al. (1984), Nature, 312, 517-520 and Storb, et al. (1986), Immunol. Rev., 89, 85-102  
35   (transgenic mice expressing rearranged  $\kappa$  transgene capable of forming stable heavy/light chain complex only rearrange endogenous  $\kappa$  genes in B-cells that fail to correctly rearrange endogenous heavy chain gene); and Manz, et al. (1988), J. Exp.

Med., 168, 1363-1381 (transgenic mice containing  $\kappa$  gene encoding light chain incapable of combining with heavy chains, show only a low level of allelic exclusion). See also Nussenzweig, et al. (1988), Nature, 336, 446-450); Durdik, et al. (1989), Proc. Natl. Acad. Sci. USA, 86, 2346-2350; and Shimizu, et al. (1989), Proc. Natl. Acad. Sci. USA, 86, 8020-8023.

Somatic mutation has also been reported in a 15 kb mouse  $\kappa$  gene construct in hyperimmunized transgenic mice (O'Brien, et al. (1987), Nature, 326, 405-409; Storb (1989) in Immunoglobulin Genes, Academic Press, T. Honjo, F.W. Alt, and T.H. Rabbitts, eds. pp. 303-326) and in the variable portion of a  $\mu$  heavy chain transgene (Durdik, et al. (1989), Proc. Natl. Acad. Sci. USA, 86, 2346-2350).

Ig gene rearrangement, though studied in tissue culture cells, has not been extensively examined in transgenic mice. Only a handful of reports have been published describing rearrangement test constructs introduced into mice [Buchini, et al. (1987), Nature, 326, 409-411 (unrearranged chicken  $\lambda$  transgene); Goodhart, et al. (1987), Proc. Natl. Acad. Sci. USA, 84, 4229-4233) (unrearranged rabbit  $\kappa$  gene); and Bruggemann, et al. (1989), Proc. Natl. Acad. Sci. USA, 86, 6709-6713 (hybrid mouse-human heavy chain)]. The results of such experiments, however, have been variable, in some cases, producing incomplete or minimal rearrangement of the transgene.

Based on the foregoing, it is clear that a need exists for heterologous monoclonal antibodies, e.g. antibodies of human origin, derived from a species other than human. Thus, it is an object of the invention herein to provide a source of monoclonal antibodies that may be used therapeutically in the particular species for which they are designed.

In accordance with the foregoing object transgenic nonhuman animals are provided which are capable of producing a heterologous antibody, such as a human antibody.

Further, it is an object to provide B-cells from such transgenic animals which are capable of expressing heterologous antibodies wherein such B-cells are immortalized to provide a

source of a monoclonal antibody specific for a particular antigen.

In accordance with this foregoing object, it is a further object of the invention to provide hybridoma cells that are capable of producing such heterologous monoclonal antibodies.

Still further, it is an object herein to provide heterologous unrearranged and rearranged immunoglobulin heavy and light chain transgenes useful for producing the aforementioned non-human transgenic animals.

Still further, it is an object herein to provide methods to disrupt endogenous immunoglobulin loci in the transgenic animals.

Still further, it is an object herein to provide methods to induce heterologous antibody production in the aforementioned transgenic non-human animal.

A further object of the invention is to provide methods to generate an immunoglobulin variable region gene segment repertoire that is used to construct one or more transgenes of the invention.

The references discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.

#### SUMMARY OF THE INVENTION

In accordance with the foregoing objects, in one aspect of the invention, transgenic non-human animals are provided that contain rearranged, unrearranged or a combination of rearranged and unrearranged heterologous immunoglobulin heavy and light chain transgenes in the germline of the transgenic animal. For each of the foregoing animals, functionally rearranged heterologous heavy and light chain immunoglobulin transgenes are found in the B-cells of the transgenic animal.

Heterologous heavy and/or light unrearranged immunoglobulin transgenes are introduced into a host non-human

animal to produce a transgenic non-human animal containing a heavy and a light heterologous immunoglobulin gene or an intermediate animal containing one or the other transgene. When incorporated into the germline of such intermediate  
5 animals, crosses between one containing a heavy chain transgene and one containing a light chain transgene produces a transgenic non-human animal containing both heavy and light heterologous immunoglobulin transgenes.

The transgenes of the invention include a heavy chain  
10 transgene comprising DNA encoding at least one variable gene segment, one diversity gene segment, one joining gene segment and one constant region gene segment. The immunoglobulin light chain transgene comprises DNA encoding at least one variable  
15 gene segment, one joining gene segment and one constant region gene segment. The gene segments encoding the light and heavy chain gene segments are heterologous to the transgenic non-human animal in that they are derived from, or correspond to, DNA encoding immunoglobulin heavy and light chain gene segments from a species not consisting of the transgenic  
20 non-human animal. In one aspect of the invention, the transgene is constructed such that the individual gene segments are unrearranged, i.e., not rearranged so as to encode a functional immunoglobulin light or heavy chain. Such unrearranged transgenes permit recombination of the gene  
25 segments (functional rearrangement) and somatic mutation of the resultant rearranged immunoglobulin heavy and/or light chains within the transgenic non-human animal when exposed to antigen.

In one aspect of the invention, heterologous heavy and light immunoglobulin transgenes comprise relatively large  
30 fragments of unrearranged heterologous DNA. Such fragments typically comprise a substantial portion of the C, J (and in the case of heavy chain, D) segments from a heterologous immunoglobulin locus. In addition, such fragments also comprise a substantial portion of the variable gene segments.

35 In an alternate embodiment, HP LaserJet Series IIHPLASEII.PRSegments. In such transgene constructs, the various regulatory sequences, e.g. promoters, enhancers, class switch regions, recombination signals and the like, comprise

corresponding sequences derived from the heterologous DNA. Alternatively, such regulatory sequences may be incorporated into the transgene from the same or a related species of the non-human animal used in the invention. For example, human immunoglobulin gene segments may be combined in a transgene with a rodent immunoglobulin enhancer sequence for use in a transgenic mouse.

In a method of the invention, a transgenic non-human animal containing germline unrearranged light and heavy immunoglobulin transgenes - that undergo VDJ joining during D-cell differentiation - is contacted with an antigen to induce production of a heterologous antibody in a secondary repertoire B-cell. Such induction causes somatic mutation in the rearranged heavy and/or light chain transgenes contained in primary repertoire B-cells to produce a heterologous antibody having high affinity and specificity for the antigen.

Such antibody producing B-cells may be immortalized by transforming with a virus, or with an oncogene containing DNA construct, or alternatively, immortalized by fusing with a myeloma cell line to form antibody secreting hybridomas. In each instance, clones having sufficient affinity and specificity for a particular antigen are selected to provide a source of monoclonal antibody having low immunogenicity in the species from which the immunoglobulin gene segments of the transgenes are derived.

Also included in the invention are vectors and methods to disrupt the endogenous immunoglobulin loci in the non-human animal to be used in the invention. Such vectors and methods utilize a transgene, preferably positive-negative selection vector, which is constructed such that it targets the functional disruption of a class of gene segments encoding a heavy and/or light immunoglobulin chain endogenous to the non-human animal used in the invention. Such endogenous gene segments include diversity, joining and constant region gene segments. In this aspect of the invention, the positive-negative selection vector is contacted with at least one embryonic stem cell of a non-human animal after which cells are selected wherein the positive-negative selection vector has

integrated into the genome of the non-human animal by way of homologous recombination. After transplantation, the resultant transgenic non-human animal is substantially incapable of mounting an immunoglobulin-mediated immune response as a result of homologous integration of the vector. Such immune deficient non-human animals may thereafter be used for study of immune deficiencies or used as the recipient of heterologous immunoglobulin heavy and light chain transgenes.

The invention also includes methods for generating a synthetic variable region gene segment repertoire to be used in the transgenes of the invention. The method comprises generating a population of immunoglobulin V segment DNAs wherein each of the V segment DNAs encodes an immunoglobulin V segment and contains at each end a cleavage recognition site of a restriction endonuclease. The population of immunoglobulin V segment DNAs is thereafter concatenated to form the synthetic immunoglobulin V segment repertoire.

Another aspect of the invention includes transgenic nonhuman animals that contain functionally rearranged heterologous heavy and light chain immunoglobulin transgenes in the germline of the transgenic animal. Such animals contain primary repertoire B-cells that express such rearranged heavy and light transgenes. Such B-cells are capable of undergoing somatic mutation when contacted with an antigen to form a heterologous antibody having high affinity and specificity for the antigen.

The invention also includes transgenic animals containing germ line cells having a heavy and light transgene wherein one of the said transgenes contains rearranged gene segments with the other containing unrearranged gene segments. In the preferred embodiments, the rearranged transgene is a light chain immunoglobulin transgene and the unrearranged transgene is a heavy chain immunoglobulin transgene.

The invention also includes methods for producing heterologous antibodies in a transgenic animal containing primary repertoire B-cells having rearranged heavy and light heterologous immunoglobulin transgenes. Such transgenic animals may be obtained from any of the aforementioned

transgenic animals. Thus, the transgenic animal containing unrearranged heavy and light transgenes, the transgenic animal containing rearranged heavy and light transgenes or the animal containing one rearranged and one unrearranged transgene in the germline of the animal, each contain primary repertoire B-cells having rearranged, heterologous heavy and light immunoglobulin transgenes. In the method of the invention, a desired first heterologous antibody is produced which is capable of binding a first antigen. The rearranged immunoglobulin heavy and light transgenes in the primary repertoire B-cells of such animals are known to produce primary repertoire antibodies having sufficient affinity for a second known antigen. In this method, the transgenic non-human animal is contacted, sequentially or simultaneously, with the first and second antigen to induce production of the first heterologous antibody by somatic mutation of the rearranged transgenes. The secondary repertoire B-cells so produced are then manipulated as previously described to immortalize the production of the desired monoclonal antibody capable of binding the first antigen.

The present invention also includes plasmids, useful in cloning large DNA fragments (e.g., immunoglobulin genomic fragments), that have an origin of replication (ORI), a copy control region (e.g., ROP, or the copy control region of pACYC177, or others known to those skilled in the art), and a cloning site. The plasmids also include a transcription terminator (e.g., trpR or others known to those skilled in the art) downstream of endogenous plasmid-derived promoters such as that of the ampicillin resistance gene (amp<sup>R</sup>). The transcription termination is located upstream of the cloning site so that transcripts originating at the promoter are terminated upstream of the cloning site. In a preferred embodiment, the cloning site is flanked by rare restriction sites, which are sites consisting of seven, eight, or more nucleotides, instead of the six or fewer nucleotides that make up more common restriction sites; e.g., Not I, Sfi I, and Pac I. Rare restriction sites also include sites that contain nucleotide sequences occurring rarely in natural DNA sequences;

i.e., less frequently than about once in every 8,000-10,000 nucleotides.

#### BRIEF DESCRIPTION OF THE FIGURES

5           Fig. 1 depicts the complementarity determining regions CDR1, CDR2 and CDR3 and framework regions FR1, FR2, FR3 and FR4 in unrearranged genomic DNA and mRNA expressed from a rearranged immunoglobulin heavy chain gene,

          Fig. 2 depicts the human  $\lambda$  chain locus,

10           Fig. 3 depicts the human  $\kappa$  chain locus,

          Fig. 4 depicts the human heavy chain locus,

          Figs. 5 and 6 depict the strategy for generating a synthetic V segment repertoire.

          Fig. 7 depicts the strategy for functional disruption  
15 of endogenous immunoglobulin loci.

          Fig. 8 depicts the T-cell mediated secondary response leading to maturation of the B-cell.

          Fig. 9 depicts somatic mutation and clonal expansion of B-cells in response to two different antigens.

20           Fig. 10 depicts a transgene construct containing a rearranged IgM gene ligated to a 25 kb fragment that contains human  $\gamma 3$  and  $\gamma 1$  constant regions followed by a 700 bp fragment containing the rat chain 3' enhancer sequence.

          Fig. 11 is a restriction map of the human  $\kappa$  chain  
25 locus depicting the fragments to be used to form a light chain transgene by way of in vivo homologous recombination.

          Fig. 12 depicts the construction of pGP1.

          Fig. 13 depicts the construction of the polylinker contained in pGP1.

30           Fig. 14 depicts the fragments used to construct a human heavy chain transgene of the invention.

          Fig. 15 depicts the construction of pHIG1 and pCON1.

          Fig. 16 depicts the human C $\gamma 1$  fragments which are inserted into pRE3 (rat enhancer 3') to form pREG2.

35           Fig. 17 depicts the construction of pHIG3' and PCON.

          Fig. 18 depicts the fragment containing human D region segments used in construction of the transgenes of the invention.

Fig. 19 depicts the construction of pHIG2 (D segment containing plasmid).

Fig. 20 depicts the fragments covering the human J $\kappa$  and human C $\kappa$  gene segments used in constructing a transgene of  
5 the invention.

Fig. 21 depicts the structure of pE $\mu$ .

Fig. 22 depicts the construction of pKapH.

Figs. 23A through 23D depict the construction of a positive-negative selection vector for functionally disrupting  
10 the endogenous heavy chain immunoglobulin locus of mouse.

Figs. 24A through 24C depict the construction of a positive-negative selection vector for functionally disrupting the endogenous immunoglobulin light chain loci in mouse.

Figs. 25 a through e depict the structure of a kappa  
15 light chain targeting vector.

Figs. 26 a through f depict the structure of a mouse heavy chain targeting vector.

Fig. 27 depicts the map of vector pGPe.

Fig. 28 depicts the structure of vector pJM2.

Fig. 29 depicts the structure of vector pCOR1.  
20

Fig. 30 depicts the transgene constructs for pIGM1, pHCl and pHCl2.

Fig. 31 depicts the structure of p $\gamma$ e2.

Fig. 32 depicts the structure of pVGE1.

Fig. 33 depicts the assay results of human Ig  
25 expression in a pHCl transgenic mouse.

Fig. 34 depicts the structure of pJCK1.

Fig. 35 depicts the construction of a synthetic heavy chain variable region.

Table 1 depicts the sequence of vector pGPe.  
30

Table 2 depicts the sequence of gene V $\mu$ 49.8.

#### DETAILED DESCRIPTION

The design of a transgenic non-human animal that responds to foreign antigen stimulation with a heterologous  
35 antibody repertoire, requires that the heterologous immunoglobulin transgenes contained within the transgenic animal function correctly throughout the pathway of B-cell development. Accordingly, the transgenes in one aspect of the

invention are constructed so as to produce one or all of the following: (1) high level and cell-type specific expression, (2) functional gene rearrangement, (3) activation of and response to allelic exclusion, (4) expression of a sufficient  
5 primary repertoire, (5) signal transduction, (6) class switching, (7) somatic hypermutation, and (8) domination of the transgene antibody locus during the immune response.

As will be apparent from the following disclosure, not all of the foregoing criteria need be met. For example, in  
10 those embodiments wherein the endogenous immunoglobulin loci of the transgenic animal are functionally disrupted, the transgene need not activate allelic exclusion. Further, in those embodiments wherein the transgene comprises a functionally rearranged heavy and/or light chain immunoglobulin gene, the  
15 second criteria of functional gene rearrangement is unnecessary, at least for that transgene which is already rearranged. For background on molecular immunology, see, Fundamental Immunology, 2nd edition (1989), Paul William E., ed. Raven Press, N.Y.

#### 20 The Structure and Generation of Antibodies

Immunoglobulins, also known as antibodies, are a group of glycoproteins present in the serum and tissue fluids of all mammals. They are produced in large amounts by plasma cells (also referred to herein as "secondary repertoire B-cells")  
25 which develop from precursor B lymphocytes (referred to herein as "primary repertoire B-cells"). Such primary repertoire B-cells carry membrane-bound immunoglobulin which is similar to that produced by the fully differentiated secondary repertoire B-cell. Contact between primary repertoire B-cells and foreign  
30 antigen is required for the induction of antibody formation.

The basic structure of all immunoglobulins is based upon a unit consisting of two identical light polypeptide chains and two identical heavy polypeptide chains linked together by disulfide bonds. Each light chain comprises two  
35 regions known as the variable light chain region and the constant light chain region. Similarly, the immunoglobulin heavy chain comprises two regions designated the variable heavy chain region and the constant heavy chain region. The constant

region for the heavy or light chain is encoded by genomic sequences referred to as heavy or light constant region gene segments. The use of a particular heavy chain gene segment defines the class of immunoglobulin. For example, in humans, the  $\mu$  constant region gene segments define the IgM class of antibody whereas the use of a  $\gamma$ ,  $\gamma$ 2,  $\gamma$ 3 or  $\gamma$ 4 constant region gene segment defines the IgG class of antibodies as well as the IgG subclasses IgG1 through IgG4.

The variable regions of the heavy and light immunoglobulin chains together contain the antigen binding domain of the antibody. Because of the need for diversity in this region of the antibody to permit binding to a wide range of antigens, the DNA encoding the initial or primary repertoire variable region comprises a number of different DNA segments derived from families of specific variable region gene segments. In the case of the light chain variable region, such families comprise variable (V) gene segments and joining (J) gene segments. Thus, the initial variable region of the light chain is encoded by one V gene segment and one J gene segment each selected from the family of V and J gene segments contained in the genomic DNA of the organism. In the case of the heavy chain variable region, the DNA encoding the initial or primary repertoire variable region of the heavy chain comprises one heavy chain V gene segment, one heavy chain diversity (D) gene segment and one J gene segment, each selected from the appropriate V, D and J families of immunoglobulin gene segments in genomic DNA.

#### The Primary Repertoire

The process for generating DNA encoding the heavy and light chain immunoglobulin genes occurs primarily in developing B-cells. Prior to the joining of various immunoglobulin gene segments, the V, D, J and constant (C) gene segments are found, for the most part, in clusters of V, D, J and C gene segments in the precursors of primary repertoire B-cells. Generally, all of the gene segments for a heavy or light chain are located in relatively close proximity on a single chromosome. Such genomic DNA prior to recombination of the various

immunoglobulin gene segments is referred to herein as "unrearranged" genomic DNA. During B-cell differentiation, one of each of the appropriate family members of the V, D, J (or only V and J in the case of light chain genes) gene segments are recombined to form functionally rearranged heavy and light immunoglobulin genes. Such functional rearrangement is of the variable region segments to form DNA encoding a functional variable region. This gene segment rearrangement process appears to be sequential. First, heavy chain D-to-J joints are made, followed by heavy chain V-to-DJ joints and light chain V-to-J joints. The DNA encoding this initial form of a functional variable region in a light and/or heavy chain is referred to as "functionally rearranged DNA" or "rearranged DNA". In the case of the heavy chain, such DNA is referred to as "rearranged heavy chain DNA" and in the case of the light chain, such DNA is referred to as "rearranged light chain DNA". Similar language is used to describe the functional rearrangement of the transgenes of the invention.

The recombination of variable region gene segments to form functional heavy and light chain variable regions is mediated by recombination signal sequences (RSS's) that flank recombinationally competent V, D and J segments. RSS's necessary and sufficient to direct recombination, comprise a dyad-symmetric heptamer, an AT-rich nonamer and an intervening spacer region of either 12 or 23 base pairs. These signals are conserved among the different loci and species that carry out D-J (or V-J) recombination and are functionally interchangeable. See Oettinger, et al. (1990), Science, 248, 1517-1523 and references cited therein. The heptamer comprises the sequence CACAGTG or its analogue followed by a spacer of unconserved sequence and then a nonamer having the sequence ACAAAAACC or its analogue. These sequences are found on the J, or downstream side, of each V and D gene segment. Immediately preceding the germline D and J segments are again two recombination signal sequences, first the nonamer and then the heptamer again separated by an unconserved sequence. The heptameric and nonameric sequences following a  $V_L$ ,  $V_H$  or D segment are complementary to those preceding the  $J_L$ , D or  $J_H$

segments with which they recombine. The spacers between the heptameric and nonameric sequences are either 12 base pairs long or between 22 and 24 base pairs long.

In addition to the rearrangement of V, D and J segments, further diversity is generated in the primary repertoire of immunoglobulin heavy and light chain by way of variable recombination between the V and J segments in the light chain and between the D and J segments of the heavy chain. Such variable recombination is generated by variation in the exact place at which such segments are joined. Such variation in the light chain typically occurs within the last codon of the V gene segment and the first codon of the J segment. Similar imprecision in joining occurs on the heavy chain chromosome between the D and J<sub>H</sub> segments and may extend over as many as 10 nucleotides. Furthermore, several nucleotides may be inserted between the D and J<sub>H</sub> and between the V<sub>H</sub> and D gene segments which are not encoded by genomic DNA. The addition of these nucleotides is known as N-region diversity.

After VJ and/or VDJ rearrangement, transcription of the rearranged variable region and one or more constant region gene segments located downstream from the rearranged variable region produces a primary RNA transcript which upon appropriate RNA splicing results in an mRNA which encodes a full length heavy or light immunoglobulin chain. Such heavy and light chains include a leader signal sequence to effect secretion through and/or insertion of the immunoglobulin into the transmembrane region of the B-cell. The DNA encoding this signal sequence is contained within the first exon of the V segment used to form the variable region of the heavy or light immunoglobulin chain. Appropriate regulatory sequences are also present in the mRNA to control translation of the mRNA to produce the encoded heavy and light immunoglobulin polypeptides which upon proper association with each other form an antibody molecule.

The net effect of such rearrangements in the variable region gene segments and the variable recombination which may occur during such joining, is the production of a primary

antibody repertoire. Generally, each B-cell which has differentiated to this stage, produces a single primary repertoire antibody. During this differentiation process, cellular events occur which suppress the functional rearrangement of gene segments other than those contained within the functionally rearranged Ig gene. The process by which diploid B-cells maintain such mono-specificity is termed allelic exclusion.

#### 10 The Secondary Repertoire

B-cell clones expressing immunoglobulins from within the set of sequences comprising the primary repertoire are immediately available to respond to foreign antigens. Because of the limited diversity generated by simple VJ and VDJ joining, the antibodies produced by the so-called primary response are of relatively low affinity. Two different types of B-cells make up this initial response: precursors of primary antibody-forming cells and precursors of secondary repertoire B-cells (Linton, et al. (1989), Cell, 59, 1049-1059). The first type of B-cell matures into IgM-secreting plasma cells in response to certain antigens. The other B-cells respond to initial exposure to antigen by entering a T-cell dependent maturation pathway. It is during this T-cell dependent maturation of B-cells that a second level of diversity is generated by a process termed somatic mutation (sometimes also referred to as hypermutation). These primary repertoire B-cells use the immunoglobulin molecules on their surfaces to bind and internalize the foreign antigen. If the foreign antigen is a protein or is physically linked to another protein antigen, that protein antigen is then processed and presented on the cell surface by a major histocompatibility complex (MHC) molecule to a helper T-cell which in turn induces maturation of the B-cell. Lanzavecchia (1985), Nature, 314, 537. This overall maturation of the B-cell is known as the secondary response.

During the T-cell dependent maturation of antigen stimulated B-cell clones, the structure of the antibody molecule on the cell surface changes in two ways: the constant

region switches to a non-IgM subtype and the sequence of the variable region is modified by multiple single amino acid substitutions to produce a higher affinity antibody molecule. It is this process of somatic mutation, followed by the  
5 selection of higher affinity clones, that generates highly specific and tightly binding immunoglobulins characterized by the Ig mediated immune response.

As previously indicated, each variable region of a heavy or light Ig chain contains an antigen binding domain. It  
10 has been determined by amino acid and nucleic acid sequencing that somatic mutation during the secondary response occurs throughout the V region including the three complementary determining regions (CDR1, CDR2 and CDR3) also referred to as hypervariable regions 1, 2 and 3. The CDR1 and CDR2 are  
15 located within the variable gene segment whereas the CDR3 is largely the result of recombination between V and J gene segments or V, D and J gene segments. Those portions of the variable region which do not consist of CDR1, 2 or 3 are commonly referred to as framework regions designated FR1, FR2,  
20 FR3 and FR4. See Fig. 1. During hypermutation, the rearranged DNA is mutated to give rise to new clones with altered Ig molecules. Those clones with higher affinities for the foreign antigen are selectively expanded by helper T-cells, giving rise to affinity maturation of the expressed antibody. Clonal  
25 selection typically results in expression of clones containing new mutation within the CDR1, 2 and/or 3 regions. However, mutations outside these regions also occur which influence the specificity and affinity of the antigen binding domain.

30 Transgenic Non-Human Animals Capable  
of Producing Heterologous Antibody

Transgenic non-human animals in one aspect of the invention are produced by introducing at least one of the  
35 immunoglobulin transgenes of the invention (discussed hereinafter) into a zygote or early embryo of a non-human animal. The non-human animals which are used in the invention generally comprise any mammal which is capable of rearranging immunoglobulin gene segments to produce a primary antibody

response and, which, in addition, are capable of mounting a secondary response by way of somatic mutation of such rearranged Ig genes. A particularly preferred non-human animal is the mouse or other members of the rodent family. Mice are particularly useful since their immune system has been extensively studied, including the genomic organization of the mouse heavy and light immunoglobulin loci. See e.g. Immunoglobulin Genes, Academic Press, T. Honjo, F.W. Alt and T.H. Rabbitts, eds. (1989).

However, the invention is not limited to the use of mice. Rather, any non-human mammal which is capable of mounting a primary and secondary antibody response may be used. Such animals include non-human primates, such as chimpanzee, bovine, ovine and porcine species, other members of the rodent family, e.g. rat, as well as rabbit and guinea pig. Particular preferred animals are mouse, rat, rabbit and guinea pig, most preferably mouse.

As used herein, the term "antibody" refers to a glycoprotein comprising at least two identical light polypeptide chains and two identical heavy polypeptide chains linked together by disulfide bonds. Each of the heavy and light polypeptide chains contains a variable region (generally the amino terminal portion of the polypeptide chain) which contains a binding domain which interacts with antigen. Each of the heavy and light polypeptide chains also comprises a constant region of the polypeptide chains (generally the carboxyl terminal portion) some of which sequences mediate the binding of the immunoglobulin to host tissues including various cells of the immune system, some phagocytic cells and the first component (C1q) of the classical complement system.

As used herein, a "heterologous antibody" is defined in relation to the transgenic non-human organism producing such an antibody. It is defined as an antibody having an amino acid sequence or an encoding DNA sequence corresponding to that found in an organism not consisting of the transgenic non-human animal. Thus, prior to rearrangement of a transgene containing various heavy or light chain gene segments, such gene segments may be readily identified, e.g. by hybridization or DNA

sequencing, as being from a species of organism other than the transgenic animal. For example, in one embodiment of the invention, various gene segments from the human genome are used in heavy and light chain transgenes in an unrearranged form.

5 In this embodiment, such transgenes are introduced into mice. The unrearranged gene segments of the light and/or heavy chain transgene have DNA sequences unique to the human species which are distinguishable from the endogenous immunoglobulin gene segments in the mouse genome. They may be readily detected in  
10 unrearranged form in the germ line and somatic cells not consisting of B-cells and in rearranged form in B-cells.

In an alternate embodiment of the invention, the transgenes comprise rearranged heavy and/or light immunoglobulin transgenes. Specific segments of such  
15 transgenes corresponding to functionally rearranged VDJ or VJ segments, contain immunoglobulin DNA sequences which are also clearly distinguishable from the endogenous immunoglobulin gene segments in the mouse.

Such differences in DNA sequence are also reflected in  
20 the amino acid sequence encoded by such human immunoglobulin transgenes as compared to those encoded by mouse B-cells. Thus, human immunoglobulin amino acid sequences may be detected in the transgenic non-human animals of the invention with antibodies specific for immunoglobulin epitopes encoded by  
25 human immunoglobulin gene segments.

Transgenic B-cells containing unrearranged transgenes from human or other species functionally recombine the appropriate gene segments to form functionally rearranged light and heavy chain variable regions. It is to be understood that  
30 the DNA of such rearranged transgenes for the most part will not correspond exactly to the DNA sequence of the gene segments from which such rearranged transgenes were obtained. This is due primarily to the variations introduced during variable recombination and because of mutations introduced by  
35 hypermutation during the secondary response. Notwithstanding such modifications in DNA (as well as in amino acid) sequence, it will be readily apparent that the antibody encoded by such rearranged transgenes has a DNA and/or amino acid sequence

which is heterologous to that normally encountered in the non-human animal used to practice the invention.

The term "substantial identity", when referring to polypeptides, indicates that the polypeptide or protein in question exhibits at least about 30% identity with an entire naturally occurring protein or a portion thereof, usually at least about 70% identity, and preferably at least about 95% identity. As used herein, the terms "isolated", "substantially pure" and "substantially homogenous" are used interchangeably herein and describe a polypeptide protein which has been separated from components which naturally accompany it. Typically, a monomeric protein is substantially pure when at least about 60 to 75% of a sample exhibits a single polypeptide backbone. Minor variants or chemical modifications typically share the same polypeptide sequence. A substantially pure protein will typically comprise over about 85 to 90% of a protein sample, more usually about 95%, and preferably will be over about 99% pure. Protein purity or homogeneity may be indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band on a polyacrylamide gel upon staining. For certain purposes high resolution will be needed and HPLC or a similar means for purification utilized. A polypeptide is substantially free of naturally-associated components when it is separated from the native contaminants which accompany it in its natural state. Thus, a polypeptide which is synthesized in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally-associated components.

#### Unrearranged Transgenes

As used herein, an "unrearranged immunoglobulin heavy chain transgene" comprises DNA encoding at least one variable gene segment, one diversity gene segment, one joining gene segment and one constant region gene segment. Each of the gene segments of said heavy chain transgene are derived from, or has a sequence corresponding to, DNA encoding immunoglobulin heavy chain gene segments from a species not consisting of the

non-human animal into which said transgene is introduced. Similarly, as used herein, an "unrearranged immunoglobulin light chain transgene" comprises DNA encoding at least one variable gene segment, one joining gene segment and at least one constant region gene segment wherein each gene segment of said light chain transgene is derived from, or has a sequence corresponding to, DNA encoding immunoglobulin light chain gene segments from a species not consisting of the non-human animal into which said light chain transgene is introduced.

Such heavy and light chain transgenes in this aspect of the invention contain the above-identified gene segments in an unrearranged form. Thus, interposed between the V, D and J segments in the heavy chain transgene and between the V and J segments on the light chain transgene are appropriate recombination signal sequences (RSS's). In addition, such transgenes also include appropriate RNA splicing signals to join a constant region gene segment with the VJ or VDJ rearranged variable region.

To the extent that the heavy chain transgene contains more than one C region gene segment, e.g. C $\mu$  and C $\gamma$ 1 from the human genome, as explained below "switch regions" are incorporated upstream from each of the constant region gene segments and downstream from the variable region gene segments to permit recombination between such constant regions to allow for immunoglobulin class switching, e.g. from IgM to IgG. Such heavy and light immunoglobulin transgenes also contain transcription control sequences including promoter regions situated upstream from the variable region gene segments which contain OCTA and TATA motifs.

In addition to promoters, other regulatory sequences which function primarily in B-lineage cells are used. Thus, for example, a light chain enhancer sequence situated preferably between the J and constant region gene segments on the light chain transgene is used to enhance transgene expression, thereby facilitating allelic exclusion. In the case of the heavy chain transgene, regulatory enhancers and also employed.

Although the foregoing promoter and enhancer regulatory control sequences have been generically described, such regulatory sequences may be heterologous to the nonhuman animal being derived from the genomic DNA from which the  
5 heterologous transgene immunoglobulin gene segments are obtained. Alternately, such regulatory gene segments are derived from the corresponding regulatory sequences in the genome of the non-human animal, or closely related species, which contains the heavy and light transgene. Such regulatory  
10 sequences are used to maximize the transcription and translation of the transgene so as to induce allelic exclusion and to provide relatively high levels of transgene expression.

In the preferred embodiments, each of the immunoglobulin gene segments contained on the heavy and light  
15 Ig transgenes are derived from, or have sequences corresponding to, genomic DNA, cDNA or portions thereof from a species or individual which is heterologous to the non-human animal into which the transgene is to be introduced. As a consequence, when such gene segments are functionally rearranged and  
20 hypermutated in the transgenic non-human animal, the heterologous antibody encoded by such heavy and light transgenes will have an amino acid sequence and overall secondary and tertiary structure which provides specific utility against a desired antigen when used therapeutically in  
25 the organism from which the Ig gene segments are derived. In addition, such antibodies demonstrate substantially reduced immunogenicity as compared to antibodies which are "foreign" to the organism treated.

For example, in the preferred embodiments, gene  
30 segments are derived from human beings. The transgenic non-human animals harboring such heavy and light transgenes are capable of mounting an Ig-mediated immune response to a specific antigen administered to such an animal. B-cells are produced within such an animal which are capable of producing  
35 heterologous human antibody. After immortalization, and the selection for an appropriate monoclonal antibody (Mab), e.g. a hybridoma, a source of therapeutic human monoclonal antibody is

provided. Such human Mabs have significantly reduced immunogenicity when therapeutically administered to humans.

Examples of antigens which may be used to generate heterologous antibodies in the transgenic animals of the invention containing human immunoglobulin transgenes include bacterial, viral and tumor antigen as well as particular human B- and T-cell antigens associated with graft rejection or autoimmunity.

Although the preferred embodiments disclose the construction of heavy and light transgenes containing human gene segments, the invention is not so limited. In this regard, it is to be understood that the teachings described herein may be readily adapted to utilize immunoglobulin gene segments from a species other than human beings. For example, in addition to the therapeutic treatment of humans with the antibodies of the invention, therapeutic antibodies encoded by appropriate gene segments may be utilized to generate monoclonal antibodies for use in the veterinary sciences. For example, the treatment of livestock and domestic animals with species-related monoclonal antibodies is also contemplated by the invention. Such antibodies may be similarly generated by using transgenes containing immunoglobulin gene segments from species such as bovine, ovine, porcine, equine, canine, feline and the like.

25

#### Class Switching

The use of  $\mu$  or  $\delta$  constant regions is largely determined by alternate splicing, permitting IgM and IgD to be coexpressed in a single cell. The other heavy chain isotypes ( $\gamma$ ,  $\alpha$ , and  $\epsilon$ ) are only expressed natively after a gene rearrangement event deletes the  $C\mu$  and  $C\delta$  exons. This gene rearrangement process, termed class switching, occurs by recombination between so called switch segments located immediately upstream of each heavy chain gene (except  $\delta$ ). The individual switch segments are between 2 and 10 kb in length, and consist primarily of short repeated sequences. The exact point of recombination differs for individual class switching events.

The ability of a transgene construction to switch isotypes during B-cell maturation has not been directly tested in transgenic mice; however, transgenes should carry out this function. Durdik et al. (1989) Proc. Natl. Acad. Sci. USA, 86, 2346-2350) microinjected a rearranged mouse  $\mu$  heavy chain gene construct and found that in four independent mouse lines, a high proportion of the transgenic B-cells expressed the transgene-encoded variable region associated with IgG rather than IgM. Thus, isotype switching appears to have taken place between the transgene and the endogenous  $\gamma$  constant region on another chromosome.

As used herein, the term switch sequence thus refers to those DNA sequences responsible for switch recombination. A "switch donor" sequence, typically a  $\mu$  switch region, will be 5' (i.e., upstream) of the construct region to be deleted during the switch recombination. The "switch acceptor" region will be between the construct region to be deleted and the replacement constant region (e.g.,  $\gamma$ ,  $\epsilon$ , etc.). As there is no specific site where recombination always occurs, the final gene sequence will typically not be predictable from the construct.

The switch (S) region of the  $\mu$  gene,  $S_\mu$ , is located about 1 to 2 kb 5' to the coding sequence and is composed of numerous tandem repeats of sequences of the form (GAGCT)<sub>n</sub>(GGGGT), where n is usually 2 to 5 but can range as high as 17. (See T. Nikaido, et al. (1981): Nature, 292:845-848.)

Similar internally repetitive switch sequences spanning several kilobases have been found 5' of the other C<sub>H</sub> genes. The S $\alpha$  region has been sequenced and found to consist of tandemly repeated 80-bp homology units, whereas S $\gamma_{2a}$ , S $\gamma_{2b}$ , and S $\gamma_3$  all contain repeated 49-bp homology units very similar to each other. (See, P. Szurek, et al. (1985): J. Immunol, 135:620-626 and T. Nikaido, et al. (1982): J. Biol. Chem., 257:7322-7329.) All the sequenced S regions include numerous occurrences of the pentamers GAGCT and GGGGT that are the basic repeated elements of the  $S_\mu$  gene (T. Nikaido, et al. (1982): J. Biol. Chem., 257:7322-7329); in the other S regions these

pentamers are not precisely tandemly repeated as in  $S_{\mu}$ , but instead are embedded in larger repeat units.

The  $S_{\gamma 1}$  region has an additional higher-order structure: two direct repeat sequences flank each of two  
5 clusters of 49-bp tandem repeats. (See M. R. Mowatt, et al (1986): J. Immunol., 136:2674-2683). Switch regions of human H chain genes have been found very similar to their mouse homologs. Generally, unlike the enzymatic machinery of V-J recombination, the switch machinery can apparently accommodate  
10 different alignments of the repeated homologous regions of germline S precursors and then join the sequences at different positions within the alignment. (See, T. H. Rabbits, et al. (1981): Nucleic Acids Res., 9:4509-4524 and J. Ravetch, et al. (1980): Proc. Natl. Acad. Sci. USA, 77:6734-6738.)

15 Induction of class switching appears to be associated with sterile transcripts that initiate upstream of the switch segments (Lutzker et al., 1988 Mol. Cell. Biol., 8, 1849; Stavnezer et al. 1988 Proc. Natl. Acad. Sci. USA, 85, 7704; Esser and Radbruch 1989 EMBO J., 8, 483; Berton et al. 1989  
20 Proc. Natl. Acad. Sci. USA, 86, 2829; Rothman et al. 1990 Int. Immunol. 2, 621). For example, the observed induction of the  $\gamma 1$  sterile transcript by IL-4 and inhibition by IFN- $\gamma$  correlates with the observation that IL-4 promotes class switching to  $\gamma 1$  in B-cells in culture, while IFN- $\gamma$  inhibits  $\gamma 1$   
25 expression. Ideally then, transgene constructs that are intended to undergo class switching should include all of the cis-acting sequences necessary to regulate these sterile transcripts. An alternative method for obtaining class switching in transgenic mice ( $\sigma\mu$  and  $\epsilon\mu$ ) involves the inclusion  
30 of the 400 bp direct repeat sequences that flank the human  $\mu$  gene (Yasui et al. 1989 Eur. J. Immunol., 19, 1399). Homologous recombination between these two sequences deletes the  $\mu$  gene in IgD-only B-cells.

### 35 Monoclonal Antibodies

Monoclonal antibodies can be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen

are immortalized, commonly by fusion with a myeloma cell (see, Kohler and Milstein, Eur. J. Immunol., 6:511-519 (1976)). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Various techniques useful in these arts are discussed, for example, in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor, New York (1988) including: immunization of animals to produce immunoglobulins; production of monoclonal antibodies; labeling immunoglobulins for use as probes; immunoaffinity purification; and immunoassays.

### The Transgenic Primary Repertoire

#### A. The Human Immunoglobulin Loci

An important requirement for transgene function is the generation of a primary antibody repertoire that is diverse enough to trigger a secondary immune response for a wide range of antigens. The size of the human immunoglobulin loci encoding the various gene segments for heavy and light chains is quite large. For example, in the human genome the three separate loci for the  $\lambda$  light chain locus, the  $\kappa$  light chain locus and the heavy chain locus together occupy over 5 Mb of DNA or almost 0.2% of the entire genome. Each locus consists of multiple variable segments that recombine during B-cell development with a joining region segment (and, the heavy chain locus with diversity region segments) to form complete V region exons. Such rearranged light chain genes consist of three exons: a signal peptide exon, a variable region exon and a constant region exon. The rearranged heavy chain gene is somewhat more complex. It consists of a signal peptide exon, a variable region exon and a tandem array of multi-domain constant region regions, each of which is encoded by several exons. Each of the constant region genes encode the constant

portion of a different class of immunoglobulins. During B-cell development, V region proximal constant regions are deleted leading to the expression of new heavy chain classes. For each heavy chain class, alternative patterns of RNA, splicing give  
5 rise to both transmembrane and secreted immunoglobulins.

Approximately 40% of human serum antibody molecules contain  $\lambda$  light chains. The structure of this locus, which maps to chromosome 22, is the least well characterized (Fig. 2). It consists of an unknown number of V segments upstream of  
10 a tandem array of six constant region genes, each of which is linked to a single J segment. In addition, two more constant region segments with associated J segments have been isolated, although their linkage with the rest of the  $\lambda$  cluster has not been established, and it is not known if they are used. E.  
15 Selsing, et al., "Immunoglobulin Genes", Academic Press, T. Honjo, F.W. Alt and T.H. Rabbitts, eds. (1989).

The  $\kappa$  light chain locus is spread out over three clusters on chromosome 2 (Fig. 3). The first two clusters, covering 850 and 250 kb respectively contain only variable  
20 region gene segments. The third cluster, covering about 1 Mb, contains approximately 40 V gene segments upstream of a cluster of 5 J segments followed by a single constant region gene segment. A total of 84 V gene segments have been identified, and approximately half of these are thought to be pseudogenes  
25 (Zachau (1989) in Immunoglobulin Genes, Academic Press, T. Honjo, F.W. Alt, and T.H. Rabbitts, eds. pp. 91-110).

Approximately 25 kb downstream of the CK region there is a "k deleting element" ( $\kappa$ de). The  $\kappa$ de sequence recombines with upstream sequences, causing the deletion of the  $\kappa$  constant  
30 region in  $\lambda$  light chain expressing B-cells. This leads to isotopic exclusion in cells that successfully rearrange both  $\kappa$  and  $\lambda$  genes.

The human heavy chain locus is the largest and most diverse. It consists of approximately 200 V gene segments  
35 spanning 2 Mb, approximately 30 D gene segments spanning about 40 kb, six J segments clustered within a 3 kb span, and nine constant region gene segments spread out over approximately 300 kb. The entire locus spans approximately 2.5 Mb of the distal

portion of the long arm of chromosome 14 (Fig. 4). The heavy chain V segments can be grouped into six families on the basis of sequence similarity. There are approximately 60 members of the  $V_H1$  family, 30  $V_H2$  segments, 80  $V_H3$  segments, 30  $V_H4$  segments, three  $V_H5$  segments, and one  $V_H6$  segment. Berman, J.E., et al. (1988), EMBO J., 7, 727-738. In the human heavy chain locus, the members of individual V families are intermingled, unlike the mouse locus where related V segments are clustered. The single member of the  $V_H6$  family is the most proximal of the V segments, mapping to within 90 kb of the constant region gene segments. Sato, T., et al. (1988), Biochem. Biophys. Res. Comm., 154, 265-271. All of the functional D and J segments appear to lie in this 90 kb region (Siebenlist, et al. (1981), Nature, 294, 631-635; Matsuda, et al. (1988), EMBO J., 7, 1047-1051; Buluwela, et al. (1988), EMBO J., 7, 2003-2010; Ichihara, et al. (1988), EMBO J., 7, 4141-4150; Berman, et al. (1988), EMBO J., 7, 727-738).

#### B. Gene Fragment Transgenes

##### 20 1. Heavy Chain Transgene

In a preferred embodiment, immunoglobulin heavy and light chain transgenes comprise unrearranged genomic DNA from humans. In the case of the heavy chain, a preferred transgene comprises a NotI fragment having a length between 670 to 830 kb. The length of this fragment is ambiguous because the 3' restriction site has not been accurately mapped. It is known, however, to reside between the  $\alpha 1$  and  $\psi\alpha$  gene segments (see Fig. 4). This fragment contains members of all six of the known  $V_H$  families, the D and J gene segments, as well as the  $\mu$ ,  $\delta$ ,  $\gamma 3$ ,  $\gamma 1$  and  $\alpha 1$  constant regions. Berman, et al. (1988), EMBO J., 7, 727-738. A transgenic mouse line containing this transgene correctly expresses all of the heavy chain classes required for B-cell development as well as a large enough repertoire of variable regions to trigger a secondary response for most antigens.

## 2. Light Chain Transgene

A genomic fragment containing all of the necessary gene segments and regulatory sequences from a human light chain locus may be similarly constructed. Such a construct is  
5 described in the Examples.

### C. Transgenes Generated Intracellularly by In Vivo Recombination

10 It is not necessary to isolate the all or part of the heavy chain locus on a single DNA fragment. Thus, for example, the 670-830 kb NotI fragment from the human immunoglobulin heavy chain locus may be formed in vivo in the non-human animal during transgenesis. Such in vivo transgene construction is  
15 produced by introducing two or more overlapping DNA fragments into an embryonic nucleus of the non-human animal. The overlapping portions of the DNA fragments have DNA sequences which are substantially homologous. Upon exposure to the recombinases contained within the embryonic nucleus, the  
20 overlapping DNA fragments homologously recombined in proper orientation to form the 670-830 kb NotI heavy chain fragment.

It is to be understood, however, that in vivo transgene construction can be used to form any number of immunoglobulin transgenes which because of their size are  
25 otherwise difficult, or impossible, to make or manipulate by present technology. Thus, in vivo transgene construction is useful to generate immunoglobulin transgenes which are larger than DNA fragments which may be manipulated by YAC vectors (Murray and Szostak (1983), Nature, 305, 189-193). Such in  
30 vivo transgene construction may be used to introduce into a non-human animal substantially the entire immunoglobulin loci from a species not consisting of the transgenic non-human animal. Thus, although several groups have successfully constructed libraries containing 50-200 kb of DNA fragments in  
35 YAC vectors (Burke, et al. (1987), Science, 236, 806-812; Traver, et al. (1989), Proc. Natl. Acad. Sci. USA, 86, 5898--5902) and used polyamine condensation to produce YAC libraries ranging in size from 200 to approximately 1000 kb (McCormick, et al. (1989), Proc. Natl. Acad. Sci USA, 86, 9991-9995),

multiple overlapping fragments covering substantially more than the 670-830 kb NotI fragment of the human constant region immunoglobulin loci are expected to readily produce larger transgenes by the methods disclosed herein.

5 In addition to forming genomic immunoglobulin transgenes, in vivo homologous recombination may also be utilized to form "mini-locus" transgenes as described in the Examples.

10 In the preferred embodiments utilizing in vivo transgene construction, each overlapping DNA fragment preferably has an overlapping substantially homologous DNA sequence between the end portion of one DNA fragment and the end portion of a second DNA fragment. Such overlapping portions of the DNA fragments preferably comprise about 500 bp  
15 to about 2000 bp, most preferably 1.0 kb to 2.0 kb. Homologous recombination of overlapping DNA fragments to form transgenes in vivo is further described in commonly assigned U.S. Patent Application entitled "Intracellular Generation of DNA by Homologous Recombination of DNA Fragments" filed August 29,  
20 1990, under U.S.S.N. 07/574,747.

#### D. Minilocus Transgenes

As used herein, the term "immunoglobulin minilocus" refers to a DNA sequence (which may be within a longer  
25 sequence), usually of less than about 150 kb, typically between about 25 and 100 kb, containing at least one each of the following: a functional variable (V) gene segment, a functional joining (J) region segment, a functional constant (C) region gene segment, and--if it is a heavy chain minilocus--  
30 a functional diversity (D) region segment, such that said DNA sequence contains at least one substantial discontinuity (e.g., a deletion, usually of at least about 2 to 5 kb, preferably 10-25 kb or more, relative to the homologous genomic DNA  
sequence). A light chain minilocus transgene will be at least  
35 25 kb in length, typically 50 to 60 kb. A heavy chain transgene will typically be about 70 to 80 kb in length, preferably at least about 60 kb with two constant regions operably linked to switch regions, versus at least about 30 kb

with a single constant region and incomplete switch regions. Furthermore, the individual elements of the minilocus are preferably in the germline configuration and capable of undergoing gene rearrangement in the pre-B cell of a transgenic animal so as to express functional antibody molecules with diverse antigen specificities encoded entirely by the elements of the minilocus.

In an alternate preferred embodiment, immunoglobulin heavy and light chain transgenes comprise one or more of each of the V, D, J and C gene segments. At least one of each appropriate type gene segment is incorporated into the minilocus transgene. With regard to the C segments for the heavy chain transgene, it is preferred that the transgene contain at least one  $\mu$  gene segment and at least one other constant region gene segment, more preferably a  $\gamma$  gene segment, and most preferably  $\gamma 3$  or  $\gamma 1$ . This preference is to allow for class switching between IgM and IgG forms of the encoded immunoglobulin to provide for somatic mutation and the production of a secretable form of high affinity non-IgM immunoglobulin. Other constant region gene segments may also be used such as those which encode for the production of IgD, IgA and IgE.

The heavy chain J region segments in the human comprise six functional J segments and three pseudo genes clustered in a 3 kb stretch of DNA. Given its relatively compact size and the ability to isolate these segments together with the  $\mu$  gene and the 5' portion of the  $\delta$  gene on a single 23 kb Sfil/SpeI fragment (Sado, et al. (1988), Biochem. Bioshys. Res. Comm., 154, 264271), it is preferred that all of the J region gene segments be used in the mini-locus construct. Since this fragment spans the region between the  $\mu$  and  $\delta$  genes, it is likely to contain all of the 3' cis-linked regulatory elements required for  $\mu$  expression. Furthermore, because this fragment includes the entire J region, it contains the heavy chain enhancer and the  $\mu$  switch region (Mills, et al. (1983), Nature, 306, 809; Yancopoulos and Alt (1986), Ann. Rev. Immunol., 4, 339-368). It also contains the transcription start sites which trigger VDJ joining to form primary

repertoire B-cells (Yancopoulos and Alt (1985), Cell, 40, 271-281). Alternatively, a 36 kb BssHII/SpeI fragment, which includes part on the D region, may be used in place of the 23 kb SfiI/SpeI fragment. The use of such a fragment increases the amount of 5' flanking sequence to facilitate efficient D-to-J joining.

The human D region consists of 4 or 5 homologous 9 kb subregions, linked in tandem (Siebenlist, et al. (1981), Nature, 294, 631-635). Each subregion contains up to 10 individual D segments. Some of these segments have been mapped and are shown in Fig. 4. Two different strategies are used to generate a mini-locus D region. The first strategy involves using only those D segments located in a short contiguous stretch of DNA that includes one or two of the repeated D subregions. A candidate is a single 15 kb fragment that contains 12 individual D segments. This piece of DNA consists of 2 contiguous EcoRI fragments and has been completely sequenced (Ichihara, et al. (1988), EMBO J., 7, 4141-4150). Twelve D segments should be sufficient for a primary repertoire. However, given the dispersed nature of the D region, an alternative strategy is to ligate together several non-contiguous D-segment containing fragments, to produce a smaller piece of DNA with a greater number of segments.

At least one, and preferably more than one V gene segment is used to construct the heavy chain minilocus transgene. A 10-15 kb piece of DNA containing one or two unrearranged V segments together with flanking sequences is isolated. A clone containing such DNA is selected using a probe generated from unique 5' sequences determined from the transcribed V region of a characterized human hybridoma such as that which produces anti-cytomegalovirus antibody (Newkirk et al. (1988) J. Clin. Invest., 81, 1511-1518). The 5' untranslated sequence of the heavy chain mRNA is used to construct a unique nucleotide probe (preferably about 40 nucleotides in length) for isolating the original germline V segment that generated this antibody. Using a V segment that is known to be incorporated in an antibody against a known antigen not only insures that this V segment is functional, but

aids in the analysis of transgene participation in secondary immune responses. This V segment is fused with the minilocus D region and constant region fragments, discussed previously, to produce a mini-locus heavy chain transgene.

5 Alternatively, a large, contiguous stretch of DNA containing multiple V region segments is isolated from a YAC library. Different sized pieces of DNA, containing different numbers of V region segments, are tested for their ability to provide a human antibody repertoire in the minilocus transgene  
10 construct. It is also possible to build one large fragment from several non-contiguous V segment containing fragments using YAC vectors (Murray and Szostak (1983), Nature, 305, 189-193), F factor-based plasmids (O'Conner, et al. (1989), Science, 244, 1307-1312) or the aforementioned in vivo  
15 construction using recombination of overlapping fragments. Alternatively, a synthetic V region repertoire (described hereinafter) may be used.

A minilocus light chain transgene may be similarly constructed from the human  $\lambda$  or  $\kappa$  immunoglobulin locus.  
20 Construction of a  $\kappa$  light chain mini-locus is very similar to construction of the heavy chain mini-locus, except that it is much simpler because of its smaller size and lower complexity. The human  $\kappa$  locus contains only one constant region segment; and this segment, together with 5' and 3' enhancers, and all 5  
25 of the functional J segments, can be isolated on a single 10 kb DNA fragment. This fragment is co-injected together with a minilocus V region constructed as described for the heavy chain minilocus.

Thus, for example, an immunoglobulin heavy chain  
30 minilocus transgene construct, e.g., of about 75 kb, encoding V, D, J and constant region sequences can be formed from a plurality of DNA fragments, at least two, three or four of which each are either a V region sequence, a D region sequence, a J and constant region sequence, a D and J and constant region  
35 sequence or a constant region sequence, with each sequence being substantially homologous to human gene sequences. Preferably, the sequences are operably linked to transcription regulatory sequences and are capable of undergoing

rearrangement. With two or more appropriately placed constant region sequences (e.g.,  $\mu$  and  $\gamma$ ) and switch regions, switch recombination also occurs. An exemplary light chain transgene construct similarly formed from a plurality of DNA fragments, substantially homologous to human DNA and capable of undergoing rearrangement will include at least two, three or four DNA fragments, encoding V, D and constant regions, each fragment comprising either a V region sequence, J and constant region sequence or a constant region sequence.

10

E. Methods for Determining Functional  
V Gene Segments and for Generating  
Synthetic V Segment Repertoire

Of the various families of gene segments, i.e., V, D, J and C region gene segments, the number of V gene segments generally far surpasses the number of corresponding gene segments for the D, J and C region gene segments. By analogy to the rabbit system wherein a single V gene segments is utilized by approximately 90% of the antibodies produced (Knight and Becker (1990), Cell, 60, 963-970), it is possible to produce heavy and light transgenes containing a limited number of V region gene segments, and as few as one V region gene segments. Therefore, it is desirable to have a method to determine which V region gene segments are utilized by a particular organism, such as the human being, when mounting an immunoglobulin-mediated immune response. According to this approach, a single V gene segment when combining with the J or DJ gene segments is capable of providing sufficient diversity at CDR3 for the generation of a primary repertoire which upon somatic mutation is able to provide further diversity throughout the variable region, e.g. at CDR1 and CDR2 for the production of high affinity antibodies.

In this aspect of the invention, methods and vectors are provided for determining which V gene segments are commonly utilized by an organism during an immune response. This method is based on determining which V segments are found in cDNA synthesized from B-cell polyA+ RNA. Such methods and vectors may also be used to facilitate the construction of a synthetic V segment repertoire.

The outline of this strategy for identifying heavy chain V segments and for generating a synthetic V segment repertoire is depicted in Figs 5 and 6. It is similarly applicable for identifying light chain V segments with appropriate modification. The first step is the construction of a cloning vector. The preferred starting material is a DNA fragment (approximately 2 kb) containing an unrearranged V segment together with 5' and 3' flanking sequences. This fragment is cloned into a plasmid such as pGP1 or pGP2 described hereinafter containing a polylinker site flanked by the rare cutting restriction sites designated "w" and "z" in the Figs. 5 and 6 (the polylinkers and restriction sites of pGP1 and pGP2 are described in the Examples). Oligonucleotide directed mutagenesis is then used to introduce two new restriction sites, "x" and "y" (generally each about 6 nucleotides in length). Restriction site "x" is placed approximately 20 nucleotides from the 3' end of the intron between the signal and V segment exon. Restriction site "y" is placed approximately 20 nucleotides 3' of the V segment junction, within the 23 bp spacer between the heptamer and nonomer recombination signal sequences. Cutting the resulting plasmid with enzymes "x" and "y" removes the second exon (V segment), leaving the 5' flanking sequences, the V region promoter, the signal peptide exon, the intron, a gap flanked by "x" and "y" ends, the outside half of the recombination signal sequence, and the 3' flanking sequences. This plasmid is called pVH1.

The second step is the synthesis of four sets of oligonucleotide primers, P1 through P4. P1 and P2 are non-unique oligomers having approximately 50 nucleotides each which are used to prime double stranded cDNA synthesis. P1 starts (going 5' to 3') with about 20 nucleotides of sequence homologous to the antisense strand of the recombination signal sequence in pVH1 (including the recognition sequence of restriction enzyme "y"), and continues with approximately 30 nucleotides of antisense sequence hybridizing with about the last 30 nucleotides of the VH framework region 3 (FR3). Random bases are incorporated over about the last 30 nucleotides so as

to generate a set of primers that hybridize with all of the different VH families. The second oligonucleotide, P2, is in the sense orientation, and is homologous to the approximately 50 nucleotides beginning with the restriction site "x" in pVH1.

5 This includes the "x" restriction site, about the last 20 nucleotides of the intron, and about the first 30 nucleotides of FR1. Again, about the last 30 nucleotides are non-unique so as to accommodate different VH region segments.

Oligonucleotides P3 and P4 are homologous to about the first 20  
10 nucleotides of P1 and P2 respectively. These oligos are unique so as to avoid introducing new mutations into the V segments and are used to amplify double stranded cDNA by way of the polymerase chain reaction (PCR).

The 3' terminal portions of primers P1 and P2 which  
15 are capable of hybridizing to and priming the synthesis of the variable segments of the heavy or light immunoglobulin locus may be readily determined by one skilled in the art. For example, the nucleotide sequence for a number of human VH genes have been published, see e.g. Berman, J.E., et al.  
20 (1988), EMBO J., 7, 727-738 and Kabat, E.A., et al. (1987), Sequences of Protein of Immunological interests, U.S. Dept. Health & Human Services, Washington, D.C. Similarly, when used to identify and/or generate V segments of the human light immunoglobulin locus, the appropriate 3' sequence portions of  
25 primers P1 and P2 may readily be determined from published sequences. See e.g Kabat, E.A., et al., supra. In general, those nucleotide positions which are conserved amongst various V segments are also conserved in the 3' portion of the P1 and P2 primers. For those nucleotide positions wherein variation  
30 is observed amongst variable segments, such nucleotide positions in the corresponding P1 and P2 primers are similarly varied to provide P1 and P2 primers which comprise a pool of primers which are capable of hybridizing to different VH or VL segments.

35 The next step is to use these oligonucleotide primers to generate a library of human heavy-chain V-region cDNA sequences in the vector pVH1. P1 is used to prime first strand cDNA synthesis from human B-cell polyA+ RNA. The RNA is base

hydrolyzed, and second strand synthesis primed with P2. Full length, double stranded cDNA is then purified on an acrylamide gel, electroeluted, and used as template for polymerase chain reaction (PCR) amplification using oligonucleotide primers P3 and P4. Alternatively, cDNA is first synthesized by conventional methods and this cDNA is used as a template for the P1 primed reactor. The amplified product (approximately 0.3 kb) is then gel purified, cleaved with restriction enzymes "x" and "y", and cloned into pHV1.

10           The resulting cDNA library represents a synthetic genomic library of variable region segments and offers three advantages over a conventional genomic library of variable segments. First, this library contains no pseudogenes, while a conventional library would contain up to 50% pseudogene sequences. Second, the synthetic library is more compact than a conventional library, containing one functional V segment per 2 kb of DNA, as opposed to one functional segment per 20 kb. Finally, this approach leaves the V segment promoter sequences accessible to manipulation.

20           Such a cDNA library may be biased towards particular germline V segments because of differential expression. The two sources of bias are: (i) differential rates of V segment recombination, and (ii) differential selection of V segment expressing B-cell clones. The first source of bias is dealt with in two ways. First, fetal tissue is avoided as a source of B-cell RNA, as the bias is most pronounced in the fetal immunoglobulin repertoire. Second, the semi-random primers, P1 and P2, are divided into pools, each of which selectively cross-hybridizes with different V segment families. These primers are then used to generate 4 to 6 separate libraries, thus insuring that all of the V region families are represented. The second source of bias, differential selection of B-cell clones, is also dealt with in two analogous ways. First, a source of RNA that includes the minimum fraction of antigen selected B-cells is used. Lymph nodes and spleen are avoided. Adult bone marrow is one source of unselected B-cells. However, it may contain a high proportion of transcribed pseudogene sequences from pre-B-cells. Another

source of RNA is whole blood. Ninety percent of circulating B-cells are immature  $\mu$  or  $\mu$ ,  $\delta$  expressing cells, and are recent bone marrow immigrants. However, the level of antigen selected IgG expressing cells can vary depending on the immune state of the individual. Therefore, isolated polyA<sup>+</sup> RNA is checked for selected B-cell sequences by northern blot hybridization with specific probes. If it is more practical to use spleen RNA, and if this RNA contains a high fraction of IgG sequences, a second approach is used to minimize selection bias. The first strand of cDNA synthesis is primed with about a 40 nucleotide constant-region exon 2 primer that is specific for IgM transcripts. Second strand synthesis is then primed with P2, and a third round of synthesis primed with P1. The cDNA from this third round of synthesis provides the template for PCR amplification using P3 and P4.

Once the variable region library has been generated, the V segments used therein may be identified by standard techniques, e.g. by way of sequencing and/or hybridization with family specific or segment specific oligonucleotides as well as differential amplification by PCR methods. Such characterization of the V segment library provides information as to the frequency and distribution of V segment utilization in a particular organism and as a consequence, the identification of V segments which may be used in the construction of the various transgenes of the invention. Thus, one or more predominant V gene segments may be used in the above described mini-locus transgene construct. Further, selected clones from such a library may be used to identify genomic fragments containing frequently used V segments to facilitate identification of genomic fragments containing a particular desired V segment.

In addition, a synthetic V segment repertoire may be constructed by concatenation of the library sequences. Large repeating transgene tandem arrays, containing hundreds of copies of the injected sequence, are commonly generated in the production of transgenic mice. These tandem arrays are usually quite stable. However, to ensure the stability of the synthetic V region, blocks of random DNA between each 2 kb

region segment are preferably introduced. These blocks of random DNA are prepared by digesting and then religating genomic DNA, so as to prevent the insertion of dominant regulatory elements. Genomic DNA is preferably digested with  
5 four frequent cutting restriction enzymes: AluI, DpnI, HaeIII, and RsaI. This digest produces blunt ended fragments with an average length of 64 nucleotides. Fragments in the size range of 50 to 100 nucleotides are eluted from an acrylamide gel, and religated. The religated DNA is partially digested with MboI  
10 and size fractionated. Fragments in the range of 0.5 to 2 kb are cloned into the BamHI or BglII site of the polylinker of the vector used to generate pVH1.

The random sequence library is combined with the synthetic V segment library to create a synthetic V segment  
15 repertoire. Inserts from the random sequence library are released with the enzymes "w" and "z", and purified away from vector sequences. Inserts from the synthetic V segment library are isolated by cutting with "w" and "z". Before purifying the V segment inserts, this DNA is treated with calf-intestinal  
20 phosphatase, to prevent self ligation. The V segment inserts are then ligated together with the random inserts to generate an alternating tandem array comprising a synthetic V segment repertoire. This ligation mixture is size selected on a sucrose gradient, and the 50-100 kb fraction microinjected  
25 together with, for example, a D-J-constant mini-locus construct. By directly injecting the synthetic V segment repertoire without an intervening cloning step, it is possible to take advantage of the fact that tandem arrays of injected fragments become inserted at a single site. In this case such  
30 tandem arrays are not completely redundant but lead to further diversity. Alternatively, the synthetic V segment repertoire may be combined with a D-J-C minilocus to form a heavy chain transgene.

• A synthetic light chain immunoglobulin segment  
35 repertoire may be similarly constructed using appropriate primers for the light chain locus.

Functional Disruption of  
Endogenous Immunoglobulin Loci

The expression of successfully rearranged  
5 immunoglobulin heavy and light transgenes is expected to have a  
dominant effect by suppressing the rearrangement of the  
endogenous immunoglobulin genes in the transgenic nonhuman  
animal. However, another way to generate a nonhuman that is  
devoid of endogenous antibodies is by mutating the endogenous  
10 immunoglobulin loci. Using embryonic stem cell technology and  
homologous recombination, the endogenous immunoglobulin  
repertoire can be readily eliminated. The following describes  
the functional description of the mouse immunoglobulin loci.  
The vectors and methods disclosed, however, can be readily  
15 adapted for use in other non-human animals.

Briefly, this technology involves the inactivation of  
a gene, by homologous recombination, in a pluripotent cell line  
that is capable of differentiating into germ cell tissue. A  
DNA construct that contains an altered, copy of a mouse  
20 immunoglobulin gene is introduced into the nuclei of embryonic  
stem cells. In a portion of the cells, the introduced DNA  
recombines with the endogenous copy of the mouse gene,  
replacing it with the altered copy. Cells containing the newly  
engineered genetic lesion are injected into a host mouse  
25 embryo, which is reimplanted into a recipient female. Some of  
these embryos develop into chimeric mice that possess germ  
cells entirely derived from the mutant cell line. Therefore,  
by breeding the chimeric mice it is possible to obtain a new  
line of mice containing the introduced genetic lesion (reviewed  
30 by Capecchi (1989), Science, 244, 1288-1292).

Because the mouse  $\lambda$  locus contributes to only 5% of  
the immunoglobulins, inactivation of the heavy chain and/or  
 $\kappa$ -light chain loci is sufficient. There are three ways to  
35 disrupt each of these loci, deletion of the J region, deletion  
of the J-C intron enhancer, and disruption of constant region  
coding sequences by the introduction of a stop codon. The last  
option is the most straightforward, in terms of DNA construct  
design. Elimination of the  $\mu$  gene disrupts B-cell maturation  
thereby preventing class switching to any of the functional

heavy chain segments. The strategy for knocking out these loci is outlined below.

To disrupt the mouse  $\mu$  and  $\kappa$  genes, targeting vectors are used based on the design employed by Jaenisch and co-workers (Zijlstra, et al. (1989), Nature, 342, 435-438) for the successful disruption of the mouse  $\beta 2$ -microglobulin gene. The neomycin resistance gene (neo), from the plasmid pMCIneo is inserted into the coding region of the target gene. The pMCIneo insert uses a hybrid viral promoter/enhancer sequence to drive neo expression. This promoter is active in embryonic stem cells. Therefore, neo can be used as a selectable marker for integration of the knock-out construct. The HSV thymidine kinase (tk) gene is added to the end of the construct as a negative selection marker against random insertion events (Zijlstra, et al., supra.).

The targeting vectors for disrupting the heavy chain locus are illustrated in Fig. 7. The primary strategy for disrupting the heavy chain locus is the elimination of the J region. This region is fairly compact in the mouse, spanning only 1.3 kb. To construct a gene targeting vector, a 15 kb KpnI fragment containing all of the secreted A constant region exons from mouse genomic library is isolated. The 1.3 kb J region is replaced with the 1.1 kb insert from pMCIneo. The HSV tk gene is then added to the 5' end of the KpnI fragment. Correct integration of this construct, via homologous recombination, will result in the replacement of the mouse  $J_H$  region with the neo gene (Fig. 7). Recombinants are screened by PCR, using a primer based on the neo gene and a primer homologous to mouse sequences 5' of the KpnI site in the D region.

Alternatively, the heavy-chain locus is knocked out by disrupting the coding region of the  $\mu$  gene. This approach involves the same 15 kb KpnI fragment used in the previous approach. The 1.1 kb insert from pMCIneo is inserted at a unique BamHI site in exon II, and the HSV tk gene added to the 3' KpnI end. Double crossover events on either side of the neo insert, that eliminate the tk gene, are then selected for. These are detected from pools of selected clones by PCR

amplification. One of the PCR primers is derived from neo sequences and the other from mouse sequences outside of the targeting vector. The functional disruption of the mouse immunoglobulin loci is presented in the Examples.

5

Transgenic Non-Human Animals Containing Rearranged  
Immunoglobulin Heavy and Light Transgenes

A premise underlying the previously discussed  
10 transgenic animals containing unrearranged mini-locus Ig  
transgenes is that it is possible to generate a complete  
antibody repertoire without including all of the variable gene  
segments found in the natural immunoglobulin locus.  
Theoretically, it is possible to reduce the number of different  
15 sequences that contribute to the primary repertoire without  
reducing the secondary repertoire. As long as there is enough  
diversity in the primary repertoire to trigger a T-cell  
dependent response for any given antigen, somatic hypermutation  
should be capable of delivering a high affinity antibody  
20 against that antigen.

This concept is taken a step further in this aspect of  
the invention wherein a full heterologous antibody repertoire  
is generated entirely by somatic mutation. The antigen  
combining site is created by the interface between the  
25 amino-terminal heavy chain domain and the amino-terminal light  
chain domain. The CDR1, 2 and 3 residues within each of these  
domains that interact with the antigen are located on three  
different loops that connect  $\beta$  strands. As previously  
described, these regions have the greatest sequence diversity  
30 between different antibody molecules recognizing different  
antigens. Thus, the antibody repertoire is determined by  
sequence diversity at CDR1, 2, and 3. The diversity at CDR1, 2,  
and 3 that gives rise to a complete antibody repertoire comes  
from three sources: recombinational diversity, junctional  
35 diversity, and somatic mutation. Recombinational diversity at  
CDR1 and 2 comes from the choice of different V segments  
containing different CDR1 and 2 sequences. Recombinational  
diversity at CDR 3 comes from the choice of different D and J  
segments. Junctional diversity contributes only to CDR3

diversity, while somatic mutation, acting across the entire V region, contributes to diversity at all three complementarity determining regions. Recombinational and junctional diversity together constitute the diversity of the primary repertoire (Fig. 1). Thus VDJ joining generates a set of IgM expressing primary B-cells.

Any primary repertoire B-cell that expresses a cell surface IgM molecule with a certain minimal affinity for a foreign antigen, internalizes that antigen as IgM and cycle off the cell surface. The antigen is then processed and associated peptides are presented on the cell surface by class II MHC molecules. If enough foreign antigen is presented at the cell surface this, triggers a T-cell response that in turn triggers the T-cell dependent maturation of the B-cell. This is the so-called secondary response (Fig. 8). Part of this response involves the hypermutation of the variable portion of the immunoglobulin genes. Thus a B-cell clone undergoing a secondary response constantly gives rise to new clones with altered immunoglobulin molecules. Those clones with higher affinities for the foreign antigen are selectively expanded by helper T-cells, giving rise to affinity maturation of the expressed antibody. Because somatic hypermutation takes place across the entire V region, there is no theoretical limit to the process of affinity maturation.

In this aspect of the invention, CDR1 and 2 diversity is not necessary for generating a complete antibody response. Rather, diversity at CDR3, created by VJ and VDJ joining provides sufficient minimal affinity to trigger the T-cell dependent maturation to give rise to high affinity antibodies for a large number of different antigens. Thus, methods and transgenic animals are provided for generating a broad antibody repertoire without primary diversity. Such diversity relies on somatic mutation for the generation of antibody diversity. During the process of affinity maturation, somatic mutation gives rise to a large number of clones with lower, rather than higher, affinities for the stimulating antigen. Most of these clones are not selected for and die off. However, if one of these clones has affinity for a new antigen that is also

present, this clone expands and undergoes affinity maturation for the new antigen (Fig. 9). In this aspect of the invention, a transgenic non-human animal, such as a mouse, with rearranged human heavy and light chains combine to form an antibody that  
5 has a low affinity for a known antigen. If this animal is injected with the known antigen, its B-cells undergo a secondary response leading to the production of high affinity antibodies for that antigen. However, if this mouse is first injected with a mixture of the known antigen and a new antigen,  
10 and then subsequently challenged with the new antigen alone, high affinity antibodies against the new antigen are produced by the branching process described above. This approach has two major advantages: first the transgene constructs are easy to generate; and second, the rearranged transgenes are capable  
15 of allelicly and isotypically excluding the rearrangement of the endogenous mouse genes, thus making it unnecessary to eliminate those genes by homologous recombination as previously described.

The first step in this embodiment of the invention is  
20 the isolation of rearranged heavy and light chain genes from a human hybridoma that expresses an IgM antibody directed against a known antigen. The ideal hybridoma recognizes a readily available antigen that is capable of generating a good mouse T-cell response. There are a number of such human hybridomas  
25 in existence, including several that react with promising antigens such as tetanus toxoid, pseudomonas, or gram negative bacteria (reviewed by James and Bourla (1987), J. Immunol. Methods., 100, 5-40). The entire rearranged heavy chain gene is isolated on a single piece of DNA (approximately 20 kb)  
30 while the rearranged  $\kappa$  light chain gene, including the 3' enhancer, is isolated on a second DNA fragment (about 20 kb). Each of these fragments are pieced together from clones isolated from a phage  $\lambda$  library made from DNA isolated from the hybridoma. Two constructs are generated, a heavy chain  
35 construct and a light chain construct.

The heavy chain construct (Fig. 10) consists of the 20 kb hybridoma fragment, containing the rearranged IgM gene, ligated to a 25 kb fragment that contains the human  $\gamma 3$  and  $\gamma 1$

constant regions followed by a 700 bp fragment containing the rat heavy chain 3' enhancer (Pettersson, et al. (1990), Nature, 344, 165-168). The light chain construct consists of the intact 20 kb piece of DNA containing the rearranged  $\kappa$  chain and 3' enhancer. These two constructs are coinjected so that they are integrated at a single site in the mouse genome. Transgenic mice are tested by Northern blot analysis for expression of the transgene mRNA. FACS analysis is then carried-out on tail blood samples to detect cell surface expression of the transgene encoded protein. Mice are then immunized with the antigen recognized by the original hybridoma. ELISA and FACS analysis are carried out on tail blood to detect class switching. Finally, the mice are tested for their ability to respond to a number of different antigens by co-injecting a panel of antigens together with the original antigen. Tail blood are analyzed by ELISA to detect the production of high affinity human IgG antibodies directed against individual antigens.

To use this transgenic mouse to generate human antibodies directed against a given antigen, that antigen preferably is first coinjected together with the antigen associated with the hybridoma from which the genes were isolated. This hybridoma associated antigen is referred to as the co-antigen (sometimes as a second antigen), and the new antigen simply as the antigen (or first antigen). If possible, the second antigen is chemically cross-linked to the first antigen prior to injection. This causes the first antigen to be internalized and presented by the primary transgene presenting B-cells, thus ensuring the existence of a pool of activated helper T-cells that recognize the first antigen. A typical immunization schedule is as follows. Day 1: Mice are injected ip with first antigen mixed with, or cross-linked to, second antigen in complete Freund's adjuvant. Day 14: first antigen (without second antigen) is injected ip in incomplete Freund's adjuvant. Day 35: repeat injection with first antigen in incomplete Freund's. Day 45: Test for antibody response by ELISA on tail blood samples. Day 56: repeat injection of good

responders with antigen in incomplete Freund's. Day 59: Fuse spleens of good responders.

In an alternate aspect of this invention, the antigen recognized by the hybridoma from which the Ig genes were isolated, is used as an immunogen. New transgenic hybridomas are then isolated from the immunized animal that express somatically mutated versions of the original antibody. These new antibodies will have a higher affinity for the original antigen. This antibody "sharpening" procedure can also be applied to antibody genes generated by CDR grafting (E.P. Pub. No. 239400, published Sept. 30, 1987) or isolated from bacterial (W.D. Huse et al. (1989) Science, 246, 1275) or phage (T. Clackson et al. (1991) Nature, 352, 624) expression libraries.

15

Transgenic Non-Human Animals Containing  
Rearranged and Unrearranged Immunoglobulin  
Heavy and/or Light Transgene

The previous embodiments described the use of fully rearranged or fully unrearranged heavy and light immunoglobulin transgenes to produce transgenic non-human animals capable of producing a heterologous antibody. In a further aspect of the invention, transgenic animals contain at least one rearranged and at least one unrearranged immunoglobulin transgene are produced by utilizing any of the aforementioned unrearranged and rearranged transgenes in combination to provide heavy and light transgenes in the transgenic animal. In this regard, the unrearranged transgene may comprise a heavy or light genomic or mini-locus transgene construct with the rearranged transgene comprising an appropriate rearranged transgene. For example, if a unrearranged mini-locus light chain transgene is used, the appropriate other transgene is a fully rearranged heavy chain transgene. It is preferred, however, that the rearranged transgene comprise a rearranged immunoglobulin light chain transgene and that the unrearranged transgene comprise an immunoglobulin heavy chain genomic or mini-locus transgene, most preferably an unrearranged heavy chain transgene with associated A and y constant regions.

The combination of rearranged and unrearranged transgene provides an intermediate level of diversity within the primary repertoire B-cells. Thus, although primary diversity at CD1, CD2 and CD3 in the rearranged transgene is fixed in the primary repertoire B-cell, the primary diversity at the CDR1, CDR2 and CDR3 produced by the rearrangement of the unrearranged transgene provides a population of primary repertoire of B-cells having greater potential diversity than the B-cell clone obtained when rearranged heavy and light transgenes are used. Such primary diversity provides broadened secondary diversity when such cells respond to foreign antigen by way of somatic mutation.

#### Nucleic Acids

The nucleic acids, the term "substantial homology" indicates that two nucleic acids, or designated sequences thereof, when optimally aligned and compared, are identical, with appropriate nucleotide insertions or deletions, in at least about 80% of the nucleotides, usually at least about 90% to 95%, and more preferably at least about 98 to 99.5% of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to the complement of the strand. The nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form. A nucleic acid is "isolated" or "rendered substantially pure" when purified away from other cellular components or other contaminants, e.g., other cellular nucleic acids or proteins, by standard techniques, including alkaline/SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis and others well known in the art. See, F. Ausubel, et al., ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley-Interscience, New York (1987).

The nucleic acid compositions of the present invention, while often in a native sequence (except for modified restriction sites and the like), from either cDNA, genomic or mixtures may be mutated, thereof in accordance with standard techniques to provide gene sequences. For coding

sequences, these mutations, may affect amino acid sequence as desired. In particular, DNA sequences substantially homologous to or derived from native V, D, J, constant, switches and other such sequences described herein are contemplated (where  
5 "derived" indicates that a sequence is identical or modified from another sequence).

A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably  
10 linked to a coding sequence if it affects the transcription of the sequence. With respect to transcription regulatory sequences, operably linked means that the DNA sequences being linked are contiguous and, where necessary to join two protein  
coding regions, contiguous and in reading frame. For switch  
15 sequences, operably linked indicates that the sequences are capable of effecting switch recombination.

#### Specific Preferred Embodiments

A preferred embodiment of the invention is an animal  
20 containing a single copy of the transgene described in Example 14 (pHC2) bred with an animal containing a single copy of the transgene described in Example 16, and the offspring bred with the JH deleted animal described in Examples 9 and 12. Animals are bred to homozygosity for each of these three traits. Such  
25 animals have the following genotype: a single copy (per haploid set of chromosomes) of a human heavy chain unrearranged mini-locus (described in Example 14), a single copy (per haploid set of chromosomes) of a rearranged human  $\kappa$  light chain construct (described in Example 16), and a deletion at each  
30 endogenous mouse heavy chain locus that removes all of the functional JH segments (described in Examples 9 and 12). Such animals are bred with mice that are homozygous for the deletion of the JH segments (Examples 9 and 12) to produce offspring that are homozygous for the JH deletion and hemizygous for the  
35 human heavy and light chain constructs. The resultant animals are injected with antigens and used for production of human monoclonal antibodies against these antigens.

B cells isolated from such an animal are monospecific with regards to the human heavy and light chains because they contain only a single copy of each gene. Furthermore, they will be monospecific with regards to human or mouse heavy chains because both endogenous mouse heavy chain gene copies are nonfunctional by virtue of the deletion spanning the JH region introduced as described in Example 9 and 12. Furthermore, a substantial fraction of the B cells will be monospecific with regards to the human or mouse light chains because expression of the single copy of the rearranged human  $\kappa$  light chain gene will allelically and isotypically exclude the rearrangement of the endogenous mouse  $\kappa$  and lambda chain genes in a significant fraction of B-cells.

The transgenic mouse of the preferred embodiment will exhibit immunoglobulin production with a significant repertoire, ideally substantially similar to that of a native mouse. Thus, for example, when the endogenous Ig genes have been inactivated, the total immunoglobulin levels will range from about 0.1 to 10 mg/ml of serum, preferably 0.5 to 5 mg/ml, ideally at least about 1.0 mg/ml. When a transgene capable of effecting a switch to IgG from IgM has been introduced into the transgenic mouse, the adult mouse ratio of serum IgG to IgM is preferably about 10:1. Of course, the IgG to IgM ratio will be much lower in the immature mouse. In general, greater than about 10%, preferably 40 to 80% of the spleen and lymph node B cells express exclusively human IgG protein.

The repertoire will ideally approximate that shown in a non-transgenic mouse, usually at least about 10% as high, preferably 25 to 50% or more. Generally, at least about a thousand different immunoglobulins (ideally IgG), preferably  $10^4$  to  $10^6$  or more, will be produced, depending primarily on the number of different V, J and D regions introduced into the mouse genome. These immunoglobulins will typically recognize about one-half or more of highly antigenic proteins, including, but not limited to: pigeon cytochrome C, chicken lysozyme, pokeweed mitogen, bovine serum albumin, keyhole limpet hemocyanin, influenza hemagglutinin, staphylococcus protein A, sperm whale myoglobin, influenza neuraminidase, and lambda

repressor protein. Some of the immunoglobulins will exhibit an affinity for preselected antigens of at least about  $10^{-7}M^{-1}$ , preferably  $10^{-8}M^{-1}$  to  $10^{-9}M^{-1}$  or greater.

Although the foregoing describes a preferred embodiment of the transgenic animal of the invention, other embodiments are defined by the disclosure herein and more particularly by the transgenes described in the Examples. Four categories of transgenic animal may be defined:

- I. Transgenic animals containing an unrearranged heavy and rearranged light immunoglobulin transgene.
- II. Transgenic animals containing an unrearranged heavy and unrearranged light immunoglobulin transgene
- III. Transgenic animal containing rearranged heavy and an unrearranged light immunoglobulin transgene, and
- IV. Transgenic animals containing rearranged heavy and rearranged light immunoglobulin transgenes.

Of these categories of transgenic animal, the preferred order of preference is as follows I > II > III > IV.

Within each of these categories of the transgenic animal, a number of possible combinations are preferred. Such preferred embodiments comprise the following:

#### Category I

- (a) Example 1 and 2 or 19 and 20 animal bred with Example 7 or 16 animal.
- (b) Example 1 or 19 fragment coinjected with Example 7 or 16 fragment.
- (c) Example 5 (H, I or J) or 14, 17 or 21 animal bred with Example 7 or 16 animal.
- (d) Example 5(H) or 14 construct coinjected with Example 7 or 16 construct.
- (e) All of the above bred with the animal of Example 9 or 11, 12 or 13. Particularly preferred embodiments are all of the above bred the with animal of Example 9 or 12 or 13.

Category II

- (a) Example 1, 2, 19 or 20 animal bred with Example 6, 3, 4, 16, 22 or 23 animal.
- (b) Fragment in Example 1 or 19 coinjected with  
5 fragment in Example 2 or 20.
- (c) Example 5 (H, I or J) or 14, 17 or 21 animal bred with Example 6(B, C or D) or 16 animal.
- (d) Construct 5(H) or 14 coinjected with construct 6(B) or 16.
- 10 (e) Animal of Example 1, 2, 19 or 20 bred with animal of Example 6(B, C or D) or 16.
- (f) Animal of Example 3, 4, 22 or 23 bred with animal of Example 5(H, I or J) or 14, 17 or 21.
- (g) All of the above bred with animal of Example 9,  
15 10, 11, 12 or 13.

Category III

- (a) Example 3, 4, 22 or 23 animal bred with Example 8 or 15 animal.
- 20 (b) Example 3 or 23 fragment coinjected with Example 8 or 15 fragment.
- (c) Example 6(B, C or D) or 16 animal bred with Example 8 or 15 animal.
- (d) Example 6(B) or 15 construct coinjected with  
25 Example 8 or 15 construct.
- (e) All of the above bred with animal of Example 9 to 13.

Category IV

- 30 (a) Animal of Example 7 or 16, bred with animal of Example 8 or 15.
- (b) Construct of Example 7 or 16 coinjected with construct of Example 8 or 15.
- (c) All of the above bred with animal of Example 9 to  
35 13.

The following is presented by way of example and is not to be construed as a limitation to the scope of the claims.

## METHODS AND MATERIALS

Transgenic mice are derived according to Hogan, et al., "Manipulating the Mouse Embryo: A Laboratory Manual",  
5 Cold Spring Harbor Laboratory.

Embryonic stem cells are manipulated according to published procedures (Teratocarcinomas and embryonic stem cells: a practical approach, E.J. Robertson, ed., IRL Press, Washington, D.C., 1987; Zijlstra, et al. (1989), Nature, 342,  
10 435-438; and Schwartzberg, P., et al. (1989), Science, 246, 799-803).

DNA cloning procedures are carried out according to J. Sambrook, et al. in Molecular Cloning: A Laboratory Manual, 2d ed., 1989, Cold Spring Harbor Laboratory Press, Cold Spring  
15 Harbor, N.Y.

Oligonucleotides are synthesized on an Applied Bio Systems oligonucleotide synthesizer according to specifications provided by the manufacturer.

Hybridoma cells and antibodies are manipulated  
20 according to "Antibodies: A Laboratory Manual", Ed Harlow and David Lane, Cold Spring Harbor Laboratory (1988).

### EXAMPLE 1

#### Genomic Heavy Chain Human Ig Transgene

25 This Example describes the cloning and microinjection of a human genomic heavy chain immunoglobulin transgene which is microinjected into a murine zygote.

Nuclei are isolated from fresh human placental tissue as described by Marzluff, W.F., et al. (1985), "Transcription and Translation: A Practical Approach", B.D. Hammes and  
30 S.J. Higgins, eds., pp. 89-129, IRL Press, Oxford). The isolated nuclei (or PBS washed human spermatocytes) are embedded in a low melting point agarose matrix and lysed with EDTA and proteinase K to expose high molecular weight DNA,  
35 which is then digested in the agarose with the restriction enzyme NotI as described by M. Finney in Current Protocols in Molecular Biology (F. Ausubel, et al., eds. John Wiley & Sons, Supp. 4, 1988, Section 2.5.1).

The NotI digested DNA is then fractionated by pulsed field gel electrophoresis as described by Anand, R., et al. (1989), Nucl. Acids Res., 17, 3425-3433. Fractions enriched for the NotI fragment are assayed by Southern hybridization to detect one or more of the sequences encoded by this fragment. Such sequences include the heavy chain D segments, J segments,  $\mu$  and  $\gamma 1$  constant regions together with representatives of all 6 VH families (although this fragment is identified as 670 kb fragment from HeLa cells by Berman, et al. (1988), supra., we have found it to be as 830 kb fragment from human placental an sperm DNA). Those fractions containing this NotI fragment (see Fig. 4) are pooled and cloned into the NotI site of the vector pYACNN in Yeast cells. Plasmid pYACNN is prepared by digestion of pYAC-4 Neo (Cook, H., et al. (1988), Nucleic Acids Res., 16, 11817) with EcoRI and ligation in the presence of the oligonucleotide 5' - AAT TGC GGC CGC - 3'.

YAC clones containing the heavy chain NotI fragment are isolated as described by Brownstein, et al. (1989), Science, 244, 1348-1351, and Green, E., et al. (1990), Proc. Natl. Acad. Sci. USA, 87, 1213-1217. The cloned NotI insert is isolated from high molecular weight yeast DNA by pulse field gel electrophoresis as described by M. Finney, opcit. The DNA is condensed by the addition of 1 mM spermine and microinjected directly into the nucleus of single cell embryos previously described.

## EXAMPLE 2

### Discontinuous Genomic Heavy Chain Ig Transgene

A 110 kb SpeI fragment of human genomic DNA containing VH6, D segments, J segments, the  $\mu$  constant region and part of the  $\gamma$  constant region (see Fig. 4) is isolated by YAC cloning as described in Example 1.

A 570 kb NotI fragment upstream of the 670-830 kb NotI fragment described above containing multiple copies of VI through V5 is isolated as described. (Berman, et al. (1988), supra detected two 570 kb NotI fragments. Each of those contain multiple V segments.)

The two fragments are coinjected into the nucleus of a mouse single cell embryo as described in Example 1.

Coinjection of two different DNA fragments will usually result in the integration of both fragments at the same insertion site within the chromosome. Therefore, approximately 50% of the resulting transgenic animals that contain at least one copy of each of the two fragments will have the V segment fragment inserted upstream of the constant region containing fragment. Of these animals, 50% will carry out V to DJ joining by DNA inversion and 50% by deletion, depending on the orientation of the 570 kb NotI fragment relative to the position of the 110 kb SpeI fragment. DNA is isolated from resultant transgenic animals and those animals found to be containing both transgenes by Southern blot hybridization (specifically, those animals containing both multiple human V segments and human constant region genes) are tested for their ability to express human immunoglobulin molecules.

### EXAMPLE 3

#### 20        Genomic $\kappa$ Light Chain Human Ig Transgene Formed by In Vivo Homologous Recombination

A map of the human  $\kappa$  light chain has been described in Lorenz, W., et al. (1987), Nucl. Acids Res., 15, 9667-9677 and is depicted in Fig. 11.

A 450 kb XhoI to NotI fragment that includes all of Ck, the 3' enhancer, all J segments, and at least five different V segments (a) is isolated and microinjected into the nucleus of single cell embryos as described in Example 1.

### EXAMPLE 4

#### 35        Genomic $\kappa$ Light Chain Human Ig Transgene Formed by In Vivo Homologous Recombination

A 750 kb MluI to NotI fragment that includes all of the above plus at least 20 more V segments (b) is isolated as described in Example 1 (see Fig. 11) and digested with BssHII to produce a fragment of about 400 kb (c) .

40        The 450 kb XhoI to NotI fragment (a) plus the approximately 400 kb MluI to BssHII fragment (c) have sequence

overlap defined by the BssHII and XhoI restriction sites shown in Fig. 11. Homologous recombination of these two fragments upon microinjection of a mouse zygote results in a transgene containing at least an additional 15-20 V segments over that found in the 450 kb XhoI/NotI fragment (Example 3).

#### EXAMPLE 5

##### Construction of Heavy Chain Mini-Locus

##### A. Construction of pGP1 and pGP2

pBR322 is digested with EcoRI and StyI and ligated with the following oligonucleotides to generate pGP1 which contains a 147 base pair insert containing the restriction sites shown in Fig. 13. The general overlapping of these oligos is also shown in Fig. 13.

The oligonucleotides are:

oligo-1 5' - CTT GAG CCC GCC TAA TGA GCG GGC TTT  
TTT TTG CAT ACT GCG GCC - 3'

oligo-2 5' - GCA ATG GCC TGG ATC CAT GGC GCG CTA  
GCA TCG ATA TCT AGA GCT CGA GCA -3'

oligo-3 5' - TGC AGA TCT GAA TTC CCG GGT ACC AAG  
CTT ACG CGT ACT AGT GCG GCC GCT -3'

oligo-4 5' - AAT TAG CGG CCG CAC TAG TAC GCG TAA  
GCT TGG TAC CCG GGA ATT - 3'

oligo-5 5' - CAG ATC TGC ATG CTC GAG CTC TAG ATA  
TCG ATG CTA GCG CGC CAT GGA TCC - 3'

oligo-6 5' - AGG CCA TTG CGG CCG CAG TAT GCA AAA  
AAA AGC CCG CTC ATT AGG CGG GCT - 3'

This plasmid contains a large polylinker flanked by rare cutting NotI sites for building large inserts that can be isolated from vector sequences for microinjection. The plasmid is based on pBR322 which is relatively low copy compared to the pUC based plasmids (pGP1 retains the pBR322 copy number control region near the origin of replication). Low copy number reduces the potential toxicity of insert sequences. In addition, pGP1 contains a strong transcription terminator sequence derived from trpA (Christie, G.E., et al. (1981), Proc. Natl. Acad. Sci. USA) inserted between the ampicillin

resistance gene and the polylinker. This further reduces the toxicity associated with certain inserts by preventing readthrough transcription coming from the ampicillin promoters.

Plasmid pGP2 is derived from pGP1 to introduce an additional restriction site (SfiI) in the polylinker. pGP1 is digested with MluI and SpeI to cut the recognition sequences in the polylinker portion of the plasmid.

The following adapter oligonucleotides are ligated to the thus digested pGP1 to form pGP2.

5' CGC GTG GCC GCA ATG GCC A 3'  
5' CTA GTG GCC ATT GCG GCC A 3'

pGP2 is identical to pGP1 except that it contains an additional Sfi I site located between the MluI and SpeI sites. This allows inserts to be completely excised with SfiI as well as with NotI.

#### B. Construction of pRE3 (rat enhancer 3')

An enhancer sequence located downstream of the rat constant region is included in the heavy chain constructs.

The heavy chain region 3' enhancer described by S. Pettersson, et al. (1990), Nature, 344, 165-168) is isolated and cloned. The rat IGH 3' enhancer sequence is PCR amplified by using the following oligonucleotides:

5' CAG GAT CCA GAT ATC AGT ACC TGA AAC AGG GCT TGC 3'  
5' GAG CAT GCA CAG GAC CTG GAG CAC ACA CAG CCT TCC 3'

The thus formed double stranded DNA encoding the 3' enhancer is cut with BamHI and SphI and clone into BamHI/SphI cut pGP2 to yield pRE3 (rat enhancer 3').

#### C. Cloning of Human J- $\mu$ Region

A substantial portion of this region is cloned by combining two or more fragments isolated from phage lambda inserts. See Fig. 14.

A 6.3 kb BamHI/HindIII fragment that includes all human J segments (Matsuda, et al. (1988), EMBO J., 7, 1047--1051; Ravetech, et al. (1981), Cell, 27, 583-591) is isolated

from human genomic DNA library using the oligonucleotide GGA  
'CTG TGT CCC TGT GTG ATG CTT TTG ATG TCT GGG GCC AAG.

An adjacent 10 kb HindIII/BamII fragment that contains  
enhancer, switch and constant region coding exons (Yasui, et  
5 al. (1989), Eur. J. Immunol., 19, 1399-1403) is similarly  
isolated using the oligonucleotide:

CAC CAA GTT GAC CTG CCT GGT CAC AGA CCT GAC CAC CTA TGA

An adjacent 3' 1.5 kb BamHI fragment is similarly  
isolated using clone pMUM insert as probe (pMUM is 4 kb  
10 EcoRI/HindIII fragment isolated from human genomic DNA library  
with oligonucleotide:

CCT GTG GAC CAC CGC CTC CAC CTT CAT

CGT CCT CTT CCT CCT

mu membrane exon 1) and cloned into pUC19.

15 pGP1 is digested with BamHI and BglII followed by  
treatment with calf intestinal alkaline phosphatase.

Fragments (a) and (b) from Fig. 14 are cloned in the  
digested pGP1. A clone is then isolated which is oriented such  
that 5' BamHI site is destroyed by BamHI/Bgl fusion. It is  
20 identified as pMU (see Fig. 15). pMU is digested with BamHI  
and fragment (c) from Fig. 14 is inserted. The orientation is  
checked with HindIII digest. The resultant plasmid pHIG1 (Fig.  
15) contains an 18 kb insert encoding J and C $\mu$  segments.

#### 25 D. Cloning of C $\mu$ Region

pGP1 is digested with BamHI and HindIII is followed by  
treatment with calf intestinal alkaline phosphatase (Fig. 14).  
The so treated fragment (b) of Fig. 14 and fragment (c) of Fig.  
14 are cloned into the BamHI/HindIII cut pGP1. Proper  
30 orientation of fragment (c) is checked by HindIII digestion to  
form pCON1 containing a 12 kb insert encoding the C $\mu$  region.

Whereas pHIG1 contains J segments, switch and  $\mu$   
sequences in its 18 kb insert with an SfiI 3' site and a SpeI  
5' site in a polylinker flanked by NotI sites, will be used for  
35 rearranged VDJ segments. pCON1 is identical except that it  
lacks the J region and contains only a 12 kb insert. The use  
of pCON1 in the construction of fragment containing rearranged  
VDJ segments will be described hereinafter.

#### E. Cloning of $\gamma$ -1 Constant Region (pREG2)

The cloning of the human  $\gamma$ -1 region is depicted in Fig. 16.

5 Yamamura, et al. (1986), Proc. Natl. Acad. Sci. USA,  
83, 2152-2156 reported the expression of membrane bound human  
 $\gamma$ -1 from a transgene construct that had been partially deleted  
on integration. Their results indicate that the 3' BamHI site  
delineates a sequence that includes the transmembrane  
10 rearranged and switched copy of the gamma gene with a V-C  
intron of less than 5kb. Therefore, in the unrearranged,  
unswitched gene, the entire switch region is included in a  
sequence beginning less than 5 kb from the 5' end of the first  
 $\gamma$ -1 constant exon. Therefore it is included in the 5' 5.3 kb  
15 HindIII fragment (Ellison, J.W., et al. (1982), Nucleic Acids  
Res., 10, 4071-4079). Takahashi, et al. (1982), Cell, 29,  
671-679 also reports that this fragment contains the switch  
sequence, and this fragment together with the 7.7 kb HindIII to  
BamHI fragment must include all of the sequences we need for  
20 the transgene construct.

Phage clones containing the  $\gamma$ -1 region are identified  
and isolated using the following oligonucleotide which is  
specific for the third exon of  $\gamma$ -I (CH3).

25 5' TGA GCC ACG AAG ACC CTG AGG  
TCA AGT TCA ACT GGT ACG TGG 3'

A 7.7 kb HindIII to BglII fragment (fragment (a) in  
Fig. 16) is cloned into HindIII/BglII cut pRE3 to form pREG1.  
The upstream 5.3 kb HindIII fragment (fragment (b) in Fig. 16)  
is cloned into HindIII digested pREG1 to form pREG2. Correct  
30 orientation is confirmed by BamHI/SpeI digestion.

#### F. Combining C $\gamma$ and C $\mu$

The previously described plasmid pHIG1 contains human  
J segments and the C $\mu$  constant region exons. To provide a  
35 transgene containing the C $\mu$  constant region gene segments,  
pHIG1 was digested with SfiI (Fig. 15). The plasmid pREG2 was  
also digested with SfiI to produce a 13.5 kb insert containing  
human C $\gamma$  exons and the rat 3' enhancer sequence. These  
sequences were combined to produce the plasmid pHIG3' (Fig. 17)

containing the human J segments, the human C $\mu$  constant region, the human C $\gamma$ 1 constant region and the rat 3' enhancer contained on a 31.5 kb insert.

A second plasmid encoding human C $\mu$  and human C $\gamma$ 1 without J segments is constructed by digesting pCON1 with SfiI and combining that with the SfiI fragment containing the human C $\gamma$  region and the rat 3' enhancer by digesting pREG2 with SfiI. The resultant plasmid, pCON (Fig. 17) contains a 26 kb NotI/SpeI insert containing human C $\mu$ , human  $\gamma$ 1 and the rat 3' enhancer sequence.

#### G. Cloning of D Segment

The strategy for cloning the human D segments is depicted in Fig. 18. Phage clones from the human genomic library containing D segments are identified and isolated using probes specific for diversity region sequences (Y. Ichihara, et al. (1988), EMBO J., 7, 4141-4150). The following oligonucleotides are used:

DXP1: 5' - TGG TAT TAC TAT GGT TCG GGG AGT TAT TAT  
AAC CAC AGT GTC - 3'

DXP4: 5' - GCC TGA AAT GGA GCC TCA GGG CAC AGT GGG  
CAC GGA CAC TGT - 3'

DN4: 5' - GCA GGG AGG ACA TGT TTA GGA TCT GAG GCC  
GCA CCT GAC ACC - 3'

A 5.2 kb XhoI fragment (fragment (b) in Fig. 18) containing DLR1, DXP1, DXP'1, and DA1 is isolated from a phage clone identified with oligo DXP1.

A 3.2 kb XbaI fragment (fragment (c) in Fig. 18) containing DXP4, DA4 and DK4 is isolated from a phage clone identified with oligo DXP4.

Fragments (b), (c) and (d) from Fig. 18 are combined and cloned into the XbaI/XhoI site of pGP1 to form pHIG2 which contains a 10.6 kb insert.

This cloning is performed sequentially. First, the 5.2 kb fragment (b) in Fig. 18 and the 2.2 kb fragment (d) of Fig. 18 are treated with calf intestinal alkaline phosphatase and cloned into pGP1 digested with XhoI and XbaI. The resultant clones are screened with the 5.2 and 2.2 kb insert. Half of those clones testing positive with the 5.2 and 2.2 kb inserts have the 5.2 kb insert in the proper orientation as determined by BamHI digestion. The 3.2 kb XbaI fragment from Fig. 18 is then cloned into this intermediate plasmid containing fragments (b) and (d) to form pHIG2 (Fig. 9). This plasmid contains diversity segments cloned into the polylinker with a unique 5' SfiI site and unique 3' SpeI site. The entire polylinker is flanked by NotI sites.

#### 15 H. Construction of Heavy Chain Minilocus

The following describes the construction of a human heavy chain mini-locus which contain one or more V segments.

An unrearranged V segment corresponding to that identified as the V segment contained in the hybridoma of Newkirk, et al. (1988), J. Clin. Invest., 81, 1511-1518, is isolated using the following oligonucleotide:

5' - GAT CCT GGT TTA GTT AAA GAG GAT TTT  
ATT CAC CCC TGT GTC - 3'

A restriction map of the unrearranged V segment is determined to identify unique restriction sites which provide upon digestion a DNA fragment having a length approximately 2 kb containing the unrearranged V segment together with 5' and 3' flanking sequences. The 5' prime sequences will include promoter and other regulatory sequences whereas the 3' flanking sequence provides recombination sequences necessary for V-DJ

joining. This approximately 3.0 kb V segment insert is cloned into the polylinker of pGB2 to form pVH1.

pVH1 is digested with SfiI and the resultant fragment is cloned into the SfiI site of pHIG2 to form a pHIG5'. Since  
5 pHIG2 contains D segments only, the resultant pHIG5' plasmid contains a single V segment together with D segments. The size of the insert contained in pHIG5 is 10.6 kb plus the size of the V segment insert.

The insert from pHIG5 is excised by digestion with  
10 NotI and SpeI and isolated. pHIG3' which contains J, C $\mu$  and C $\gamma$ 1 segments is digested with SpeI and NotI and the 3' kb fragment containing such sequences and the rat 3' enhancer sequence is isolated. These two fragments are combined and ligated into NotI digested pGP1 to produce pHIG which contains  
15 insert encoding a V segment, nine D segments, six functional J segments, C $\mu$ , C $\gamma$  and the rat 3' enhancer. The size of this insert is approximately 43 kb plus the size of the V segment insert.

20 I. Construction of Heavy Chain Minilocus by Homologous Recombination

As indicated in the previous section, the insert of pHIG is approximately 43 to 45 kb when a single V segment is  
25 employed. This insert size is at or near the limit of that which may be readily cloned into plasmid vectors. In order to provide for the use of a greater number of V segments, the following describes in vivo homologous recombination of overlapping DNA fragments which upon homologous recombination  
30 within a zygote or ES cell form a transgene containing the rat 3' enhancer sequence, the human C $\mu$ , the human C $\gamma$ 1, human J segments, human D segments and a multiplicity of human V segments.

A 6.3 kb BamHI/HindIII fragment containing human J  
35 segments (see fragment (a) in Fig. 14) is cloned into MluI/SpeI digested pHIG5' using the following adapters:

5' GAT CCA AGC AGT 3'

5' CTA GAC TGC TTG 3'

5' CGC GTC GAA CTA 3'

5' AGC TTA GTT CGA 3'

The resultant is plasmid designated pHIG5'O (overlap).

5 The insert contained in this plasmid contains human V, D and J segments. When the single V segment from pVH1 is used, the size of this insert is approximately 17 kb plus 2 kb. This insert is isolated and combined with the insert from pHIG3' which contains the human J, C $\mu$ ,  $\gamma$ 1 and rat 3' enhancer  
10 sequences. Both inserts contain human J segments which provide for approximately 6.3 kb of overlap between the two DNA fragments. When coinjected into the mouse zygote, in vivo homologous recombination occurs generating a transgene equivalent to the insert contained in pHIG.

15 This approach provides for the addition of a multiplicity of V segments into the transgene formed in vivo. For example, instead of incorporating a single V segment into pHIG5', a multiplicity of V segments contained on (1) isolated genomic DNA, (2) ligated DNA derived from genomic DNA, or (3)  
20 DNA encoding a synthetic V segment repertoire is cloned into pHIG2 at the SfiI site to generate pHIG5' V<sub>N</sub>. The J segments fragment (a) of Fig. 14 is then cloned into pHIG5' V<sub>N</sub> and the insert isolated. This insert now contains a multiplicity of V segments and J segments which overlap with the J segments  
25 contained on the insert isolated from pHIG3'. When reintroduced into the nucleus of a mouse zygote, homologous recombination occurs to generate in vivo the transgene encoding multiple V segments and multiple J segments, multiple D segments, the C $\mu$  region, the  $\gamma$ 1 region (all from human) and  
30 the rat 3' enhancer sequence.

J. Construction of Heavy Chain Mini-Locus by  
Coinjection of Synthetic VH Region Fragment  
Together with Heavy Chain DJC Construct

35 Synthetic V<sub>H</sub> region fragments are generated and isolated as previously described. These fragments are coinjected with the purified NotI insert of plasmid pHIG (or a version of pHIG that does not contain any V segments). The  
40 coinjected DNA fragments are inserted into a single site in the chromosome. Some of the resulting transgenic animals will

contain transgene inserts that have synthetic V regions located adjacent and upstream of the sequences in the pHIG construct. These animals will have a larger human heavy chain primary repertoire than the animals described in Example 5(H).

5

#### EXAMPLE 6

##### Construction of Light Chain Minilocus

###### 10 A. Construction of pE $\mu$ 1

The construction of pE $\mu$ 1 is depicted in Fig. 21. The mouse heavy chain enhancer is isolated on the XbaI to EcoRI 678 bp fragment (J. Banerji, et al. (1983), Cell, 33, 729-740) from  
15 phage clones using oligo:

5' GAA TGG GAG TGA GGC TCT CTC ATA CCC  
TAT TCA GAA CTG ACT 3'

This E $\mu$  fragment is cloned into EcoRV/XbaI digested  
20 pGP1 by blunt end filling in EcoRI site. The resultant plasmid is designated pE $\mu$ 1.

###### B. Construction Of $\kappa$ Light chain Minilocus

The  $\kappa$  construct contains at least one human V $\kappa$   
25 segment, all five human J $\kappa$  segments, the human J-C $\kappa$  enhancer, human  $\kappa$  constant region exon, and, ideally, the human 3'  $\kappa$  enhancer (K. Meyer, et al. (1989), EMBO J., 8, 1959-1964). The  $\kappa$  enhancer in mouse is 9 kb downstream from C $\kappa$ . However, it is as yet unidentified in the human. In addition, the  
30 construct contains a copy of the mouse heavy chain J-C $\mu$  enhancers.

The minilocus is constructed from four component fragments:

(a) A 16 kb SmaI fragment that contains the human C $\kappa$   
35 exon and the 3' human enhancer by analogy with the mouse locus (fragment (a) in Fig. 20);

(b) A 5' adjacent 5 kb SmaI fragment, which contains all five J segments (fragment (b) in Fig. 20);

(c) The mouse heavy chain intronic enhancer isolated  
40 from pE $\mu$ 1 (this sequence is included to induce expression of the light chain construct as early as possible in B-cell

development. Because the heavy chain genes are transcribed earlier than the light chain genes, this heavy chain enhancer is presumably active at an earlier stage than the intronic  $\kappa$  enhancer); and

- 5 (d) A fragment containing one or more V segments.

The preparation of this construct is as follows.

Human placental DNA is digested with SmaI and fractionated on agarose gel by electrophoresis. Similarly, human placental DNA is digested with BamHI and fractionated by electrophoresis.  
10 The 16 kb fraction is isolated from the SmaI digested gel and the 11 kb region is similarly isolated from the gel containing DNA digested with BamHI.

The 16 kb SmaI fraction is cloned into Lambda FIX II (Stratagene, La Jolla, California) which has been digested with  
15 XhoI, treated with klenow fragment DNA polymerase to fill in the XhoI restriction digest product. Ligation of the 16 kb SmaI fraction destroys the SmaI sites and lases XhoI sites in tact.

The 11 kb BamHI fraction is cloned into  $\lambda$  EMBL3  
20 (Stratagene, La Jolla, California) which is digested with BamHI prior to cloning.

Clones from each library were probed with the C $\kappa$  specific oligo:

25 5' GAA CTG TGG CTG CAC CAT CTG TCT  
TCA TCT TCC CGC CAT CTG 3'

A 16 kb XhoI insert that was subcloned into the XhoI cut pE $\mu$ 1 so that C $\kappa$  is adjacent to the SmaI site. The resultant plasmid was designated pKap1. See Fig. 22.

30 The above C $\kappa$  specific oligonucleotide is used to probe the  $\lambda$  EMBL3/BamHI library to identify an 11 kb clone corresponding to fragment (d) of Fig. 20. A 5 kb SmaI fragment (fragment (b) in Fig. 20) is subcloned and subsequently inserted into pKap1 digested with SmaI. Those plasmids  
35 containing the correct orientation of J segments, C $\kappa$  and the E $\mu$  enhancer are designated pKap2.

One or more V $\kappa$  segments are thereafter subcloned into the MluI site of pKap2 to yield the plasmid pKapH which encodes the human V $\kappa$  segments, the human J $\kappa$  segments, the human C $\kappa$

segments and the human E $\mu$  enhancer. This insert is excised by digesting pKapH with NotI and purified by agarose gel electrophoresis. The thus purified insert is microinjected into the pronucleus of a mouse zygote as previously described.

5

C. Construction of  $\kappa$  Light Chain Minilocus by  
In Vivo Homologous Recombination

The 11 kb BamHI fragment (fragment (d) in Fig. 20) is  
10 cloned into BamHI digested pGP1 such that the 3' end is toward the SfiI site. The resultant plasmid is designated pKAPint. One or more V $\kappa$  segments is inserted into the polylinker between the BamHI and SpeI sites in pKAPint to form pKapHV. The insert of pKapHV is excised by digestion with NotI and purified. The  
15 insert from pKap2 is excised by digestion with NotI and purified. Each of these fragments contain regions of homology in that the fragment from pKapHV contains a 5 kb sequence of DNA that include the J $\kappa$  segments which is substantially homologous to the 5 kb SmaI fragment contained in the insert  
20 obtained from pKap2. As such, these inserts are capable of homologously recombining when microinjected into a mouse zygote to form a transgene encoding V $\kappa$ , J $\kappa$  and C $\kappa$ .

25 D. Construction of  $\kappa$  Light Chain Mini-Locus  
by Coinjection of Synthetic V $\kappa$  Region Fragment  
Together with Light Chain JC Construct

Synthetic V $\kappa$ , region fragments are generated and isolated as previously described. These DNA fragments are  
30 coinjected with the purified NotI insert of plasmid pKap2 or plasmid pKapH. The coinjected DNA fragments are inserted into a single site in the chromosome. Some of the resulting transgenics will contain transgene inserts that have synthetic V regions located adjacent and upstream of the sequences in the  
35 pKap2 or pKapH construct. These animals will have a larger human  $\kappa$  light chain primary repertoire than those described in Example 6(B).

EXAMPLE 7

Isolation of Genomic Clones  
Corresponding to Rearranged and Expressed  
Copies of Immunoglobulin  $\kappa$  Light Chain Genes

This example describes the cloning of immunoglobulin  $\kappa$  light chain genes from cultured cells that express an immunoglobulin of interest. Such cells may contain multiple alleles of a given immunoglobulin gene. For example, a hybridoma might contain four copies of the  $\kappa$  light chain gene, two copies from the fusion partner cell line and two copies from the original B-cell expressing the immunoglobulin of interest. Of these four copies, only one encodes the immunoglobulin of interest, despite the fact that several of them may be rearranged. The procedure described in this example allows for the selective cloning of the expressed copy of the  $\kappa$  light chain.

20 A. Double Stranded cDNA

Cells from human hybridoma, or lymphoma, or other cell line that synthesizes either cell surface or secreted or both forms of IgM with a  $\kappa$  light chain are used for the isolation of polyA<sup>+</sup> RNA. The RNA is then used for the synthesis of oligo dT primed cDNA using the enzyme reverse transcriptase. The single stranded cDNA is then isolated and G residues are added to the 3' end using the enzyme polynucleotide terminal transferase. The Gtailed single-stranded cDNA is then purified and used as template for second strand synthesis (catalyzed by the enzyme DNA polymerase) using the following oligonucleotide as a primer:

5' - GAG GTA CAC TGA CAT ACT GGC ATG CCC  
CCC CCC CCC - 3'

35 The double stranded cDNA is isolated and used for determining the nucleotide sequence of the 5' end of the mRNAs encoding the heavy and light chains of the expressed immunoglobulin molecule. Genomic clones of these expressed genes are then isolated. The procedure for cloning the expressed light chain gene is outlined in part B below.

### B. Light Chain

The double stranded cDNA described in part A is denatured and used as a template for a third round of DNA synthesis using the following oligonucleotide primer:

5' - GTA CGC CAT ATC AGC TGG ATG AAG TCA TCA GAT  
GGC GGG AAG ATG AAG ACA GAT GGT GCA - 3'

This primer contains sequences specific for the constant portion of the  $\kappa$  light chain message (TCA TCA GAT GGC GGG AAG ATG AAG ACA GAT GGT GCA) as well as unique sequences that can be used as a primer for the PCR amplification of the newly synthesized DNA strand (GTA CGC CAT ATC AGC TGG ATG AAG). The sequence is amplified by PCR using the following two oligonucleotide primers:

5' - GAG GTA CAC TGA CAT ACT GGC ATG -3'  
5' - GTA CGC CAT ATC AGC TGG ATG AAG -3'

The PCR amplified sequence is then purified by gel electrophoresis and used as template for dideoxy sequencing reactions using the following oligonucleotide as a primer:

5' - GAG GTA CAC TGA CAT ACT GGC ATG -3'

The first 42 nucleotides of sequence will then be used to synthesize a unique probe for isolating the gene from which immunoglobulin message was transcribed. This synthetic 42 nucleotide segment of DNA will be referred to below as o-kappa.

A Southern blot of DNA, isolated from the Ig expressing cell line and digested individually and in pairwise combinations with several different restriction endonucleases including SmaI, is then probed with the 32-P labelled unique oligonucleotide o-kappa. A unique restriction endonuclease site is identified upstream of the rearranged V segment.

DNA from the Ig expressing cell line is then cut with SmaI and second enzyme (or BamHI or KpnI if there is SmaI site inside V segment). Any resulting non-blunted ends are treated with the enzyme T4 DNA polymerase to give blunt ended DNA molecules. Then add restriction site encoding linkers (BamHI, EcoRI or XhoI depending on what site does not exist in fragment) and cut with the corresponding linker enzyme to give DNA fragments with BamHI, EcoRI or XhoI ends. The DNA is then size fractionated by agarose gel electrophoresis, and the

fraction including the DNA fragment covering the expressed V segment is cloned into lambda EMBL3 or Lambda FIX (Stratagene, La Jolla, California). V segment containing clones are isolated using the unique probe o-kappa. DNA is isolated from positive clones and subcloned into the polylinker of pKap1. The resulting clone is called pRKL.

#### EXAMPLE 8

#### Isolation of Genomic Clones Corresponding to Rearranged Expressed Copies of Immunoglobulin Heavy Chain $\mu$ Genes

This example describes the cloning of immunoglobulin heavy chain  $\mu$  genes from cultured cells of expressed and immunoglobulin of interest. The procedure described in this example allows for the selective cloning of the expressed copy of a  $\mu$  heavy chain gene.

Double-stranded cDNA is prepared and isolated as described in part A of Example 7. The double-stranded cDNA is denatured and used as a template for a third round of DNA synthesis using the following oligonucleotide primer:

5' - GTA CGC CAT ATC AGC TGG ATG AAG ACA GGA GAC  
GAG GGG GAA AAG GGT TGG GGC GGA TGC - 3'

This primer contains sequences specific for the constant portion of the  $\mu$  heavy chain message (ACA GGA GAC GAG GGG GAA AAG GGT TGG GGC GGA TGC) as well as unique sequences that can be used as a primer for the PCR amplification of the newly synthesized DNA strand (GTA CGC CAT ATC AGC TGG ATG AAG). The sequence is amplified by PCR using the following two oligonucleotide primers: 5' - GAG GTA CAC TGA CAT ACT GGC ATG - 3'

5' - GTA CTC CAT ATC AGC TGG ATG AAG - 3'

The PCR amplified sequence is then purified by gel electrophoresis and used as template for dideoxy sequencing reactions using the following oligonucleotide as a primer:

5' - GAG GTA CAC TGA CAT ACT GGC ATG - 3'

The first 42 nucleotides of sequence are then used to synthesize a unique probe for isolating the gene from which immunoglobulin message was transcribed. This synthetic 42 nucleotide segment of DNA will be referred to below as o- $\mu$ .

A Southern blot of DNA, isolated from the Ig expressing cell line and digested individually and in pairwise combinations with several different restriction endonucleases including MluI (MluI is a rare cutting enzyme that cleaves  
5 between the J segment and mu CH1), is then probed with the 32-P labelled unique oligonucleotide o-mu. A unique restriction endonuclease site is identified upstream of the rearranged V segment.

DNA from the IG expressing cell line is then cut with  
10 MluI and second enzyme. MluI or SpeI adapter linkers are then ligated onto the ends and cut to convert the upstream site to MluI or SpeI. The DNA is then size fractionated by agarose gel electrophoresis, and the fraction including the DNA fragment covering the expressed V segment is cloned directly into the  
15 plasmid pGPI. V segment containing clones are isolated using the unique probe o-mu, and the insert is subcloned into MluI or MluI/SpeI cut plasmid pCON2. The resulting plasmid is called pRMGH.

20

#### EXAMPLE 9

##### Deletion of the Mouse Heavy Chain Gene by Homologous Recombination

25 This example describes the deletion of the endogenous mouse heavy chain gene by homologous recombination in embryonic stem (ES) cells (Zijlstra, et al. (1989), Nature, 342, 435-438) followed by the transplantation of those ES cells into a mouse blastocyst embryo such that the ES cells colonize the germline  
30 of the resultant chimeric mouse (Teratocarcinomas and embryonic stem cells: a practical approach, E.J. Robertson, ed., IRL press, Washington, D.C., 1987).

The construction of a DNA sequence that will homologously recombine into the mouse chromosome so as to  
35 delete the heavy chain J segments, thus eliminating the possibility of successful gene rearrangement at the heavy chain locus. The design of this construct is outlined below.

Plasmid pGPI is digested with the restriction endonucleases BamHI and BglII and religated to form the plasmid

pGP1d1. This plasmid is then used to build the so-called gene knockout construct.

To obtain sequences homologous to the desired target region of the mouse genome, mouse genomic clones are isolated from a phage library derived from non-lymphoid tissue (such as liver) using the  $J_H$  specific oligonucleotide probe:

5' - GGT CTA TGA TAG TGT GAC TAC TTT GAC TAC TGG  
GGC CAA GGC - 3'

10 A 3.5 kb KpnI to EcoRI fragment that hybridizes with this probe is isolated from DNA derived from positive phage clones. This fragment is subcloned into KpnI/EcoRI digested pGP1d1 to form the plasmid pMKO1.

Neomycin resistance (Neo) and Herpes Simplex Virus thymidine k inase (TK) genes for drug selection of recombinants (M. Capecchi (1989), Science, 244, 1288-1292) are then isolated as follows. The plasmid pGEM7(KJ1) (M.A. Rudnicki, 3/15/89) is digested with HindIII and the ends blunted with the klenow form of DNA pol I. The DNA is then cut with EcoRI and the pGKNeo fragment is isolated and cloned into SphI/NaeI cut pMKO1 using the following oligonucleotide as an adapter:

5' - AATTCATG -3'

The resulting plasmid is designated pMKO2. This plasmid contains the neomycin resistance gene flanked by sequences that flank the mouse  $J_H$  segments. This plasmid alone can be used for deletion of the heavy chain gene.

Alternatively the Herpes TK gene can be added to the construct to improve the frequency of homologous recombination events in Neo resistant clones (M. Capecchi (1989), Science, 244, 1288-1292). This is done as follows. The EcoRI to HindIII PGKTK fragment of pGEM7(TK) (M.A. Rudnicki) is isolated and cloned into the KpnI site of pMKO2 using the following oligonucleotide as adapters:

5' - AATTGTAC - 3'

35 . 5' - AGCTGTAC - 3'

The resulting plasmid is designated pMKO3.

To further improve the overall efficiency of homologous recombination, a large segment of DNA that is homologous to the target sequence is then added to the

construct. A 13 kb EcoRI fragment, that hybridizes with the  $C\mu$  specific oligonucleotide described below:

5' - GCA TCC TGG AAG GTT CAG ATG AAT ACC  
TTG TAT GCA AAA TCC - 3'

5 This 12 kb fragment includes the  $C\mu$  coding exons, or a substantial portion of that fragment which includes the 5' EcoRI end, is isolated from a mouse genomic phage library and subcloned into the EcoRI site of pMKO3. The resultant plasmid is designated pMKO4.

10 The insert of pMKO4 is isolated by digestion with NotI and electroporated into ES cells. Homologous recombinant clones are isolated used to generate a  $J_H$  deleted mouse as described by Zijlstra, et al. (1989), Nature, 342, 435-438.

15 EXAMPLE 10

Deletion of the Mouse Light Chain Gene  
by Homologous Recombination

This example describes the deletion of the endogenous  
20 mouse light chain gene by homologous recombination in embryonic stem cells (see previous Example).

A DNA sequence that homologously recombines into the mouse chromosome to delete the  $\kappa$  light chain constant region exon is constructed. The design of this construct is outlined  
25 below.

A 2 kb BamHII to EcoRI thymidine kinase fragment from pGEM7(TK)Sal (M.A. Rudnicki, Whitehead Institute) is isolated and subcloned into the BamHI/SfiI digested pGP1 using the following oligonucleotide adapter:

30 5' - AATTTTG - 3'

The resulting plasmid is designated pKKO1.

To obtain sequences homologous to the desired target region of the mouse genome, mouse genomic clones are isolated from a phage library derived from non-lymphoid tissue (such as  
35 liver) using the mouse  $\kappa$  light chain specific oligo designated o-MKC given below:

5' - GGC TGA TGC TGC ACC AAC TGT ATC CAT  
CTT CCC ACC ATC CAG - 3'

DNA is isolated from positive clone and a 2.3 kb BglII  
40 fragment (P.S. Neumaier and H.G. Zachau (1983), Nucl. Acids

Res., 11, 3631-3656) that hybridizes with probe o-MK3 is isolated. The sequence of probe o-MK3 is as follows:

5' - CAT TCT GGG TAT GAA GAG CCC ACG TAT  
CAA AGG TTA CAT TAG - 3'

5 This 2.3 kb BglII fragment is subcloned into BamHI digested pKK01 such that the 3' end of the fragment is adjacent to the polylinker SfiI site. The resulting plasmid is designated pKK02.

10 The 4 kb SphI to HpaI DNA fragment that hybridizes with oligonucleotide o-MKC is isolated from positive phage clone and subcloned into EcoRV to SphI digested plasmid pKK02. The resulting plasmid is designated pKK03.

15 A 2 kb SalI to EcoRI fragment of pGEM7(KJ1)Sal (M.A. Rudnicki, 3/15/89) is isolated and cloned into the BssHII site of plasmid pKK03 using linker adapters. This is carried out by first ligating a mixture of the following three oligonucleotides to the 2 kb SalI to EcoRI fragment:

5' - CAGCGCGC - 3'

5' - GATCGCGCGCTG - 3

20 5' - AATTGCGCGCTG - 3'

The ligation mixture is then digested with the enzyme BssHII and ligated to BssHII digested plasmid pKK03. The resulting plasmid is designated pKK04.

25 The insert of pKK04 is isolated by digesting with NotI and electroporated into ES cells. Homologous recombinant clones are isolated and used to generate a C<sub>x</sub> deleted mouse as described by Zijlstra, et al. (1989), Nature, 342, 435-438.

#### EXAMPLE 11

#### 30 Inactivation of the Mouse Kappa Light Chain Gene by Homologous Recombination

35 This example describes the inactivation of the mouse endogenous kappa locus by homologous recombination in embryonic stem (ES) cells followed by introduction of the mutated gene into the mouse germ line by injection of targeted ES cells bearing an inactivated kappa allele into early mouse embryos (blastocysts).

The strategy is to delete  $J_k$  and  $C_k$  by homologous recombination with a vector containing DNA sequences homologous to the mouse kappa locus in which a 4.5 kb segment of the locus, spanning the  $J_k$  gene and  $C_k$  segments, is deleted and replaced by the selectable marker neo.

#### Construction of the kappa targeting vector

The plasmid pGEM7 (KJ1) (M. A. Rudnicki, Whitehead Institute) contains the neomycin resistance gene (neo), used for drug selection of transfected ES cells, under the transcriptional control of the mouse phosphoglycerate kinase (pgk) promoter (XbaI/I/TaqI fragment; Adra, C.N. et al., (1987) Gene, 60, 65-74) in the cloning vector pGEM-72f(+). The plasmid also includes a heterologous polyadenylation site for the neo gene, derived from the 3' region of the mouse pgk gene (PvuII/HindIII fragment; Boer, P.H., et al., (1990) Biochemical Genetics, 28, 299-308). This plasmid was used as the starting point for construction of the kappa targeting vector. The first step was to insert sequences homologous to the kappa locus 3' of the neo expression cassette.

Mouse kappa chain sequences (Fig. 25a) were isolated from a genomic phage library derived from liver DNA using oligonucleotide probes specific for the  $C_k$  locus:

5'- GGC TGA TGC TGC ACC AAC TGT ATC CAT CTT CCC ACC ATC CAG  
-3'

and for the  $J_{k5}$  gene segment:

5'- CTC ACG TTC GGT GCT GGG ACC AAG CTG GAG CTG AAA CGT AAG -  
3'.

An 8 kb BglII/SacI fragment extending 3' of the mouse  $C_k$  segment was isolated from a positive phage clone in two pieces, as a 1.2 kb BglII/SacI fragment and a 6.8 kb SacI fragment, and subcloned into BglII/SacI digested pGEM7 (KJ1) to generate the plasmid pNEO-K3' (Fig. 25b).

A 1.2 kb EcoRI/SphI fragment extending 5' of the J<sub>K</sub> region was also isolated from a positive phage clone. An SphI/XbaI/BglIII/EcoRI adaptor was ligated to the SphI site of this fragment, and the resulting EcoRI fragment was ligated  
5 into EcoRI digested pNEO-K3', in the same 5' to 3' orientation as the neo gene and the downstream 3' kappa sequences, to generate pNEO-K5'3' (Fig. 25c).

The Herpes Simplex Virus (HSV) thymidine kinase (TK) gene was then included in the construct in order to allow for  
10 enrichment of ES clones bearing homologous recombinants, as described by Mansour et al. ((1988) Nature, 336, 348-352). The HSV TK cassette was obtained from the plasmid pGEM7 (TK) (M.A. Rudnicki), which contains the structural sequences for the HSV TK gene bracketed by the mouse pgk promoter and polyadenylation  
15 sequences as described above for pGEM7 (KJ1). The EcoRI site of pGEM7 (TK) was modified to a BamHI site and the TK cassette was then excised as a BamHI/HindIII fragment and subcloned into pGP1b to generate pGP1b-TK. This plasmid was linearized at the XhoI site and the XhoI fragment from pNEO-K5'3', containing the  
20 neo gene flanked by genomic sequences from 5' of J<sub>K</sub> and 3' of C<sub>K</sub>, was inserted into pGP1b-TK to generate the targeting vector J/C KI (Fig. 25d). The putative structure of the genomic kappa locus following homologous recombination with J/C K1 is shown in Fig. 25e.

25

#### Generation and analysis of ES cells with targeted inactivation of a kappa allele

AB-1 ES cells were grown on mitotically inactive SNL76/7 cell feeder layers (McMahon, A.P. and Bradley, A. (1990) Cell, 62, 1073-1085) essentially as described (Robertson, E.J. (1987) in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. E.J. Robertson, ed. (Oxford: IRL Press), p. 71-112).

The kappa chain inactivation vector J/C K1 was  
35 digested with NotI and electroporated into AB-1 cells by the methods described (Hasty, P.R., et al. (1991) Nature, 350, 243-246). Electroporated cells were plated onto 100 mm dishes at a density of 2-5 x 10<sup>6</sup> cells/dish. After 24 hours, G416

(200 $\mu$ g/ml of active component) and FIAU (0.5 $\mu$ M) were added to the medium, and drug-resistant clones were allowed to develop over 10-11 days. Clones were picked, trypsinized, divided into two portions, and further expanded. Half of the cells derived from each clone were then frozen and the other half analyzed for homologous recombination between vector and target sequences.

DNA analysis was carried out by Southern blot hybridization. DNA was isolated from the clones as described (Laird, P.W. et al., (1991) Nucl. Acids Res., 19,) digested with XbaI and probed with the 800 bp EcoRI/XbaI fragment indicated in Fig. 25e as the diagnostic probe. This probe detects a 3.7 kb XbaI fragment in the wild type locus, and a diagnostic 1.8 kb band in a locus which has homologously recombined with the targeting vector (see Fig. 25a and e). Of 358 G418 and FIAU resistant clones screened by Southern blot analysis, 4 displayed the 1.8 kb XbaI band indicative of a homologous recombination at the kappa locus. These 4 clones were further digested with the enzymes BglII, SacI, and PstI to verify that the vector integrated homologously into one of the kappa alleles. When probed with the diagnostic 800 bp EcoRI/XbaI fragment, BglII, SacI, and PstI digests of wild type DNA produce fragments of 4.1, 5.4, and 7 kb, respectively, whereas the presence of a targeted kappa allele would be indicated by fragments of 2.4, 7.5, and 5.7 kb, respectively (see Fig. 25a and e). All 4 positive clones detected by the XbaI digest showed the expected BglII, SacI, and PstI restriction fragments diagnostic of a homologous recombination at the kappa light chain.

30

#### Generation of mice bearing the inactivated kappa chain

The 4 targeted ES clones described in the previous section were injected into C57Bl/6J blastocysts as described (Bradley, A. (1987) in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. E.J. Robertson, ed. (Oxford: IRL Press), p. 113-151) and transferred into the uteri of pseudopregnant females to generate chimeric mice representing a mixture of cells derived from the input ES cells and the host

blastocyst. Chimeric animals are visually identified by the presence of agouti coat coloration, derived from the ES cell line, on the black C57Bl/6J background. The AB1 ES cells are an XY cell line, thus male chimeras are bred with C57BL/6J females and the offspring monitored for the presence of the dominant agouti coat color. Agouti offspring are indicative of germline transmission of the ES genome. The heterozygosity of agouti offspring for the kappa chain inactivation is verified by Southern blot analysis of DNA from tail biopsies using the diagnostic probe utilized in identifying targeted ES clones. Brother-sister matings of heterozygotes are then carried out to generate mice homozygous for the kappa chain mutation.

#### EXAMPLE 12

##### 15 Inactivation of the Mouse Heavy Chain Gene by Homologous Recombination

This example describes the inactivation of the endogenous murine immunoglobulin heavy chain locus by homologous recombination in embryonic stem (ES) cells. The strategy is to delete the endogenous heavy chain J segments by homologous recombination with a vector containing heavy chain sequences from which the J<sub>H</sub> region has been deleted and replaced by the gene for the selectable marker neo.

##### 25 Construction of a heavy chain targeting vector

Mouse heavy chain sequences containing the J<sub>H</sub> region (Fig. 26a) were isolated from a genomic phage library derived from the D3 ES cell line (Gossler, et al., (1986) Proc. Natl. Acad. Sci. U.S.A., 83, 9065-9069) using a J<sub>H</sub>4 specific oligonucleotide probe:

5'- ACT ATG CTA TGG ACT ACT GGG GTC AAG GAA CCT CAG TCA CCG -3'

A 3.5 kb genomic SacI/StuI fragment, spanning the J<sub>H</sub> region, was isolated from a positive phage clone and subcloned into SacI/SmaI digested puc18. The resulting plasmid was designated puc18 J<sub>H</sub>. The neomycin resistance gene (neo), used for drug selection of transfected ES cells, was derived from the plasmid pGEM7 (KJ1). The HindIII site in pGEM7 (KJ1) was converted to a SalI site by addition of a synthetic adaptor,

and the neo expression cassette excised by digestion with XbaI/SalI. The ends of the neo fragment were then blunted by treatment with the Klenow form of DNA polI, and the neo fragment was subcloned into the NaeI site of puc18 J<sub>H</sub>, generating the plasmid puc18 J<sub>H</sub>-neo (Fig. 26b).

Further construction of the targeting vector was carried out in a derivative of the plasmid pGP1b. pGP1b was digested with the restriction enzyme NotI and ligated with the following oligonucleotide as an adaptor:

5'- GGC CGC TCG ACG ATA GCC TCG AGG CTA TAA ATC TAG AAG AAT TCC  
AGC AAA GCT TTG GC -3'

The resulting plasmid, called pGMT, was used to build the mouse immunoglobulin heavy chain targeting construct.

The Herpes Simplex Virus (HSV) thymidine kinase (TK) gene was included in the construct in order to allow for enrichment of ES clones bearing homologous recombinants, as described by Mansour et al. ((1988) Nature 336, 348-352). The HSV TK gene was obtained from the plasmid pGEM7 (TK) by digestion with EcoRI and HindIII. The TK DNA fragment was subcloned between the EcoRI and HindIII sites of pGMT, creating the plasmid pGMT-TK (Fig. 26c).

To provide an extensive region of homology to the target sequence, a 5.9 kb genomic XbaI/XhoI fragment, situated 5' of the J<sub>H</sub> region, was derived from a positive genomic phage clone by limit digestion of the DNA with XhoI, and partial digestion with XbaI. As noted in Fig. 26a and 26b, this XbaI site is not present in genomic DNA, but is rather derived from phage sequences immediately flanking the cloned genomic heavy chain insert in the positive phage clone. The fragment was subcloned into XbaI/XhoI digested pGMT-TK, to generate the plasmid pGMT-TK-J<sub>H</sub>5' (Fig. 26d).

The final step in the construction involved the excision of the 3 kb EcoRI fragment from puc18 J<sub>H</sub>-neo which contained the neo gene and flanking genomic sequences. This fragment was blunted by Klenow polymerase and subcloned into the similarly blunted XhoI site of pGMT-TK-J<sub>H</sub>5'. The resulting

construct, J<sub>H</sub>KO1 (Fig. 26e), contains 6.9 kb of genomic sequences flanking the J<sub>H</sub> locus, with a 2.3 kb deletion spanning the J<sub>H</sub> region into which has been inserted the neo gene. Fig. 25f shows the structure of an endogenous heavy chain allele after homologous recombination with the targeting construct.

### EXAMPLE 13

#### Generation and analysis of targeted ES cells

10 AB-1 ES cells (McMahon, A.P. and Bradley, A. (1990) Cell 62, 1073-1085) were grown on mitotically inactive SNL76/7 cell feeder layers essentially as described (Robertson, E.J. (1987) Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. E.J. Robertson, ed. (Oxford: IRL Press), pp. 71-112).

15 The heavy chain inactivation vector J<sub>H</sub>KO1 was digested with NotI and electroporated into AB-1 cells by the methods described (Hasty, P.R., et al. (1991) Nature 350, 243-246). Electroporated cells were plated into 100 mm dishes at a density of 2-5 x 10<sup>6</sup> cells/dish. After 24 hours, G418

20 (200mg/ml of active component) and FIAU (0.5mM) were added to the medium, and drug-resistant clones were allowed to develop over 8-10 days. Clones were picked, trypsinized, divided into two portions, and further expanded. Half of the cells derived from each clone were then frozen and the other half analyzed

25 for homologous recombination between vector and target sequences.

DNA analysis is carried out by Southern blot hybridization. DNA is isolated from the clones as described (Laird, P.W. et al., (1991) Nucl. Acids Res., 19.) digested

30 with HindIII and probed with the 500 bp EcoRI/StuI fragment designated as the diagnostic probe in Fig. 26f. This probe detects a HindIII fragment of 2.3 kb in the wild type locus, whereas a 5.3 kb band is diagnostic of a targeted locus which has homologously recombined with the targeting vector (see

35 Fig. 26a and f). Additional digests with the enzymes SpeI, StuI, and BamHI are carried out to verify the targeted disruption of the heavy chain allele.

## EXAMPLE 14

Heavy Chain Minilocus TransgeneA. Construction of plasmid vectors for cloning large DNA sequences5 1. pGP1a

The plasmid pBR322 was digested with EcoRI and StyI and ligated with the following oligonucleotides:

10 oligo-42 5'- caa gag ccc gcc taa tga gcg ggc ttt ttt ttg cat  
act gcg gcc gct -3'

oligo-43 5'- aat tag cgg ccg cag tat gca aaa aaa agc ccg ctc  
att agg cgg gct -3'

15 The resulting plasmid, pGP1a, is designed for cloning very large DNA constructs that can be excised by the rare cutting restriction enzyme NotI. It contains a NotI restriction site downstream (relative to the ampicillin resistance gene, AmpR) of a strong transcription termination  
20 signal derived from the trpA gene (Christie, G.E. et al. (1981) Proc. Natl. Acad. Sci. USA, 78, 4180). This termination signal reduces the potential toxicity of coding sequences inserted into the NotI site by eliminating readthrough transcription from the AmpR gene. In addition, this plasmid is low copy  
25 relative to the pUC plasmids because it retains the pBR322 copy number control region. The low copy number further reduces the potential toxicity of insert sequences and reduces the selection against large inserts due to DNA replication.

30 2. pGP1b

pGP1a was digested with NotI and ligated with the following oligonucleotides:

oligo-47 5'- ggc cgc aag ctt act gct gga tcc tta att aat cga  
35 tag tga tct cga ggc -3'

oligo-48 5'- ggc cgc ctc gag atc act atc gat taa tta agg atc  
cag cag taa gct tgc -3'

The resulting plasmid, pGP1b, contains a short polylinker region flanked by NotI sites. This facilitates the construction of large inserts that can be excised by NotI digestion.

5

### 3. pGPe

The following oligonucleotides:

oligo-44 5'- ctc cag gat cca gat atc agt acc tga aac agg gct  
10 tgc -3'

oligo-45 5'- ctc gag cat gca cag gac ctg gag cac aca cag cct  
tcc -3'

15 were used to amplify the immunoglobulin heavy chain 3' enhancer (S. Petterson, et al. (1990) Nature, 344, 165-168) from rat liver DNA by the polymerase chain reaction technique.

The amplified product was digested with BamHI and SphI and cloned into BamHI/SphI digested pNNO3 (pNNO3 is a pUC  
20 derived plasmid that contains a polylinker with the following restriction sites, listed in order: NotI, BamHI, NcoI, ClaI, EcoRV, XbaI, SacI, XhoI, SphI, PstI, BglII, EcoRI, SmaI, KpnI, HindIII, and NotI). The resulting plasmid, pRE3, was digested with BamHI and HindIII, and the insert containing the rat Ig  
25 heavy chain 3' enhancer cloned into BamHI/HindIII digested pGP1b. The resulting plasmid, pGPe (Fig. 27 and Table 1), contains several unique restriction sites into which sequences can be cloned and subsequently excised together with the 3' enhancer by NotI digestion.

**Table 1**      **Sequence of vector pGPe.**

B. Construction of IgM expressing minilocus transgene, pJGM1

1. Isolation of J- $\mu$  constant region clones and construction of pJGM1

5 A human placental genomic DNA library cloned into the phage vector  $\lambda$ EMBL3/SP6/T7 (Clontech Laboratories, Inc., Palo Alto, CA) was screened with the human heavy chain J region specific oligonucleotide:

10 oligo-1 5'- gga ctg tgt ccc tgt gtg atg ctt ttg atg tct ggg  
gcc aag -3'

and the phage clone  $\lambda$ 1.3 isolated. A 6 kb HindIII/KpnI fragment from this clone, containing all six J segments as well as D segment DHQ52 and the heavy chain J- $\mu$  intronic enhancer,  
15 was isolated. The same library was screened with the human  $\mu$  specific oligonucleotide:

20 oligo-2 5'- cac caa gtt gac ctg cct ggt cac aga cct gac cac  
cta tga -3'

and the phage clone  $\lambda$ 2.1 isolated. A 10.5 kb HindIII/XhoI fragment, containing the  $\mu$  switch region and all of the  $\mu$  constant region exons, was isolated from this clone. These two fragments were ligated together with KpnI/XhoI digested pNNO3  
25 to obtain the plasmid pJGM1.

2. pJGM2

A 4 kb XhoI fragment was isolated from phage clone  $\lambda$ 2.1 that contains sequences immediately downstream of the  
30 sequences in pJGM1, including the so called  $\Sigma\mu$  element involved in  $\mu$  deletion in certain IgD expressing B-cells (H. Yasui et al. (1989) Eur. J. Immunol. 19, 1399). This fragment was treated with the Klenow fragment of DNA polymerase I and ligated to XhoI cut, Klenow treated, pJGM1. The resulting  
35 plasmid, pJGM2 (Fig. 28), had lost the internal XhoI site but retained the 3' XhoI site due to incomplete reaction by the Klenow enzyme. pJGM2 contains the entire human J region, the heavy chain J- $\mu$  intronic enhancer, the  $\mu$  switch region and all

of the  $\mu$  constant region exons, as well as the two 0.4 kb direct repeats,  $\sigma\mu$  and  $\Sigma\mu$ , involved in  $\mu$  deletion.

### 3. Isolation of D region clones and construction of pDH1

5

The following human D region specific oligonucleotide:

oligo-4 5'- tgg tat tac tat ggt tcg ggg agt tat tat aac cac  
agt gtc -3'

10

was used to screen the human placenta genomic library for D region clones. Phage clones  $\lambda$ 4.1 and  $\lambda$ 4.3 were isolated. A 5.5 kb XhoI fragment, that includes the D elements  $D_{K1}$ ,  $D_{N1}$ , and  $D_{M2}$  (Y. Ichihara et al. (1988) EMBO J., 7, 4141), was isolated from phage clone  $\lambda$ 4.1. An adjacent upstream 5.2 kb XhoI fragment, that includes the D elements  $D_{LR1}$ ,  $D_{XP1}$ ,  $D_{XP.1}$ , and  $D_{A1}$ , was isolated from phage clone  $\lambda$ 4.3. Each of these D region XhoI fragments were cloned into the SalI site of the plasmid vector pSP72 (Promega, Madison, WI) so as to destroy the XhoI site linking the two sequences. The upstream fragment was then excised with XhoI and SmaI, and the downstream fragment with EcoRV and XhoI. The resulting isolated fragments were ligated together with SalI digested pSP72 to give the plasmid pDH1. pDH1 contains a 10.6 kb insert that includes at least 7 D segments and can be excised with XhoI (5') and EcoRV (3').

25

### 4. pCOR1

The plasmid pJM2 was digested with Asp718 (an isoschizomer of KpnI) and the overhang filled in with the Klenow fragment of DNA polymerase I. The resulting DNA was then digested with ClaI and the insert isolated. This insert was ligated to the XhoI/EcoRV insert of pDH1 and XhoI/ClaI digested pGPe to generate pCOR1 (Fig. 29).

30

### 35 5. pVH251

A 10.3 kb genomic HindIII fragment containing the two human heavy chain variable region segments  $V_H251$  and  $V_H105$  (C.G.

Humphries et al. (1988) Nature 331, 446) was subcloned into pSP72 to give the plasmid pVH251.

#### 6. pIGM1

5           The plasmid pCOR1 was partially digested with XhoI and the isolated XhoI/SalI insert of pVH251 cloned into the upstream XhoI site to generate the plasmid pIGM1 (Fig. 30). pIGM1 contains 2 functional human variable region segments, at least 8 human D segments all 6 human J<sub>H</sub> segments, the human J- $\mu$  enhancer, the human  $\sigma\mu$  element, the human  $\mu$  switch region, all 10 of the human  $\mu$  coding exons, and the human  $\Sigma\mu$  element, together with the rat heavy chain 3' enhancer, such that all of these sequence elements can be isolated on a single fragment, away from vector sequences, by digestion with NotI and microinjected 15 into mouse embryo pronuclei to generate transgenic animals.

#### C. Construction of IgM and IgG expressing minilocus transgene, pHCl

##### 1. Isolation of $\gamma$ constant region clones

20           The following oligonucleotide, specific for human Ig g constant region genes:

oligo-29 5'- cag cag gtg cac acc caa tgc cca tga gcc cag aca  
          ctg gac -3'

25

was used to screen the human genomic library. Phage clones 129.4 and  $\lambda$ 29.5 were isolated. A 4 kb HindIII fragment of phage clone  $\lambda$ 29.4, containing a  $\gamma$  switch region, was used to probe a human placenta genomic DNA library cloned into the 30 phage vector lambda FIX<sup>™</sup> II (Stratagene, La Jolla, CA). Phage clone  $\lambda$ Sg1.13 was isolated. To determine the subclass of the different  $\gamma$  clones, dideoxy sequencing reactions were carried out using subclones of each of the three phage clones as templates and the following oligonucleotide as a primer:

35

oligo-67 5'- tga gcc cag aca ctg gac -3'

Phage clones  $\lambda$ 29.5 and  $\lambda$ S $\gamma$ 1.13 were both determined to be of the  $\gamma$ 1 subclass.

## 2. p $\gamma$ e1

A 7.8 kb HindIII fragment of phage clone  $\lambda$ 29.5, containing the  $\gamma$ 1 coding region was cloned into pUC18. The resulting plasmid, pLT1, was digested with XhoI, Klenow treated, and religated to destroy the internal XhoI site. The resulting clone, pLT1xk, was digested with HindIII and the insert isolated and cloned into pSP72 to generate the plasmid clone pLT1xks. Digestion of pLT1xks at a polylinker XhoI site and a human sequence derived BamHI site generates a 7.6 kb fragment containing the  $\gamma$ 1 constant region coding exons. This 7.6 kb XhoI/BamHI fragment was cloned together with an adjacent downstream 4.5 kb BamHI fragment from phage clone  $\lambda$ 29.5 into XhoI/BamHI digested pGPe to generate the plasmid clone p $\gamma$ e1. p $\gamma$ e1 contains all of the  $\gamma$ 1 constant region coding exons, together with 5 kb of downstream sequences, linked to the rat heavy chain 3' enhancer.

## 3. p $\gamma$ e2

A 5.3 kb HindIII fragment containing the  $\gamma$ 1 switch region and the first exon of the pre-switch sterile transcript (P. Sideras et al. (1989) International Immunol. 1, 631) was isolated from phage clone  $\lambda$ S $\gamma$ 1.13 and cloned into pSP72 with the polylinker XhoI site adjacent to the 5' end of the insert, to generate the plasmid clone pS $\gamma$ 1s. The XhoI/SalI insert of pS $\gamma$ 1s was cloned into XhoI digested p $\gamma$ e1 to generate the plasmid clone p $\gamma$ e2 (Fig. 31). p $\gamma$ e2 contains all of the  $\gamma$ 1 constant region coding exons, and the upstream switch region and sterile transcript exons, together with 5 kb of downstream sequences, linked to the rat heavy chain 3' enhancer. This clone contains a unique XhoI site at the 5' end of the insert. The entire insert, together with the XhoI site and the 3' rat enhancer can be excised from vector sequences by digestion with NotI.

## 4. pHC1

The plasmid pIGM1 was digested with XhoI and the 43 kb insert isolated and cloned into XhoI digested p $\gamma$ e2 to generate

the plasmid pHCl (Fig. 30). pHCl contains 2 functional human variable region segments, at least 8 human D segments all 6 human  $J_H$  segments, the human J- $\mu$  enhancer, the human  $\sigma\mu$  element, the human  $\mu$  switch region, all of the human  $\mu$  coding  
5 exons, the human  $\Sigma\mu$  element, and the human  $\gamma 1$  constant region, including the associated switch region and sterile transcript associated exons, together with the rat heavy chain 3' enhancer, such that all of these sequence elements can be isolated on a single fragment, away from vector sequences, by  
10 digestion with NotI and microinjected into mouse embryo pronuclei to generate transgenic animals.

D. Construction of IgM and IgG expressing minilocus transgene, pHCl2

15 1. Isolation of human heavy chain V region gene VH49.8

The human placental genomic DNA library lambda, FIX<sup>II</sup>, Stratagene, La Jolla, CA) was screened with the following human VH1 family specific oligonucleotide:

20 oligo-49 5'- gtt aaa gag gat ttt att cac ccc tgt gtc etc tcc  
aca ggt gtc -3'

Phage clone  $\lambda 49.8$  was isolated and a 6.1 kb XbaI fragment containing the variable segment VH49.8 subcloned into  
25 pNNO3 (such that the polylinker ClaI site is downstream of VH49.8 and the polylinker XhoI site is upstream) to generate the plasmid pVH49.8. An 800 bp region of this insert was sequenced, and VH49.8 found to have an open reading frame and intact splicing and recombination signals, thus indicating that  
30 the gene is functional (Table 2).

TTCTTCAGGC	AGGATTTAGG	GCTTGGTCTC	TCAGCATCCC	ACACTTGTAC	50
AGCTGATGTG	GCATCTGTGT	TTCTTTTCTC	ATCCTAGATC	AAGCTTGTAG	100
CTGTGAAATA	CCCTGCCTCA	TGAATATGCA	AATAATCTGA	GGTCTTCTGA	150
GATAAATATA	GATATATTGG	TGCCCTGAGA	GCATCACATA	ACAACCAGAT	200
TCCTCCTCTA	AAGAAGCCCC	TGGGAGCACA	GCTCATCAAC	ATGGACTGGA	250
				MetAspTrpT	
CCCTGGAGGTT	CCTCTTTGTG	GTGGCAGCAG	CTACAGgtaa	ggggcttccr	300
hrTrpArgPh	eLeuPheVal	ValAlaAlaA	laThr		
agtcctaagg	ctgaggaagg	gatcctgggt	tagttaaaga	ggattttatt	350
caacccctgtg	tccctctccac	agGTGTCCAG	TCCCAGGTCC	AGCTGGTGC	400
		GlyValGln	SerGlnValG	InLeuValG	
GTCTGGGGCT	GAGGTGAGG	AGCCTGGGTC	CTGGGTGAAG	GTCTCCTGCA	450
nSerGlyAla	GluValLysL	ysProGlySe	rSerValLys	ValSerCysL	
AGGCTTCTGG	AGGCACCTTC	AGCAGCTATG	CTATCAGCTG	GGTGGGACAG	500
ysAlaSerGl	yGlyThrPhe	SerSerTyrA	laIleSerTr	pValArgGln	
GGCCTGGAC	AAGGGCTTGA	GTGGATGGGA	AGGATCATCC	CTATCCTTGG	550
AlaProGlyG	InGlyLeuGl	uTrpMetGly	ArgIleIleP	roIleLeuGl	
TATAGCAAAC	TACGCACAGA	AGTTCCAGGG	CAGAGTCACG	ATTACCGCGG	600
yIleAlaAsn	TyrAlaGlnL	ysPheGlnGl	yArgValThr	IleThrAlaA	
ACAAATCCAC	GAGCACAGCC	TACATGGAGC	TGAGCAGCCT	GAGATCTGAG	650
spLysSerTh	rSerThrAla	TyrMetGluL	euSerSerLe	uArgSerGlu	
GACACGGCCG	TGTATTACTG	TGCGAGAGAG	ACCGGTGGA	AACCCACATC	700
AspThrAlaV	alTyrTrCy	sAlaArg			
CTGAGAGTGT	CAGAAAGCCT	GAGGGAGAAG	GCAGCTGTGC	CGGGCTGAGG	750
AGATGACAGG	GTTTATTAGG	TTTAAGGCTG	TTTACAAAAT	GGGTTATATA	800
TTTGAGAAAA	AA				812

Table 2 Sequence of human  $V_H$ I family gene  $V_H$  49.8

2. pV2

A 4 kb XbaI genomic fragment containing the human  $V_H$ IV family gene  $V_H4-21$  (I. Sanz et al. (1989) EMBO J., 8, 3741), subcloned into the plasmid pUC12, was excised with SmaI and HindIII, and treated with the Klenow fragment of polymerase I. The blunt ended fragment was then cloned into ClaI digested, Klenow treated, pVH49.8. The resulting plasmid, pV2, contains the human heavy chain gene VH49.8 linked upstream of VH4-21 in the same orientation, with a unique SalI site at the 3' end of the insert and a unique XhoI site at the 5' end.

3. pS $\gamma$ 1-5'

A 0.7 kb XbaI/HindIII fragment (representing sequences immediately upstream of, and adjacent to, the 5.3 kb  $\gamma$ 1 switch region containing fragment in the plasmid p $\gamma$ e2) together with the neighboring upstream 3.1 kb XbaI fragment were isolated from the phage clone  $\lambda$ Sg1.13 and cloned into HindIII/XbaI digested pUC18 vector. The resulting plasmid, pS $\gamma$ 1-5', contains a 3.8 kb insert representing sequences upstream of the initiation site of the sterile transcript found in B-cells prior to switching to the  $\gamma$ 1 isotype (P. Sideras et al. (1989) International Immunol., 1, 631). Because the transcript is implicated in the initiation of isotype switching, and upstream cis-acting sequences are often important for transcription regulation, these sequences are included in transgene constructs to promote correct expression of the sterile transcript and the associated switch recombination.

4. pVGE1

The pS $\gamma$ 1-5' insert was excised with SmaI and HindIII, treated with Klenow enzyme, and ligated with the following oligonucleotide linker:

5'- ccg gtc gac cgg -3'

The ligation product was digested with SalI and ligated to SalI digested pV2. The resulting plasmid, pVP, contains 3.8 kb of  $\gamma$ 1 switch 5' flanking sequences linked downstream of the two

human variable gene segments VH49.8 and VH4-21 (see Table 2). The pVP insert is isolated by partial digestion with SalI and complete digestion with XhoI, followed by purification of the 15 kb fragment on an agarose gel. The insert is then cloned  
5 into the XhoI site of p $\gamma$ e2 to generate the plasmid clone pVGE1 (Fig. 32). pVGE1 contains two human heavy chain variable gene segments upstream of the human  $\gamma$ 1 constant gene and associated switch region. A unique SalI site between the variable and  
10 constant regions can be used to clone in D, J, and  $\mu$  gene segments. The rat heavy chain 3' enhancer is linked to the 3' end of the  $\gamma$ 1 gene and the entire insert is flanked by NotI sites.

#### 5. pHC2

15 The plasmid clone pVGE1 is digested with SalI and the XhoI insert of pIGM1 is cloned into it. The resulting clone, pHC2 (Fig. 30), contains 4 functional human variable region segments, at least 8 human D segments all 6 human J<sub>H</sub> segments, the human J-m enhancer, the human  $\sigma\mu$  element, the human  $\mu$   
20 switch region, all of the human  $\mu$  coding exons, the human  $\Sigma\mu$  element, and the human  $\gamma$ 1 constant region, including the associated switch region and sterile transcript associated exons, together with 4 kb flanking sequences upstream of the sterile transcript initiation site. These human sequences are  
25 linked to the rat heavy chain 3' enhancer, such that all of the sequence elements can be isolated on a single fragment, away from vector sequences, by digestion with NotI and microinjected into mouse embryo pronuclei to generate transgenic animals. A  
30 unique XhoI site at the 5' end of the insert can be used to clone in additional human variable gene segments to further expand the recombinational diversity of this heavy chain minilocus.

#### E. Transgenic mice

35 The NotI inserts of plasmids pIGM1 and pHC1 were isolated from vector sequences by agarose gel electrophoresis. The purified inserts were microinjected into the pronuclei of fertilized (C57BL/6 x CBA)F2 mouse embryos and transferred the

surviving embryos into pseudopregnant females as described by Hogan et al. (B. Hogan, F. Costantini, and E. Lacy, Methods of Manipulating the Mouse Embryo, 1986, Cold Spring Harbor Laboratory, New York). Mice that developed from injected

5 embryos were analyzed for the presence of transgene sequences by Southern blot analysis of tail DNA. Transgene copy number was estimated by band intensity relative to control standards containing known quantities of cloned DNA. At 3 to 8 weeks of age, serum was isolated from these animals and assayed for the

10 presence of transgene encoded human IgM and IgG1 by ELISA as described by Harlow and Lane (E. Harlow and D. Lane. Antibodies: A Laboratory Manual, 1988, Cold Spring Harbor Laboratory, New York). Microtiter plate wells were coated with mouse monoclonal antibodies specific for human IgM (clone AF6,

15 #0285, AMAC, Inc. Westbrook, ME) and human IgG1 (clone JL512, #0280, AMAC, Inc. Westbrook, ME). Serum samples were serially diluted into the wells and the presence of specific immunoglobulins detected with affinity isolated alkaline phosphatase conjugated goat anti-human Ig (polyvalent) that had

20 been pre-adsorbed to minimize cross-reactivity with mouse immunoglobulins. Fig. 33 shows the results of an ELISA assay for the presence of human IgM and IgG1 in the serum of two animals that developed from embryos injected with the transgene insert of plasmid pHCl. One of the animals (#18) was negative

25 for the transgene by Southern blot analysis, and showed no detectable levels of human IgM or IgG1. The second animal (#38) contained approximately 5 copies of the transgene, as assayed by Southern blotting, and showed detectable levels of both human IgM and IgG1. The results of ELISA assays for 11

30 animals that developed from transgene injected embryos is summarized in the table below (Table 3).

Table 3. Detection of human IgM and IgG1 in the serum of transgenic animals by ELISA assay

5	<u>animal #</u>	<u>injected transgene</u>	<u>approximate transgene copy # (per cell)</u>	<u>human IgM</u>	<u>human IgG1</u>
	6	pIGM1	1	++	-
10	7	pIGM1	0	-	-
	9	pIGM1	0	-	-
15	10	pIGM1	0	-	-
	12	pIGM1	0	-	-
	15	pIGM1	10	++	-
20	18	pHC1	0	-	-
	19	pHC1	1	-	-
25	21	pHC1	<1	-	-
	26	pHC1	2	++	+
	38	pHC1	5	++	+

Table 3 shows a correlation between the presence of integrated transgene DNA and the presence of transgene encoded immunoglobulins in the serum. Two of the animals that were found to contain the pHCl transgene did not express detectable levels of human immunoglobulins. These were both low copy animals and may not have contained complete copies of the transgenes, or the animals may have been genetic mosaics (indicated by the <1 copy per cell estimated for animal #21), and the transgene containing cells may not have populated the hematopoietic lineage. Alternatively, the transgenes may have integrated into genomic locations that are not conducive to their expression. The detection of human IgM in the serum of pIGM1 transgenics, and human IgM and IgG1 in pHCl transgenics, indicates that the transgene sequences function correctly in directing VDJ joining, transcription, and isotype switching.

#### EXAMPLE 15

##### Rearranged Heavy Chain Transgenes

##### A. Isolation of Rearranged Human Heavy Chain VDJ segments.

Two human leukocyte genomic DNA libraries cloned into the phage vector lEMBL3/SP6/T7 (Clonetech Laboratories, Inc., Palo Alto, CA) are screened with a 1 kb PacI/HindIII fragment of  $\lambda$ 1.3 containing the human heavy chain J- $\mu$  intronic enhancer. Positive clones are tested for hybridization with a mixture of the following V<sub>H</sub> specific oligonucleotides:

oligo-7 5'-tca gtg aag gtt tcc tgc aag gca tct gga tac acc ttc  
acc-3'

oligo-8 5'-tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttc  
agt-3'

Clones that hybridized with both V and J- $\mu$  probes are isolated and the DNA sequence of the rearranged VDJ segment determined.

### B. Construction of rearranged human heavy chain transgenes

Fragments containing functional VJ segments (open reading frame and splice signals) are subcloned into the plasmid vector pSP72 such that the plasmid derived XhoI site is adjacent to the 5' end of the insert sequence. A subclone containing a functional VDJ segment is digested with XhoI and PacI (PacI, a rare-cutting enzyme, recognizes a site near the J-m intronic enhancer), and the insert cloned into XhoI/PacI digested pH2 to generate a transgene construct with a functional VDJ segment, the J- $\mu$  intronic enhancer, the  $\mu$  switch element, the  $\mu$  constant region coding exons, and the  $\gamma$ 1 constant region, including the sterile transcript associated sequences, the  $\gamma$ 1 switch, and the coding exons. This transgene construct is excised with NotI and microinjected into the pronuclei of mouse embryos to generate transgenic animals as described above.

### EXAMPLE 16

#### Light Chain Transgenes

#### 20 A. Construction of Plasmid vectors

##### 1. Plasmid vector pGP1c

Plasmid vector pGP1a is digested with NotI and the following oligonucleotides ligated in:

25 oligo-81 5'-ggc cgc atc ccg ggt ctc gag gtc gac aag ctt tcg agg  
atc cgc-3'

oligo-82 5'-ggc cgc gga tcc tcg aaa gct tgt cga cct cga gac ccg  
30 gga tgc-3'

The resulting plasmid, pGP1c, contains a polylinker with XmaI, XhoI, SalI, HindIII, and BamHI restriction sites flanked by NotI sites.

35

##### 2. Plasmid vector pGP1d

Plasmid vector pGP1a is digested with NotI and the following oligonucleotides ligated in:

oligo-87 5'-ggc cgc tgt cga caa gct tat cga tgg atc ctc gag tgc  
-3'

5 oligo-88 5'-ggc cgc act cga gga tcc atc gat aag ctt gtc gac agc  
-3'

The resulting plasmid, pGP1d, contains a polylinker with SalI, HindIII, ClaI, BamHI, and XhoI restriction sites flanked by NotI sites.

10

B. Isolation of J $\kappa$  and C $\kappa$  clones

A human placental genomic DNA library cloned into the phage vector  $\lambda$ EMBL3/SP6/T7 (Clonetech Laboratories, Inc., Palo Alto, CA) was screened with the human kappa light chain J region specific oligonucleotide:

15

oligo-36 5'- cac ctt cgg cca agg gac acg act gga gat taa acg  
taa gca -3'

20 and the phage clones 136.2 and 136.5 isolated. A 7.4 kb XhoI fragment that includes the J $\kappa$ 1 segment was isolated from 136.2 and subcloned into the plasmid pNNO3 to generate the plasmid clone p36.2. A neighboring 13 kb XhoI fragment that includes J $\kappa$  segments 2 through 5 together with the C $\kappa$  gene segment was  
25 isolated from phage clone 136.5 and subcloned into the plasmid pNNO3 to generate the plasmid clone p36.5. Together these two clones span the region beginning 7.2 kb upstream of J $\kappa$ 1 and ending 9 kb downstream of C $\kappa$ .

30 C. Construction of rearranged light chain transgenes

1. pCK1, a C $\kappa$  vector for expressing rearranged variable segments

The 13 kb XhoI insert of plasmid clone p36.5 containing the C $\kappa$  gene, together with 9 kb of downstream  
35 sequences, is cloned into the SalI site of plasmid vector pGP1c with the 5' end of the insert adjacent to the plasmid XhoI site. The resulting clone, pCK1 can accept cloned fragments containing rearranged VJ $\kappa$  segments into the unique 5' XhoI

site. The transgene can then be excised with NotI and purified from vector sequences by gel electrophoresis. The resulting transgene construct will contain the human J-C $\kappa$  intronic enhancer and may contain the human 3'  $\kappa$  enhancer.

5

2. pCK2, a C $\kappa$  vector with heavy chain enhancers for expressing rearranged variable segments

A 0.9 kb XbaI fragment of mouse genomic DNA containing the mouse heavy chain J- $\mu$  intronic enhancer (J. Banerji et al. (1983) Cell 33, 729-740) was subcloned into pUC18 to generate the plasmid pJH22.1. This plasmid was linearized with SphI and the ends filled in with klenow enzyme. The klenow treated DNA was then digested with HindIII and a 1.4 kb MluI(klenow)/HindIII fragment of phage clone  $\lambda$ 1.3 (previous example), containing the human heavy chain J- $\mu$  intronic enhancer (A. Hayday et al. (1984) Nature 307, 334-340), to it. The resulting plasmid, pMHE1, consists of the mouse and human heavy chain J- $\mu$  intronic enhancers ligated together into pUC18 such that they are excised on a single BamHI/HindIII fragment. This 2.3 kb fragment is isolated and cloned into pGP1c to generate pMHE2. pMHE2 is digested with SalI and the 13 kb XhoI insert of p36.5 cloned in. The resulting plasmid, pCK2, is identical to pCK1, except that the mouse and human heavy chain J- $\mu$  intronic enhancers are fused to the 3' end of the transgene insert. To modulate expression of the final transgene, analogous constructs can be generated with different enhancers, i.e. the mouse or rat 3' kappa or heavy chain enhancer (K. Meyer and M.S. Neuberger, (1989) EMBO J., 8, 1959-1964; S. Petterson, et al. (1990) Nature, 344, 165-168).

30

2. Isolation of rearranged kappa light chain variable segments

Two human leukocyte genomic DNA libraries cloned into the phage vector  $\lambda$ EMBL3/SP6/T7 (Clonetech Laboratories, Inc., Palo Alto, CA) were screened with the human kappa light chain J region containing 3.5 kb XhoI/SmaI fragment of p36.5. Positive clones were tested for hybridization with the following V $\kappa$  specific oligonucleotide:

35

oligo-65 5'-agg ttc agt ggc agt ggg tct ggg aca gac ttc act ctc  
acc atc agc-3'

Clones that hybridized with both V and J probes are isolated  
5 and the DNA sequence of the rearranged VJ $\kappa$  segment determined.

3. Generation of transgenic mice containing rearranged human  
light chain constructs.

Fragments containing functional VJ segments (open  
10 reading frame and splice signals) are subcloned into the unique  
XhoI sites of vectors pCK1 and pCK2 to generate rearranged  
kappa light chain transgenes. The transgene constructs are  
isolated from vector sequences by digestion with NotI. Agarose  
gel purified insert is microinjected into mouse embryo  
15 pronuclei to generate transgenic animals. Animals expressing  
human kappa chain are bred with heavy chain minilocus  
containing transgenic animals (EXAMPLE 14) to generate mice  
expressing fully human antibodies.

Because not all VJ $\kappa$  combinations may be capable of  
20 forming stable heavy-light chain complexes with a broad  
spectrum of different heavy chain VDJ combinations, several  
different light chain transgene constructs are generated, each  
using a different rearranged VJ $\kappa$  clone, and transgenic mice  
that result from these constructs are bred with heavy chain  
25 minilocus transgene expressing mice. Peripheral blood, spleen,  
and lymph node lymphocytes are isolated from double transgenic  
(both heavy and light chain constructs) animals, stained with  
fluorescent antibodies specific for human and mouse heavy and  
light chain immunoglobulins (Pharmingen, San Diego, CA) and  
30 analyzed by flow cytometry using a FACScan analyzer (Becton  
Dickinson, San Jose, CA). Rearranged light chain transgenes  
constructs that result in the highest level of human  
heavy/light chain complexes on the surface of the highest  
number of B cells, and do not adversely affect the immune cell  
35 compartment (as assayed by flow cytometric analysis with B and  
T cell subset specific antibodies), are selected for the  
generation of human monoclonal antibodies.

D. Construction of unrearranged light chain minilocus transgenes

1. pJCK1, a J $\kappa$ , C $\kappa$  containing vector for constructing minilocus transgenes

5           The 13 kb C $\kappa$  containing XhoI insert of p36.5 is treated with klenow enzyme and cloned into HindIII digested, klenow treated, plasmid pGP1d. A plasmid clone is selected such that the 5' end of the insert is adjacent to the vector derived ClaI site. The resulting plasmid, p36.5-1d, is  
10 digested with ClaI and klenow treated. The J $\kappa$ 1 containing 7.4 kb XhoI insert of p36.2 is then klenow treated and cloned into the ClaI, klenow treated p36.5-1d. A clone is selected in which the p36.2 insert is in the same orientation as the p36.5 insert. This clone, pJCK1 (Fig. 34), contains the entire human  
15 J $\kappa$  region and C $\kappa$ , together with 7.2 kb of upstream sequences and 9 kb of downstream sequences. The insert also contains the human J-C $\kappa$  intronic enhancer and may contain a human 3'  $\kappa$  enhancer. The insert is flanked by a unique 3' SalI site for the purpose of cloning additional 3' flanking sequences such as  
20 heavy chain or light chain enhancers. A unique XhoI site is located at the 5' end of the insert for the purpose of cloning in unrearranged V $\kappa$  gene segments. The unique SalI and XhoI sites are in turn flanked by NotI sites that are used to isolate the completed transgene construct away from vector  
25 sequences.

2. Isolation of unrearranged V $\kappa$  gene segments and generation of transgenic animals expressing human Ig light chain protein

30           The V $\kappa$  specific oligonucleotide, oligo-65 (discussed above), is used to probe a human placental genomic DNA library cloned into the phage vector lEMBL3/SP6/T7 (Clonetech Laboratories, Inc., Palo Alto, CA). Variable gene segments from the resulting clones are sequenced, and clones that appear functional are selected. Criteria for judging functionality  
35 include: open reading frames, intact splice acceptor and donor sequences, and intact recombination sequence. DNA fragments containing selected variable gene segments are cloned into the unique XhoI site of plasmid pJCK1 to generate minilocus

constructs. The resulting clones are digested with NotI and the inserts isolated and injected into mouse embryo pronuclei to generate transgenic animals. The transgenes of these animals will undergo V to J joining in developing B-cells.

- 5 Animals expressing human kappa chain are bred with heavy chain minilocus containing transgenic animals (EXAMPLE 14) to generate mice expressing fully human antibodies.

#### EXAMPLE 17

##### 10 Synthetic Heavy Chain Variable Region

This example is outlined in Fig. 35.

##### A. Construction of Cloning Vector pVHf

###### 1. pGP1f

- 15 The plasmid pGP1a (previous example) is digested with NotI and the following oligonucleotides are ligated to it:

oligo-"a" 5'-ggc cgc atg cta ctc gag tgc aag ctt ggc cat cca-3'

oligo-"b" 5'-ggc ctg gat ggc caa gct tgc act cga gta gca tgc-3'

20

The resulting plasmid, pGP1f, contains SphI, XhoI, and HindIII sites flanked by NotI and SfiI sites.

###### 2. pVHf

- 25 The human  $V_H$ -V family variable gene segment  $V_H$ 251 (C.G. Humphries et al. (1988) Nature, 331, 446) together with approximately 2.4 kb of 5' flanking sequences and approximately 1.4 kb of 3' flanking sequences was isolated on a 4.2 kb SphI/HindIII fragment from the plasmid clone pVH251 (previous  
30 example) and cloned into the plasmid vector pSelect™-1 (Promega Corp., Madison, WI). The 5' flanking sequences, together with the promoter, first exon and first intron of  $V_H$ 251, are amplified by polymerase chain reaction (PCR) from this template using the following oligonucleotides:

35

oligo-83 5'-cag ctc gag ctc ggc aca ggc gcc tgt ggg-3'

oligo-84 5'-ctc tag agt cga cct gca ggc-3'

The 3' flanking sequences are amplified by PCR using the following oligonucleotides:

oligo-85 5'-agc ctc gag ccc gtc taa aac cct cca cac-3'

5

oligo-86 5'-ggt gac act ata gaa tac tca agc-3'

The amplified 5' sequences are digested with SphI and XhoI, and the 3' sequences digested with HindIII and XhoI. The resulting  
10 fragments are cloned together into the plasmid pGP1f to generate plasmid pVHf. Plasmid pVHf contains the cis acting regulatory elements that control transcription of  $V_H$ 251, together with the signal sequence encoding first exon. pVHf is used as an expression cassette for heavy chain variable  
15 sequences. Such sequences are cloned into the KasI/XhoI digested plasmid as described below.

#### B. Isolation of Variable Gene Coding Sequences

##### 1. Amplification of expressed $V_H$ gene cDNA sequences

20 Poly (A)<sup>+</sup> RNA is isolated from human peripheral blood lymphocytes (PBL). First strand cDNA is synthesized with reverse transcriptase, using oligo-(dT) as a primer. The first strand cDNA is isolated and tailed with oligo (dG) using terminal transferase. The 5' sequences of IgM transcripts are  
25 then specifically amplified by a modification of the method of Frohman et al. (1988, Proc. Natl. Acad. Sci. USA, 85, 8998). Oligo-(dC)<sub>13</sub> and the following oligonucleotide:

oligo-69 5'-gga att ctc aca gga gac gag-3'

30

are used as 5' and 3' primers, respectively, in a polymerase chain reaction with dG-tailed first strand PBL cDNA. Oligo-69 is complimentary to sequences encoding amino acids 11-17 of the IgM constant domain. Therefore these primers will amplify DNA  
35 fragments of approximately 0.6 kb that include expressed  $V_H$  gene sequences.

## 2. Back-conversion of cDNA sequences into germline form

The following oligonucleotide:

oligo-"c" 5'-ctg acg act ctg tat ggc gcc (ct)a(cg) t(cg)(ct)  
(cg)ag (ag)t(cg) ca(ag) ct(gt) gtg (cg)a(ag) tc(gt)  
5 gg(gt)-3'

is annealed to denatured, PCR amplified, IgM 5' sequences.

Oligo-"c" includes a 21 nucleotide nondegenerate sequence that includes a KasI site, followed by a 30 nucleotide degenerate  
10 sequence that is homologous to the 5' end of the second exon of many human V<sub>H</sub> segments (Genbank; Los Alamos, NM). The primer is extended with DNA polymerase and the product isolated from unused primer by size fractionation. The product is then denatured and annealed to the following oligonucleotide:

15 oligo-"d" 5'-ggg ctc gag gct ggt ttc tct cac tgt gtg t(cgt)t  
(acgt)(ag)(ct) aca gta ata ca(ct) (ag)g(ct)-3'

Oligo-"d" includes a 30 nucleotide nondegenerate sequence that  
20 includes an XhoI site and part of the V to DJ recombination sequence, followed by a 21 nucleotide degenerate sequence that is complimentary to the the sequence encoding the last seven amino acids in framework region three of many human variable gene segments. The annealed oligonucleotide is then extended  
25 with DNA polymerase and the product isolated from unused primer by size fractionation. Single rounds of DNA synthesis followed by removal of primers are carried out to ensure the sequence integrity of individual variable gene fragments. The product of oligo-"d" primer extension is amplified by PCR using the  
30 following two oligonucleotides as primers:

oligo-"e" 5'-ctg acg act ctg tat ggc gcc-3'

oligo-"f" 5'-ggg ctc gag gct ggt ttc tct-3'

35

The resulting 0.36 kb PCR product is purified by gel electrophoresis and digested with the restriction enzymes KasI and XhoI. Digestion products are then cloned into KasI/XhoI

digested pVHf to generate a library of expressed variable gene sequences in germline configuration. Ligation into the KsI site of pVHf recreates the splice acceptor site at the 5' end of the second exon, while ligation into the XhoI site recreates the recombination signal at the 3' end of the variable gene segment. Alternative versions of degenerate oligonucleotides "c" and "d" are used to amplify different populations of variable genes, and generate germline-configuration libraries representing those different populations (Genbank; Los Alamos, NN).

### C. Construction of Synthetic Locus

The entire library of synthetic germline-configuration V<sub>H</sub> genes is grown up together and plasmid DNA isolated. The medium copy plasmid pVHf, which includes a strong transcription terminator between the ampicillin resistance gene and the cloning site, is designed to minimize the expansion of particular clones within the library. Plasmid DNA is digested with SfiI, treated with calf intestinal phosphatase to remove 5' phosphate groups, and then digested with NotI. The calf intestinal phosphatase is removed prior to NotI digestion so that only the SfiI ends are dephosphorylated. The digested DNA is then isolated from vector sequences by agarose gel electrophoresis and ligated to the following oligonucleotides:

oligo-"g" 5'-ggc cta act gag cgt ccc ata ttg aga acc tcc -3'

oligo-"h" 5'-ggg tct caa tat ggg acg ctc agt ta-3'

Oligo-"h" is kinased while oligo-"g" is left unphosphorylated. The ligation reaction is carried out with a large molar excess of oligonucleotides so that all of the V gene fragment NotI ends will be ligated to oligonucleotides and not other V region fragments. Because the SfiI ends are not self compatible, the V segments will concatenate in the same orientation such that each V segment is separated by a single oligonucleotide spacer unit from the next V segment.

Large concatomers are sized by electrophoresis and isolated from agarose gels. The size fractionated concatomers are then directly coinjected into mouse embryo pronuclei together with D-J-C containing DNA fragments (such as the pHCl or pHCl2 inserts) to generate transgenic animals with large primary repertoires. Alternatively, the concatomers are cloned into a plasmid vector such as pGPf.

#### EXAMPLE 18

##### 10 Generation of Lymphoid Cell Receptor Subset Specific Antibodies.

The inoculation of mice with xenogeneic (i.e. human) immunoglobulins (B-cell receptors) or T-cell receptors leads predominantly to the generation of mouse antibodies directed against particular epitopes (dominant epitopes) that shared by all or most immunoglobulins or T-cell receptors of a given species, but differ between species. It is therefore difficult to isolate antibodies that distinguish particular subsets of B or T cell receptors (e.g., idiotypes or variable region families). However, the transgenic mouse expressing human immunoglobulins (described in the above examples) will be immunologically tolerant of those shared B-cell epitopes and will therefore be useful for generating antibodies that distinguish subsets of human immunoglobulins. This concept is extended by generating transgenic mice expressing human T-cell receptor coding sequences and breeding these mice with the human immunoglobulin transgenic mice. Such mice are inoculated with isolates containing human T-cell receptor proteins and monoclonal antibodies are generated that recognize T-cell receptor subsets.

Studies have demonstrated that there is a limited variability of T cell antigen receptors involved in certain autoimmune diseases (T.F. Davies et al. (1991) New England J. Med., 325, 238). Because of this limited variability, it is possible to generate human monoclonal antibodies that specifically recognize that subset of human T cells which is auto-reactive.

A. Generation of B-cell subset specific antibodies

Human immunoglobulin expressing transgenic mice are inoculated with immunoglobulins isolated from a healthy donor or from a patient with a B-cell malignancy expressing a high level of a single immunoglobulin type (Miller et al. (1982) New Eng. J. Med. 306, 517-522). Monoclonal antibody secreting hybridomas are generated as described by Harlow and Lane (E. Harlow and D. Lane. Antibodies: A Laboratory Manual. 1988. Cold Spring Harbor Laboratory, New York). Individual hybridomas that secrete human antibodies that specifically recognize B-cell subsets are selected.

B. Transgenic mice expressing human T-cell receptor sequences.

DNA fragments containing intact and fully rearranged human T-cell receptor (TCR)  $\alpha$  and  $\beta$  genes are coinjected into mouse embryo pronuclei to generate transgenic animals. Transgenic animals are assayed by FACS analysis for the expression of both transgenes on the surface of their T-cells. Animals are selected that express only low levels of the human  $\alpha$  and  $\beta$  TCR chains on a fraction of their T-cells. Only low level expression is required to obtain immunological tolerance, and high level expression will disturb the animal's immune system and interfere with the ability to mount an immune response required for the generation monoclonal antibodies. Alternatively, because correct tissue or cell type specific expression is not required to obtain immunologic tolerance, TCR  $\alpha$  and  $\beta$  chain cDNA clones are inserted into transgene expression cassettes (T. Choi et al. (1991) Mol. Cell. Biol., 11, 3070-3074) under the control of non-TCR transcription signals. TCR  $\alpha$  and  $\beta$  chain cDNA transgene constructs are coinjected into mouse embryo pronuclei to generate transgenic animals. Ectopic expression of the TCR chains will not result in cell surface expression because the TCR is a multichain complex (H. Clevers et al. 1988 Ann. Rev. Immunol., 6, 629-662); however, cell surface expression is not required for antigen presentation (Townsend et al. (1986) Nature, 324, 575-577) and tolerance induction.

T-cell receptor  $\alpha$  and  $\beta$  chain transgenic mice are bred with human immunoglobulin expressing transgenic mice to generate mice that are useful for generating human monoclonal antibodies that recognize specific subsets of human T-cells.

5 Such mice are inoculated with T-cell derived proteins isolated from a healthy donor or from a patient with a T-cell malignancy expressing a single TCR type. Monoclonal antibody secreting hybridomas are generated and individual hybridomas that secrete human antibodies that specifically recognize B-cell subsets are  
10 selected.

#### EXAMPLE 19

##### Genomic Heavy Chain Human Ig Transgene

This Example describes the cloning of a human genomic  
15 heavy chain immunoglobulin transgene which is then introduced into the murine germline via microinjection into zygotes or integration in ES cells.

Nuclei are isolated from fresh human placental tissue as described by Marzluff, W.F., et al. (1985), Transcription and  
20 Translation: A Practical Approach, B.D. Hammes and S.J. Higgins, eds., pp. 89-129, IRL Press, Oxford). The isolated nuclei (or PBS washed human spermatocytes) are embedded in 0.5% low melting point agarose blocks and lysed with 1 mg/ml proteinase K in 500mM EDTA, 1% SDS for nuclei, or with 1mg/ml  
25 proteinase K in 500mM EDTA, 1% SDS, 10mM DTT for spermatocytes at 50°C for 18 hours. The proteinase K is inactivated by incubating the blocks in 40 $\mu$ g/ml PMSF in TE for 30 minutes at 50°C, and then washing extensively with TE. The DNA is then digested in the agarose with the restriction enzyme NotI as  
30 described by M. Finney in Current Protocols in Molecular Biology (F. Ausubel et al., eds. John Wiley & Sons, Supp. 4, 1988, e.g., Section 2.5.1).

The NotI digested DNA is then fractionated by pulsed field gel electrophoresis as described by Anand, R. et al.  
35 (1989), Nuc. Acids Res., 17, 3425-3433. Fractions enriched for the NotI fragment are assayed by Southern hybridization to detect one or more of the sequences encoded by this fragment. Such sequences include the heavy chain D segments, J segments,

and  $\gamma 1$  constant regions together with representatives of all 6  $V_H$  families (although this fragment is identified as 670 kb fragment from HeLa cells by Berman et al. (1988), supra., we have found it to be an 830 kb fragment from human placental and sperm DNA). Those fractions containing this NotI fragment (see Fig. 4) are ligated into the NotI cloning site of the vector pYACNN as described (McCormick, M. et al. (1990), Technique 2, 65-71). Plasmid pYACNN is prepared by digestion of pYACneo (Clontech) with EcoRI and ligation in the presence of the oligonucleotide 5' - AAT TGC GGC CGC - 3'.

YAC clones containing the heavy chain NotI fragment are isolated as described by Traver et al. (1989), Proc. Natl. Acad. Sci. USA, 86, 5898-5902. The cloned NotI insert is isolated from high molecular weight yeast DNA by pulse field gel electrophoresis as described by M. Finney, op. cit. The DNA is condensed by the addition of 1 mM spermine and microinjected directly into the nucleus of single cell embryos previously described. Alternatively, the DNA is isolated by pulsed field gel electrophoresis and introduced into ES cells by lipofection (Gnirke et al. (1991), EMBO J., 10, 1629-1634), or the YAC is introduced into ES cells by spheroplast fusion.

#### EXAMPLE 20

##### 25 Discontinuous Genomic Heavy Chain Ig Transgene

An 85 kb SpeI fragment of human genomic DNA, containing  $V_H 6$ , D segments, J segments, the  $\mu$  constant region and part of the  $\gamma$  constant region (see Fig. 4), has been isolated by YAC cloning essentially as described in Example 1. A YAC carrying a fragment from the germline variable region, such as a 570 kb NotI fragment upstream of the 670-830 kb NotI fragment described above containing multiple copies of  $V_1$  through  $V_5$ , is isolated as described. (Berman et al. (1988), supra. detected two 570 kb NotI fragments, each containing multiple V segments.) The two fragments are coinjected into the nucleus of a mouse single cell embryo as described in Example 1.

Typically, coinjection of two different DNA fragments result in the integration of both fragments at the same insertion site within the chromosome. Therefore, approximately 50% of the resulting transgenic animals that contain at least one copy of each of the two fragments will have the V segment fragment inserted upstream of the constant region containing fragment. Of these animals, about 50% will carry out V to DJ joining by DNA inversion and about 50% by deletion, depending on the orientation of the 570 kb NotI fragment relative to the position of the 85 kb SpeI fragment. DNA is isolated from resultant transgenic animals and those animals found to be containing both transgenes by Southern blot hybridization (specifically, those animals containing both multiple human V segments and human constant region genes) are tested for their ability to express human immunoglobulin molecules in accordance with standard techniques.

#### EXAMPLE 21

##### Joining Overlapping YAC Fragments

Two YACs carrying a region of overlap are joined in yeast by meiotic recombination as described by Silverman et al. (1990), Proc. Natl. Acad. Sci. USA, 87, 9913-9917, to derive a single, large YAC carrying sequences from both smaller YACs. The two YACs are aligned with respect to the arms, such that the joined YAC will contain one centromeric vector arm and one non-centromeric vector arm. If necessary, the insert is recloned in the vector using unique restriction sites at the ends of the insert. If the insert is not a unique restriction fragment, unique sites are inserted into the vector arms by oligonucleotide transformation of yeast, as described by Guthrie and Fink, op. cit. To join YACs carrying noncontiguous sequences which do not overlap, an overlap is created as follows. The 3' terminal region of the 5' YAC and the 5' terminal region of the 3' YAC are subcloned, joined in vitro to create a junction fragment, and reintroduced into one or both YACs by homologous recombination (Guthrie and Fink, op cit). The two YACs are then meiotically recombined as described by

Silverman et al., op cit). The joined YAC is introduced into mice, e.g., as in Example 1.

## EXAMPLE 22

5 Genomic  $\kappa$  Light Chain Human Ig Transgene

A map of the human  $\kappa$  light chain has been described in Lorenz, W. et al. (1987), Nucl. Acids Res., 15, 9667-9677 and is depicted in Fig. 11. A 450 kb XhoI to NotI fragment that includes all of C $\kappa$ , the 3' enhancer, all J segments, and at  
10 least five different V segments (a), or a 750kb MluI to NotI fragment that includes all of the above plus at least 20 more V segments (b) is isolated and introduced into zygotes or ES cells as described in Example 1.

## 15 EXAMPLE 23

Genomic  $\kappa$  Light Chain Human Ig Transgene Formed by In Vivo Homologous Recombination

The 750kb MluI to NotI fragment is digested with BssHII to produce a fragment of about 400 kb (c). The 450 kb  
20 XhoI to NotI fragment (a) plus the approximately 400 kb MluI to BssHII fragment (c) have sequence overlap defined by the BssHII and XhoI restriction sites shown in Fig. 11. Homologous recombination of these two fragments upon microinjection of a mouse zygote results in a transgene containing at least an  
25 additional 15-20 V segments over that found in the 450 kb XhoI/NotI fragment (Example 22).

## EXAMPLE 24

30 Identification of functionally rearranged variable region sequences in transgenic B cells

An antigen of interest is used to immunize (see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor, New York (1988)) a mouse with the following genetic traits: homozygosity at the endogenous heavy chain locus for a  
35 deletion of J<sub>H</sub> (Examples 9 and 12); hemizygous for a single copy of unrearranged human heavy chain minilocus transgene (examples 5 and 14); and hemizygous for a single copy of a

rearranged human kappa light chain transgene (Examples 7 and 16).

Following the schedule of immunization, the spleen is removed, and spleen cells used to generate hybridomas. Cells from an individual hybridoma clone that secretes antibodies reactive with the antigen of interest are used to prepare genomic DNA. A sample of the genomic DNA is digested with several different restriction enzymes that recognize unique six base pair sequences, and fractionated on an agarose gel. Southern blot hybridization is used to identify two DNA fragments in the 2-10 kb range, one of which contains the single copy of the rearranged human heavy chain VDJ sequences and one of which contains the single copy of the rearranged human light chain VJ sequence. These two fragments are size fractionated on agarose gel and cloned directly into pUC18. The cloned inserts are then subcloned respectively into heavy and light chain expression cassettes that contain constant region sequences.

The plasmid clone p $\gamma$ el (Example 14) is used as a heavy chain expression cassette and rearranged VDJ sequences are cloned into the XhoI site. The plasmid clone pCK1 is used as a light chain expression cassette and rearranged VJ sequences are cloned into the XhoI site. The resulting clones are used together to transfect SP<sub>0</sub> cells to produce antibodies that react with the antigen of interest (M.S. Co. et al. (1991) Proc. Natl. Acad. Sci. USA 88:2869).

Alternatively, mRNA is isolated from the cloned hybridoma cells described above, and used to synthesize cDNA. The expressed human heavy and light chain VDJ and VJ sequence are then amplified by PCR and cloned (J.W. Larrich et al. (1989) Biol. Technology, 7:934-938). After the nucleotide sequence of these clones has been determined, oligonucleotides are synthesized that encode the same polypeptides, and synthetic expression vectors generated as described by C. Queen et al. (1989) Proc. Natl. Acad. Sci. USA, 84:5454-5458.

The foregoing description of the preferred embodiments of the present invention has been presented for purposes of illustration and description. They are not intended to be

exhaustive or to limit the invention to the precise form disclosed, and many modifications and variations are possible in light of the above teaching.

All publications and patent applications herein are  
5 incorporated by reference to the same extent as if each  
individual publication or patent application was specifically  
and individually indicated to be incorporated by reference.

Such modifications and variations which may be  
apparent to a person skilled in the art are intended to be  
10 within the scope of this invention.

WHAT IS CLAIMED IS:

1. An isolated immunoglobulin heavy-chain transgene comprising DNA encoding at least one variable gene segment, one  
5 diversity gene segment, one joining gene segment, and one constant region gene segment, wherein each of said gene segments is derived from DNA corresponding to immunoglobulin heavy chain gene segments from the same species or an individual of said species and wherein the segments are capable  
10 of undergoing gene rearrangement in vivo to form a rearranged gene encoding a heavy chain polypeptide.

2. An immunoglobulin heavy-chain transgene of Claim 1 wherein the length of said transgene is less than the length  
15 of the corresponding genomic DNA containing all of the gene segments contained on said heavy-chain transgene.

3. The transgene of Claim 1 wherein said at least one constant region gene segment comprises at least two  
20 constant region gene segments.

4. The transgene of Claim 3 wherein said one constant region gene segments comprises a  $\mu$  and a  $\gamma$  constant region gene segment.  
25

5. The transgene of Claim 1 wherein said at least one constant region gene segment comprises a  $\gamma$  constant region gene segment.

30 6. The transgene of Claim 1 wherein said at least one variable gene segment comprises DNA corresponding to a first functional D-proximal variable region gene segment of said species or said individual.

35 7. The transgene of Claim 1 wherein the relative positions of each of said gene segments is the same as the relative position of the corresponding gene segments in the genome of said species.

8. The transgene of Claim 1 wherein said species is human.

5           9. The transgene of Claim 1 wherein said transgene is unrearranged and capable of undergoing rearrangement to generate V region diversity, when introduced into a B-cell of a non-human transgenic animal.

10           10. An isolated immunoglobulin light-chain transgene comprising DNA encoding at least one variable gene segment, one joining gene segment, and one constant region gene segment, wherein each of said gene segments is derived from genomic DNA corresponding to immunoglobulin light chain gene segments from  
15 the same species or an individual of said species and wherein the segments are capable of undergoing gene rearrangement in vivo to form a rearranged gene encoding a light chain polypeptide.

20           11. An immunoglobulin light-chain transgene of Claim 9 wherein the length of said transgene is less than the length of the corresponding genomic DNA containing all of the gene segments contained on said light-chain transgene.

25           12. The transgene of Claim 11 wherein said at least one variable region gene segment comprises DNA corresponding to a first functional J-proximal variable gene segment of said species or said individual.

30           13. The transgene of Claim 11 wherein the relative positions of said gene segments is the same as the relative positions of the corresponding gene segments in the genome of said species or said individual.

35           14. The transgene of Claim 9 wherein said species or individual is human.

15. The transgene of Claim 10 wherein said transgene is unrearranged and capable of undergoing rearrangement to generate V region diversity, when introduced into a B-cell of a non-human transgenic animal.

5

16. A transgenic non-human animal containing heterologous immunoglobulin heavy and light chain transgenes in the germline of said animal.

10

17. The transgenic non-human animal of Claim 16 wherein said heavy and said light chain transgenes are rearranged.

15

18. The transgenic non-human animal of Claim 16 wherein said heavy and said light chain transgenes are unrearranged.

20

19. The transgenic non-human animal of Claim 16 wherein one of said heavy and said light chain transgenes is rearranged and the other of said heavy and said light transgenes is unrearranged.

25

20. The transgenic non-human animal of Claim 19 wherein said heavy chain transgene is unrearranged and said light chain transgene is rearranged.

30

21. The transgenic non-human animal of Claim 16 wherein said transgenes are functionally rearranged in B-cells of said animal.

22. The transgenic non-human animal of Claim 21 wherein said B-cells produce a heterologous antibody.

35

23. The transgenic non-human animal of Claim 16 wherein said heterologous heavy and light chain genes are human.

24. The transgenic non-human animal of Claim 16 wherein said non-human animal is a rodent.

25. A transgenic non-human animal capable of  
5 producing a heterologous antibody in at least one cell of said transgenic animal containing an immunoglobulin heavy-chain transgene and an immunoglobulin light-chain transgene, wherein said heavy chain transgene comprises DNA encoding at least one variable gene segment, one diversity gene segment, one joining  
10 gene segment, and one constant region gene segment, and said immunoglobulin light-chain transgene comprises DNA encoding at least one variable gene segment, one joining gene segment, and one constant region gene segment, wherein each of said gene segments of said heavy and light chain transgenes is isolated  
15 from or corresponds to DNA encoding immunoglobulin heavy and light chain gene segments from a species not consisting of said non-human animal or an individual of said species.

26. The transgenic animal of Claim 25 wherein said  
20 transgenic non-human animal is a rodent.

27. The transgenic non-human animal of Claim 25 wherein said transgenes encode human antibody gene segments.

28. The transgenic non-human animal of claim 25  
25 wherein at least one of the endogenous immunoglobulin loci of said transgenic animal is functionally disrupted.

29. The transgenic non-human animal of Claim 28  
30 wherein the functional disruption of said endogenous loci is produced by disrupting endogenous immunoglobulin gene segments encoding heavy or light immunoglobulin chains, said gene segments being selected from the group consisting of diversity, joining and constant gene segments.

35

30. The transgenic non-human animal of Claim 29 wherein said endogenous immunoglobulin gene segments are

joining region gene segments encoding said heavy and light immunoglobulin chains.

31. The transgenic non-human animal of Claim 29  
5 wherein said disruption is by deletion of substantially all of said selected gene segments.

32. The transgenic non-human animal of Claim 25  
10 wherein said heavy and said light chain transgenes are unrearranged.

33. The transgenic non-human animal of Claim 25  
15 wherein said heavy and said light chain transgenes are rearranged.

34. The transgenic non-human animal of Claim 25  
20 wherein one of said heavy and said light chain transgenes is rearranged and the other of said heavy and said light chain transgenes is unrearranged.

35. The transgenic non-human animal of Claim 34  
25 wherein said heavy chain transgenes is unrearranged and said light chain transgenes is rearranged.

36. A non-human B-cell derived from a transgenic non-human animal, said B-cell being capable of producing a heterologous antibody.

37. The non-human B-cell of Claim 36 wherein said B-cell  
30 contains a functionally rearranged heterologous heavy chain immunoglobulin transgene and a functionally rearranged heterologous light chain immunoglobulin transgene.

38. The non-human B-cell of Claim 37 wherein each of  
35 said functionally rearranged heavy and light chain immunoglobulin transgenes are of human origin.

39. The non-human B-cell of Claim 36 wherein said B-cell does not produce a homologous antibody.

40. A hybridoma comprising a myeloma cell fused to a non-human B-cell derived from a transgenic non-human animal, said hybridoma capable of producing a monoclonal antibody heterologous to said B-cell.

41. The hybridoma of Claim 40 wherein genomic material of said hybridoma derived from said non-human B-cell contains a functionally rearranged heavy chain immunoglobulin transgene and a functionally rearranged light chain immunoglobulin transgene, each of said functionally rearranged transgenes being heterologous to said B-cell.

15

42. The hybridoma of Claim 41 wherein said transgenes are of human origin.

43. The hybridoma of Claim 40 wherein said monoclonal antibody is a human antibody.

20

44. The hybridoma of Claim 40 wherein said B-cell is of rodent origin.

45. The hybridoma of Claim 40 wherein said myeloma cell is of murine origin.

25

46. A method of producing a transgenic non-human animal wherein at least one of the endogenous immunoglobulin gene loci of said animal has been functionally disrupted, said method comprising the steps of:

30

contacting at least one embryonic stem cell of a non-human animal with a transgene targeting the functional disruption of a family of gene segments encoding an endogenous heavy or light immunoglobulin chain, said family of gene segments being selected from the group consisting of functional endogenous diversity, joining and constant gene segment families; and

35

selecting at least one embryonic stem cell wherein said transgene has integrated into the genome of said non-human animal by homologous recombination.

5           47. The method of Claim 46 wherein said transgene comprises a positive-negative selection vector.

          48. The method of Claim 46 wherein said functional  
10 disruption comprises the deletion of all or part of said family of gene segments.

          49. The method of Claim 48 wherein said deletion is of the family of joining gene segments.

15           50. The method of Claim 46 wherein said functional disruption comprises the introduction of a transcription or translation stop sequence.

          51. The method of Claim 46 wherein said functional  
20 disruption is of a constant region gene segment.

          52. The method of Claim 51 wherein said gene segment is selected from the group consisting of the  $\mu$  heavy chain constant region gene segment, the  $\kappa$  light chain constant region  
25 gene segment and the group of functional  $\lambda$  light chain construct region gene segments.

          53. A method for producing a heterologous antibody in a transgenic non-human animal having at least one B-cell  
30 containing at least one rearranged heterologous immunoglobulin heavy chain transgene and at least one rearranged heterologous immunoglobulin light chain transgene, said antibody being capable of binding an antigen, said method comprising the step of:

35           contacting said transgenic animal with said antigen to induce the production of said heterologous antibody.

54. The method of Claim 53 wherein said contacting causes somatic mutation of at least one of said transgenes.

55. The method of Claim 53 further comprising the  
5 step of immortalizing at least one of the B-cells producing said heterologous antibody to provide a source of monoclonal antibody corresponding to said heterologous antibody.

56. The method of Claim 55 wherein said immortalizing  
10 is by fusion of said B-cell with a myeloma cell line to form a hybridoma.

57. A monoclonal antibody made according to the method of Claim 55.  
15

58. The monoclonal antibody of Claim 57 wherein said heavy and light chain transgenes comprise human immunoglobulin gene segments and said antibody is a human antibody.

59. A method for producing a first heterologous  
20 antibody in a transgenic non-human animal having at least one B-cell containing at least one rearranged heterologous immunoglobulin heavy chain transgene and at least one rearranged heterologous immunoglobulin light chain transgene,  
25 wherein said first heterologous antibody is capable of binding a first antigen and said heavy and light transgenes are capable of undergoing somatic mutation in response to a known second antigen to produce a second heterologous antibody, said method comprising the step of:

30 contacting said transgenic animal with at least said first antigen to induce the somatic mutation of at least one of said heavy or light chain transgenes to produce a B-cell capable of producing said first heterologous antibody.

60. The method of Claim 59 wherein said contacting  
35 comprises the sequential or simultaneous contacting of said first antigen and said second known antigen to produce first

and second B-cells capable of producing said first and said second heterologous antibodies respectively.

61. The method of Claim 59 further comprising the step of immortalizing at least one of said B-cells producing said first heterologous antibody to provide a source of monoclonal antibody corresponding to said first heterologous antibody.

62. The method of Claim 61 wherein said immortalizing is by fusion of said B-cell with a myeloma cell line to form a hybridoma.

63. A monoclonal antibody made according to the method of Claim 61.

64. The monoclonal antibody of Claim 63 wherein said heavy and light chain rearranged transgenes comprise human immunoglobulin gene segments and said antibody is a human antibody.

65. A method for producing a synthetic immunoglobulin V segment repertoire comprising the steps of:

(a) generating a population of immunoglobulin V segment DNAs, each of said V segment DNAs encoding an immunoglobulin V segment and containing at each end a first cleavage recognition site of a first restriction endonuclease; and

(b) concatenating said population of immunoglobulin V segment DNAs to form a synthetic immunoglobulin V segment repertoire.

66. The method of Claim 65 wherein said population of V segment DNAs is derived from genomic DNA and said generating is by PCR amplification using P1 and P2 primers, said P1 primer comprising a mixture of primers encoding, from 5' to 3', said cleavage recognition site and sequences capable of hybridizing to one strand of the C-terminal portion of a multiplicity of

immunoglobulin V segments in said genomic DNA, and said P2 primer comprising a mixture of primers encoding, from 5' to 3', said cleavage recognition site and sequences capable of hybridizing to the complementary strand of the N-terminal portion of said multiplicity of immunoglobulin V segments in said genomic DNA.

67. The method of Claim 65 wherein said population of immunoglobulin V segment DNAs is derived from B-cell mRNA and said generating comprises the steps of:

(i) priming synthesis of single stranded cDNA from said mRNA with primer P1 comprising a mixture of primers encoding, from 5' to 3', said cleavage recognition site and sequences capable of hybridizing to the coding strand of the C-terminal portion of a multiplicity of immunoglobulin V segments in the genomic DNA from which said mRNA is transcribed;

(ii) priming synthesis of double stranded cDNA from said single stranded cDNA with primer P2 comprising a mixture of primers encoding, from 5' to 3', said cleavage recognition site and sequences capable of hybridizing to the antisense strand of the N-terminal portion of said multiplicity of immunoglobulin V segments in said genomic DNA.

68. The method of Claim 67 wherein each of said immunoglobulin V segment DNAs contains a first cleavage recognition site at one end of said V segment DNA and a second different cleavage recognition site at the other end of said V segment DNA and said method further comprises the step of:

amplifying said double stranded cDNA using P3 and P4 primers, said P3 primer comprising DNA encoding said first cleavage recognition site and said P4 primer comprising DNA encoding said second cleavage recognition site.

69. The method of Claim 65 wherein said immunoglobulin V segments comprise DNA encoding the first signal sequence exon and second exon of more than one immunoglobulin V segment encoded by genomic DNA.

70. The method of Claim 65 wherein said population immunoglobulin V segment DNAs comprise DNA encoding the second exon of more than one immunoglobulin V segment encoded by  
5 genomic DNA.

71. The method of Claim 70 wherein each of the members of said population is ligated into an expression vector to form an expression cassette comprising, in order, a second  
10 cleavage site of a second restriction endonuclease, an immunoglobulin promoter, an immunoglobulin secretion signal sequence, a third cleavage recognition site of a third restriction endonuclease, a recombination signal sequence and a  
15 fourth cleavage recognition site of a fourth restriction endonuclease, said ligation being into said third cleavage recognition site to form said expression cassette between said second and said fourth cleavage recognition site.

72. The method of Claim 71 wherein said concatenation  
20 is of the expression cassette by digesting said expression vector with said second and said fourth restriction endonucleases.

73. The synthetic V segment repertoire made according  
25 to the method of Claim 65.

74. A method for producing an expressible V segment comprising the steps of:

(a) generating at least one V segment DNA  
30 encoding the second exon of a V segment and containing at each end thereof a first cleavage recognition site of a first restriction endonuclease; and

(b) ligating said V segment DNA into an expression vector, said expression vector comprising, in order,  
35 an immunoglobulin promoter, an immunoglobulin secretion signal sequence, a second cleavage recognition site of a second restriction endonuclease capable of ligating said V segment DNA

when said vector is cleaved with said second restriction endonuclease and a recombination sequence.

75. An immunoglobulin (Ig) heavy chain minilocus transgene construct formed from a plurality of DNA fragments, the construct comprising DNA sequences that encode human variable (V), diversity (D), joining (J) and constant regions of a human Ig protein, which sequences are operably linked to transcription regulatory sequences and capable of undergoing gene rearrangement in vivo to produce a rearranged gene encoding a human heavy chain polypeptide; wherein each of at least three of the DNA fragments comprises:

- a V region sequence,
- a D region sequence,
- 15 a J and constant region sequence,
- a D and J and constant region sequence, or
- a constant region sequence;

wherein all of the Ig protein coding sequences are substantially homologous to human gene sequences.

76. The minilocus transgene construct of claim 75 wherein the minilocus transgene construct is about 75 kb in length.

77. The minilocus transgene construct of claim 75 wherein the constant region gene sequences encode two different immunoglobulin isotypes.

78. The minilocus transgene construct of claim 77 wherein the constant region gene sequences are capable of undergoing switch recombination.

79. The minilocus transgene construct of claim 77 wherein the isotypes are mu and gamma.

80. The minilocus transgene construct of claim 75 wherein constant region gene sequences encode a heavy chain gamma isotype.

81. The minilocus transgene construct of claim 75 wherein the Ig coding sequences are from a single individual.

5           82. An Ig minilocus transgene construction of claim 75 wherein the constant region sequence comprises a  $\mu$  constant region 5' from a second constant region.

10           83. An Ig minilocus transgene construction of claim 82, wherein the construct further comprises a switch donor region 5' from the  $\mu$  constant region and a switch acceptor region between the  $\mu$  constant region and the second constant region, which switch regions are operably linked to effect switching in vivo.

15           84. An Ig minilocus transgene construction of claim 83, wherein the switch donor region is a human  $\mu$  switch region.

20           85. An Ig minilocus transgene construction of claim 83, wherein the switch acceptor region is a human  $\gamma_1$  switch region.

25           86. An Ig minilocus transgene construction of claim 83, wherein the second constant region is a  $\gamma_1$  constant region.

30           87. An immunoglobulin (Ig) light chain minilocus transgene construct formed from a plurality of DNA fragments, the construct comprising DNA sequences that encode human variable (V), joining (J) and constant regions of a human Ig protein, which sequences are operably linked to transcription regulating sequences and are capable of undergoing gene rearrangement in vivo to produce a rearranged gene encoding a human light chain polypeptide; wherein each of at least three of the DNA fragments comprises:

35           a V region sequence,  
            a J and constant region sequence, or  
            a constant region sequence;

wherein all of the Ig protein coding sequences are substantially homologous to human gene sequences.

88. The minilocus transgene construct of claim 87  
5 wherein the gene sequences are from a single individual.

89. The minilocus transgene construct of claim 87 wherein the minilocus transgene construct consists of about 50 kb.

10 90. The minilocus transgene construct of claim 87 wherein one variable gene is operably joined to the joining gene sequence.

91. The minilocus transgene construct of claim 87  
15 wherein the relative position of each region is the same as that of a corresponding region in a germline light chain gene.

92. A yeast artificial chromosome (YAC) containing an immunoglobulin gene insert comprising:  
20 an immunoglobulin variable gene sequence, a joining gene sequence and a constant region sequence which are capable of effecting rearrangement in vivo to form a rearranged gene of the sequences, which gene encodes an immunoglobulin polypeptide.

25

93. The YAC of claim 92 wherein the chromosome further comprises a diversity gene sequence.

94. The YAC of claim 92 wherein the chromosome  
30 further comprises a switch donor region and a switch acceptor region which are operably linked to effect isotype switching in vivo.

95. The YAC of claim 92 wherein the gene sequences  
35 are from the same individual.

96. The YAC of claim 92 wherein the insert is about 85 kb.

97. The YAC of claim 92 further comprising transcription regulatory sequences operably linked to the insert.

5

98. A method of producing a modified genome in a transgenic non-human mammal, the method comprising:

condensing two yeast artificial chromosomes having overlapping sequences, which chromosomes together encode a functional immunoglobulin locus; and

10

inserting the yeast artificial chromosomes into the mammal genome.

99. The method of claim 98 wherein the yeast artificial chromosome is condensed with polyamines.

15

100. The method of claim 98, wherein the inserting step is by transfecting or lipofecting.

101. The method of claim 98 wherein the yeast artificial chromosome is integrated into the genome.

20

102. A method of inactivating an endogenous immunoglobulin gene in a non-human mammal, the method comprising introducing into the genome of the mammal a DNA fragment comprising a nucleotide sequence homologous to the endogenous immunoglobulin gene, whereby the nucleotide fragment incorporates into the genome by homologous recombination and thereby disrupts the endogenous gene.

25

30

103. The method of claim 102 wherein the step of introducing the DNA fragment into the genome is carried out by transforming an embryonic stem cell.

104. The method of claim 102 wherein the disruption comprises deletion of joining gene segments.

35

105. The method of claim 102 wherein the disruption comprises deletion of an enhancer or of a kappa constant region.

5           106. A non-human mammal produced by the method of claim 102.

10           107. An isolated immunoglobulin chain minilocus transgene construct of claim 75 or 87, wherein the V region sequence comprises VH251.

15           108. A transgenic non-human mammal capable of producing a rearranged human immunoglobulin and having an endogenous immunoglobulin gene with a heterologous nucleotide sequence insert.

20           109. A mammal of claim 108 wherein the heterologous nucleotide sequence decreases expression of endogenous immunoglobulin polypeptides.

          110. A mammal of claim 108 wherein the heterologous nucleotide sequence decreases expression of endogenous  $\mu$  heavy chain polypeptides.

25           111. A mammal of claim 108 wherein the heterologous nucleotide sequence decreases expression of endogenous light chain polypeptides.

30           112. A mammal of claim 111 wherein the light chain polypeptides are kappa or lambda.

          113. A mammal of claim 108 wherein the heterologous nucleotide sequence introduces a transcription or translation stop sequence.

35           114. A mammal of claim 108 wherein the mammal is a mouse.

115. A mammal of claim 108 wherein the immunoglobulin is expressed from an immunoglobulin minilocus transgene construct having a variable gene segment, a joining gene segment, and a constant region gene segment.

5

116. A mammal of claim 115 wherein the minilocus transgene construct is a heavy chain gene.

117. A mammal of claim 108 comprising a rearranged immunoglobulin transgene construct.

10

118. A mammal of claim 117 wherein the rearranged transgene construct encodes a kappa light chain.

15

119. A mammal of claim 117 wherein the rearranged transgene construct encodes a heavy chain.

120. A method for producing an immunoglobulin from a transgenic non-human mammal, the mammal having a rearranged immunoglobulin transgene construct that recognizes a selected antigen, the method comprising:

20

immunizing the transgenic mammal with the selected antigen; and

screening for B cells from the transgenic mammal that produce immunoglobulins that bind the selected antigen.

25

121. The method of claim 120 wherein the step of screening includes immortalizing B cells isolated from the transgenic mammal.

30

122. An immortalized cell produced according to the method of claim 121, wherein the cell is a hybridoma formed by fusing the selected B cell with a myeloma cell.

35

123. A monoclonal antibody produced by the hybridoma of claim 120.

127

124. A method according to claim 120, further comprising the steps of:

immunizing the transgenic animal with a second antigen prior to the screening step; and

5 screening for B cells that produce immunoglobulins that bind the second antigen.

125. The method of claim 120, wherein one of the antigens is a human immunoglobulin.

10

126. The method of claim 120, wherein the mouse comprises T-cell receptor transgenes and one of the antigens is a human T-cell receptor.

15 127. A transgenic mouse having a genome comprising:

(i) a heavy chain human transgene comprising a variable gene sequence, a diversity gene sequence, a joining gene sequence, and two constant region sequences operably linked to a switch donor sequence and a switch acceptor  
20 sequence;

(ii) a light chain transgene comprising a variable gene sequence, a joining gene sequence and a constant gene sequence; and

(iii) transcription regulating sequences operably  
25 linked to each transgene; wherein the gene sequences and regulatory sequences effect production of developmentally regulated diversity in vivo to form a plurality of human immunoglobulins.

30 128. The transgenic mouse of claim 127 which produces about a mg of human immunoglobulins per ml serum

129. The transgenic mouse of claim 127 wherein greater than about 10% of the human immunoglobulins are IgG.

35

130. A transgenic mouse of claim 127 wherein the human immunoglobulins exhibit an affinity for preselected antigens of greater than about  $10^{-7}M^{-1}$ .

131. The transgenic mouse of claim 127 which mounts an immune response when immunized against foreign antigens, which immune response comprises producing human immunoglobulins that are capable of binding to at least about 10% of antigens bound by endogenous immunoglobulins of a non-transgenic mouse immunized with the antigens.

132. The transgenic mouse of claim 131 which is capable of producing greater than about 1000 different human immunoglobulins.

133. The transgenic mouse of claim 131 which is capable of producing greater than about 1000 different human IgG immunoglobulins.

134. A method of producing human immunoglobulins comprising immortalizing B cells from a transgenic mouse of claim 131 immunized with an antigen; and growing selected immortalized B-cells secreting immunoglobulins reactive with the antigen.

135. A human immunoglobulin (Ig) produced according to claim 134 which Ig is isolated with respect to human proteins natively associated with human immunoglobulins.

136. A human immunoglobulin of claim 135 which has an affinity for the antigen of greater than  $10^{-7}M^{-1}$ .

137. A transgenic mouse having a genome comprising a human immunoglobulin heavy chain minilocus transgene, the transgene being capable of rearrangement and switching in the mouse, whereby two or more rearranged human heavy chain isotypes are produced.

138. The transgenic mouse of claim 137, wherein the isotypes are  $\mu$  and  $\gamma$ .

139. An isolated human monoclonal antibody produced by a mouse of claim 137.

140. A human immunoglobulin specifically reactive with a lymphoid cell subset.

141. A human immunoglobulin of claim 140, wherein the subset is a human T-cell subset.

142. A human immunoglobulin of claim 141, wherein the subset is autoreactive T-cells.

143. A plasmid vector useful in cloning immunoglobulin DNA fragments, the vector comprising

- (i) an origin of replication;
- (ii) a copy control region;
- (iii) a cloning site flanked by rare restriction enzyme sites;
- (iv) a transcriptional terminator located downstream of a plasmid-derived promoter and upstream of the cloning site, whereby a transcript originating at the promoter is terminated upstream of the cloning site.

144. A vector according to claim 143, wherein the rare restriction enzyme sites are selected from NotI, SfiI, and PacI.

145. A vector according to claim 143, selected from the group consisting of pGP1b, pGP1c, pGP1d, pGP1f and pGPe.

146. A composition consisting essentially of a human VDJ rearranged gene fragment isolated from a B cell developed within a transgenic mouse of claim 16, 25, 108, 127, or 137.

147. A method for producing a human immunoglobulin from a transgenic rodent, the rodent having a genome comprising germline copies of human heavy and light chain immunoglobulin transgenes, the method comprising:

immunizing the rodent with an antigen; and  
screening for B cells from the rodent that produce  
immunoglobulins that bind the antigen.

5           148. The method of claim 147, wherein the light chain  
transgene is rearranged in the germline.

          149. The method of claim 148, wherein the heavy chain  
transgene is unrearranged in the rodent germline.

10

          150. An isolated human immunoglobulin produced  
according to the method of claims 40, 53, 59, 120, or 147.

1/35




FIG. 1




FIG. 2




FIG. 3



3/35




FIG. 5






FIG. 7




FIG. 8

6/35




FIG. 9




FIG. 10

7/35




FIG. 11




FIG. 12

9/35




FIG. 13

10/35




FIG. 14

11/35




FIG. 15

12/35



HUMAN C<sub>γ1</sub> GENE

FIG. 16


13/35

pHIG1/Sfi I  
+  
pREG2 Sfi I  
INSERT



31.5 Kb Not I/Spe I INSERT

pCON1/Sfi I  
+  
pREG2 Sfi I  
INSERT



25 Kb Not I/Spe I INSERT

FIG. 17

HUMAN D REGION




FIG. 18

15/35




FIG. 19

16/35




FIG. 20




FIG. 21

SUBSTITUTE SHEET

17/35




FIG. 22

18/35

## MOUSE HEAVY CHAIN LOCUS




FIG. 23a

19/35




FIG. 23b

SUBSTITUTE SHEET




FIG. 23c

SUBSTITUTE SHEET




FIG. 23d

22/35

## MOUSE KAPPA GENE




FIG. 24a




FIG. 24b





FIG. 24c



26/35





FIG. 26a



28/35




FIG. 27




FIG. 28

30/35




FIG. 29




FIG. 31

32/35




FIG. 32

33/35




FIG. 33

34/35




FIG. 34

35/35




FIG. 35

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 91/06185

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC US: 800/2; 536/27 IPC(S): A01H 1/00; C07H 21/00											
<b>II. FIELDS SEARCHED</b> <div style="text-align: center;">Minimum Documentation Searched <sup>7</sup></div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%;">Classification System</th> <th style="width: 70%;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">US:</td> <td style="padding: 5px;">800/2; 536/27</td> </tr> </table>			Classification System	Classification Symbols	US:	800/2; 536/27					
Classification System	Classification Symbols										
US:	800/2; 536/27										
Documentation Searched other than Minimum Documentation to the extent that such documents are included in the fields searched <sup>8</sup>  APS, CAS, BIO80											
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%;">Category <sup>9</sup></th> <th style="width: 70%;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 20%;">Relevant to Claim No. <sup>13</sup></th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">European Journal of Immunology, volume 19, issued 1989, Yasui <i>et al.</i>, "Class Switch from <math>\mu</math> to <math>\delta</math> is mediated by homologous recombination between <math>\gamma\mu</math> and <math>\epsilon\mu</math> sequences in human immunoglobulin gene loci," pages 1399-14-3, see entire article.</td> <td style="vertical-align: top; padding: 5px;">75,77,78 83,84 107,115,116 119</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">The EMBO Journal, volume 7, number 13, issued 1988, Ichihara <i>et al.</i>, "Organization of human immunoglobulin heavy chain diversity gene loci", pages 4141-4150, see entire document.</td> <td style="vertical-align: top; padding: 5px;">1,6,25,27 75,115,116 117, 119 127,137,146</td> </tr> </table>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	Y	European Journal of Immunology, volume 19, issued 1989, Yasui <i>et al.</i> , "Class Switch from $\mu$ to $\delta$ is mediated by homologous recombination between $\gamma\mu$ and $\epsilon\mu$ sequences in human immunoglobulin gene loci," pages 1399-14-3, see entire article.	75,77,78 83,84 107,115,116 119	Y	The EMBO Journal, volume 7, number 13, issued 1988, Ichihara <i>et al.</i> , "Organization of human immunoglobulin heavy chain diversity gene loci", pages 4141-4150, see entire document.	1,6,25,27 75,115,116 117, 119 127,137,146
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>									
Y	European Journal of Immunology, volume 19, issued 1989, Yasui <i>et al.</i> , "Class Switch from $\mu$ to $\delta$ is mediated by homologous recombination between $\gamma\mu$ and $\epsilon\mu$ sequences in human immunoglobulin gene loci," pages 1399-14-3, see entire article.	75,77,78 83,84 107,115,116 119									
Y	The EMBO Journal, volume 7, number 13, issued 1988, Ichihara <i>et al.</i> , "Organization of human immunoglobulin heavy chain diversity gene loci", pages 4141-4150, see entire document.	1,6,25,27 75,115,116 117, 119 127,137,146									
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>*</sup> Special categories of cited documents: 10</p> <p><sup>"A"</sup> document defining the general state of the art which is not considered to be of particular relevance</p> <p><sup>"E"</sup> earlier document but published on or after the international filing date</p> <p><sup>"L"</sup> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p><sup>"O"</sup> document referring to an oral disclosure, use, exhibition or other means</p> <p><sup>"P"</sup> document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 50%;"> <p><sup>"T"</sup> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p><sup>"X"</sup> document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p><sup>"Y"</sup> document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p><sup>"G"</sup> document member of the same patent family</p> </div> </div>											
<b>IV. CERTIFICATION</b> <table style="width: 100%;"> <tr> <td style="width: 50%;">Date of the Actual Completion of the International Search</td> <td style="width: 50%;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="text-align: center;">06 December 1991</td> <td style="text-align: center; font-size: 1.2em;">08 JAN 1992</td> </tr> <tr> <td style="text-align: center;">International Searching Authority ISA/US</td> <td style="text-align: center;">Signature of Authorized Officer  Suzanne Ziska</td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	06 December 1991	08 JAN 1992	International Searching Authority ISA/US	Signature of Authorized Officer  Suzanne Ziska			
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report										
06 December 1991	08 JAN 1992										
International Searching Authority ISA/US	Signature of Authorized Officer  Suzanne Ziska										

International Application No.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Nature, volume 342, issued 23 November 1989, "Germline transmission of a disrupted B2 macroglobulin gene produced by homologous recombination in embryonic stem cells", pages 435-438, see entire document, Zijlstra et al.	28,29,30,31
Y	Nucleic Acid Research, volume 15, number 23, issue 1987, Lorenz et al., "Physical map of the human immunoglobulin K locus and its implication for mechanisms of V <sub>K</sub> -J <sub>K</sub> rearrangement", pages 9667-9676, see entire document.	10-15,25 27,29,30,32 34,35,108 111-115
Y	Proceedings National Academy Sciences, volume 86, issued September 1989, Bruggemann et al., "A repertoire of monoclonal antibodies with human heavy chains from transgenic mice", page 6709-6713, see entire document.	1,2,4,6,7,8 9,25-27,32 34,35,75,76 78,79,81-84 86,107,109 110,114,116 117,119,127 128,129,130 131-138,146
Y	Nature, volume 314 issued 28 March 1985, Rusconi et al., "Transmission and Expression of a specific pair of rearranged immunoglobulin $\mu$ and K genes in a transgenic mouse line", pages 330-334, see entire document.	1-4,6-8, 10-14,25-27 33,35,75,76 79,107-115 116-119,130 137,138

International Application No.

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y

Proceedings National Academy Science, volume 83, issued April 1986, Yandmurd et al., "Cell type specific and regulated expression of human  $\gamma$ 1 heavy chain immunoglobulin gene in transgenic mice", pages 2152-2156, see entire document

1,3-5,6-8,  
25-27  
33,75,76,80  
81,85,107-110  
114-117,119  
127-129,137  
138,146

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE<sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers \_\_\_\_\_, because they relate to subject matter <sup>12</sup> not required to be searched by this Authority, namely:

2. ☐ Claim numbers \_\_\_\_\_, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out <sup>13</sup>, specifically:

3. ☐ Claim numbers \_\_\_\_\_, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING<sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

See Attached

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

1-15,25-35,75-86,107-119,127-123,137,138,146

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remarks on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

Box 4.C. (Cont'd)

The present application is a Continuation-in-Part of USSN  
575,962 filed 31 August 1990, which is a C-I-P of USSN  
574,748 filed 29 August 1990.